e424b3
Filed pursuant to Rule 424(b)(3)
Registration No. 333 - 165936
PROSPECTUS
FIBROCELL SCIENCE, INC.
10,559,461 Common Stock
This prospectus relates to the resale of our common stock by certain of our stockholders,
or Selling Stockholders, named in the section of this prospectus titled Selling Security Holders.
The following shares may be offered for resale under this prospectus: (a) 5,076,664 shares of
common stock issued pursuant to a securities purchase agreement, or the Securities Purchase
Agreement, with certain accredited investors, (b) 5,076,664 shares of common stock underlying
warrants issued pursuant to the Securities Purchase Agreement, and (c) 406,133 shares of
common stock underlying the warrants issued to the placement agents in the offering completed
pursuant to the Securities Purchase Agreement.
Although we will pay substantially all the expenses incident to the registration of the
shares, we will not receive any proceeds from the sales by the Selling Stockholders. We will,
however, to the extent the warrants are exercised for cash, as opposed to being exercised on a
cash-less basis as permitted in the warrants, receive proceeds from such exercises; to the extent
we receive such proceeds, they will be used for working capital purposes.
Our
common stock is presently quoted for trading under the symbol FCSC on the over the
counter bulletin board, or OTCBB. On June 8, 2010, the last sales price of the common stock, as
reported on the OTCBB was $0.85 per share.
Investing in our common stock is highly speculative and involves a high degree of risk. You
should purchase these securities only if you can afford a complete loss of your investment. You
should carefully consider the risks and uncertainties described under the heading Risk Factors
beginning on page 4 of this prospectus before making a decision to purchase our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or passed upon the accuracy or adequacy of this
prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is June 21, 2010
TABLE OF CONTENTS
|
|
|
|
|
|
|
Page |
|
PROSPECTUS SUMMARY |
|
|
1 |
|
|
|
|
|
|
RISK FACTORS |
|
|
4 |
|
|
|
|
|
|
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS |
|
|
19 |
|
|
|
|
|
|
USE OF PROCEEDS |
|
|
20 |
|
|
|
|
|
|
MARKET PRICE OF AND DIVIDENDS ON OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS |
|
|
20 |
|
|
|
|
|
|
MANAGEMENTS
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS |
|
|
22 |
|
|
|
|
|
|
BUSINESS
& PROPERTY
|
|
|
30 |
|
|
|
|
|
|
MANAGEMENT |
|
|
43 |
|
|
|
|
|
|
RELATED PARTY TRANSACTIONS |
|
|
49 |
|
|
|
|
|
|
PRINCIPAL STOCKHOLDERS |
|
|
49 |
|
|
|
|
|
|
DESCRIPTION OF SECURITIES |
|
|
51 |
|
|
|
|
|
|
SHARES ELIGIBLE FOR FUTURE SALE |
|
|
56 |
|
|
|
|
|
|
SELLING SECURITY HOLDERS |
|
|
58 |
|
|
|
|
|
|
PLAN OF DISTRIBUTION |
|
|
60 |
|
|
|
|
|
|
EXPERTS |
|
|
63 |
|
|
|
|
|
|
WHERE YOU CAN FIND MORE INFORMATION |
|
|
63 |
|
|
|
|
|
|
INDEX TO FINANCIAL STATEMENTS
|
|
|
F-1 |
|
PROSPECTUS SUMMARY
This summary highlights information set forth in greater detail elsewhere in this prospectus.
It may not contain all the information that may be important to you. You should read the following
summary together with the more detailed information regarding us and our common stock being sold in
this offering. Unless the
context requires otherwise, references to the Company, Fibrocell, we, our, and us, refer
to Fibrocell Science, Inc. and its subsidiaries.
Our Company
We are an aesthetic and therapeutic development stage biotechnology company focused on
developing novel skin and tissue rejuvenation products. Our clinical development product candidates
are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne
and burn scars with a patients own, or autologous, fibroblast cells produced by our proprietary
Fibrocell process. Our clinical development programs encompass both aesthetic and therapeutic
indications. Our most advanced indication is for the treatment of nasolabial folds/wrinkles (United
States adopted name, or USAN, is azficel-T) and has completed Phase III clinical studies, and the
related Biologics License Application, or BLA, has been submitted to the Food and Drug
Administration, or FDA. In October 2009, the FDAs Cellular, Tissue and Gene Therapies Advisory
Committee reviewed this indication. On December 21, 2009, Fibrocell Science received a Complete
Response letter from the FDA related to the BLA for azficel-T. A Complete Response letter is issued
by the FDAs Center for Biologics Evaluation and Research (CBER) when the review of a file is
completed and additional data are needed prior to approval. The Complete Response letter requested
that we provide data from a histopathological study on biopsied tissue samples from patients
following injection of azficel-T. The letter also requested finalized Chemistry, Manufacturing and
Controls (CMC) information regarding the manufacture of azficel-T as follow-up to discussions that
occurred during the BLA review period, as well as revised policies and procedures regarding
shipping practices, and proposed labeling.
During 2009 we completed a Phase II/III study for the treatment of acne scars. During 2008 we
completed our open-label Phase II study related to full face rejuvenation.
We also develop and market an advanced skin care product line through our Agera subsidiary, in
which we acquired a 57% interest in August 2006.
Exit from Bankruptcy
On August 27, 2009, the United States Bankruptcy Court for the District of Delaware in
Wilmington entered an order, or Confirmation Order, confirming the Joint First Amended Plan of
Reorganization dated July 30, 2009, as supplemented by the Plan Supplement dated August 21, 2009,
or the Plan, of Isolagen, Inc. and Isolagens wholly owned subsidiary, Isolagen Technologies, Inc.
The effective date of the Plan was September 3, 2009.
Our officers and directors as of the effective date were all deemed to have resigned and a new
board of directors was appointed. As of the effective date, our initial board of directors
consisted of: David Pernock, Paul Hopper and Kelvin Moore. Dr. Robert Langer was appointed to the
Board in late September 2009. Declan Daly remained as chief operating officer and chief financial
officer of the reorganized company, and in November 2009, he was appointed to the Board of
Directors. Mr. Pernock became our chief executive officer in February 2010.
Pursuant to the Plan, all of our equity interests, including without limitation our common
stock, options and warrants outstanding as of the effective date were cancelled. On the effective
date, we completed an exit financing of common stock in the amount of $2 million, after which the
equity holders of our company were:
|
|
|
7,320,000 shares, to our pre-bankruptcy lenders and the lenders that provided us our
debtor-in-possession facility, collectively; |
|
|
|
|
3,960,000 shares, to the holders of our 3.5% convertible subordinated notes; |
1
|
|
|
600,000 shares, to our management as of the effective date, which was our chief
operating officer; |
|
|
|
|
120,000 shares, to the holders of our general unsecured claims; and |
|
|
|
|
2,666,666 shares, to the purchasers of shares in the $2 million exit financing (our
pre-bankruptcy lenders, the lenders that provided us our debtor-in-possession facility
and the holders of our 3.5% convertible subordinated notes were permitted to
participate in our exit financing). |
In the Plan, in addition to the common stock set forth above, each holder of Isolagens 3.5%
convertible subordinated notes, due November 2024, in the approximate non-converted aggregate
principal amount of $81 million, received, in full and final satisfaction, settlement, release and
discharge of and in exchange for any and all claims arising out of the 3.5% convertible
subordinated notes, its pro rata share of an unsecured note in the principal amount of $6 million,
or the New Notes. The New Notes have the following features:
|
|
|
12.5% interest payable quarterly in cash or, at our option, 15% payable in kind by
capitalizing such unpaid amount and adding it to the principal as of the date it was
due; |
|
|
|
|
mature June 1, 2012; |
|
|
|
|
at any time prior to the maturity date, we may redeem any portion of the outstanding
principal of the New Notes in cash at 125% of the stated face value of the New Notes;
provided that we will be obligated to redeem all outstanding New Notes upon the
following events: (a) we or our subsidiary, Fibrocell Technologies, Inc. (formerly,
Isolagen Technologies, Inc.) successfully complete a capital campaign raising in excess
of $10,000,000; or (b) we or our subsidiary, Fibrocell Technologies, Inc., are acquired
by, or sell a majority stake to, an outside party; |
|
|
|
|
the New Notes contain customary representations, warranties and covenants, including
a covenant that we and our subsidiary, Fibrocell Technologies, Inc., shall be
prohibited from the incurrence of additional debt without obtaining the consent of 66
2/3% of the New Note holders. |
Recent Financing
On March 4, 2010 pursuant to a securities purchase agreement, we completed an offering,
referred to as the Private Offering, in which we issued to certain accredited investors in the
aggregate 5,076,664 shares of common stock at a purchase price of $0.75 per share. Each investor
also received a warrant to purchase the same number of shares of common stock acquired in the
Private Offering at an exercise price of $0.98 per share. The aggregate purchase price paid by the
investors for the common stock and the warrants was $3,807,500. The Company intends to use the
proceeds for working capital purposes.
Effect of Private Offering on Series A Preferred
With certain exceptions, the Certificate of Designation of the Series A Preferred provides
that if at any time while the Series A Preferred is outstanding, we sell or grant any option to
purchase or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any
sale, grant or any option to purchase or other disposition), any common stock or common stock
equivalents at an effective price per share that is lower than the then conversion price of the
Series A Preferred, then the conversion price of the Series A Preferred will be reduced to equal
the lower price.
Consequently, as a result of the purchase price of the common stock sold in the Private
Offering, effective as of March 4, 2010, the conversion price of the Series A Preferred has been
reduced from $1.30 to $0.75.
Effect of Private Offering on Warrants
With certain exceptions, the Class A warrants, Class B warrants and placement agent warrants
provide that if at any time while the warrants are outstanding, we sell or grant any option to
purchase or sell or grant any right to
2
reprice, or otherwise dispose of or issue (or announce any sale, grant or any option to
purchase or other disposition), any common stock or common stock equivalents at an effective price
per share that is lower than the then exercise price of the relevant warrant, then the exercise
price of such warrant will be reduced to equal the lower price and the number of shares issuable
thereunder will be increased such that the aggregate exercise price after the exercise price
adjustment will be equal to the aggregate exercise price prior to the adjustment.
Consequently, as a result of the purchase price of the common stock sold in the Private
Offering, effective as of March 4, 2010, (a) the exercise prices for the Class A, Class B and
placement agent warrants have been reduced from $1.62, $1.95 and $1.30 per share, respectively, to
$0.75 per share and (b) the numbers of shares underlying the Class A, Class B and placement agent
warrants have been increased to 1,083,331, 1,083,332 and 433,333 respectively.
Our Contact Information
Our corporate headquarters is located at 405 Eagleview Boulevard, Exton, Pennsylvania 19341.
Our phone number is (484) 713-6000. Our corporate website is www.fibrocellscience.com. Information
contained on our website or any other website does not constitute part of this prospectus.
Risks Related to Our Business
Our business is subject to a number of risks, which you should be aware of before making an
investment decision. These risks are discussed more fully under
the section entitled Risk Factors.
Securities Being Offered
The Selling Stockholders named in this prospectus may offer for resale the following
securities:
|
|
|
up to 5,076,664 shares of common stock; and |
|
|
|
|
up to 5,076,664 shares of common stock underlying the warrants issued in the Private
Offering and 406,133 shares of common stock underlying the warrants issued to the
placement agents in the Private Offering. |
Although we will pay substantially all the expenses incident to the registration of the
shares, we will not receive any proceeds from the sales by the Selling Stockholders. However, we
may receive proceeds of up to $5,373,141 (includes placement agent warrants) from the exercise of
the outstanding warrants (assuming the warrants are not exercised on a cash-less basis); if such
proceeds are received by us, they will be used for working capital purposes.
3
RISK FACTORS
Investing in our company involves a high degree of risk. Before investing in our company you should
carefully consider the following risks, together with the financial and other information contained
in this prospectus. If any of the following risks actually occurs, our business, prospects,
financial condition and results of operations
could be adversely affected. In that case, the trading price of our common stock would likely
decline and you may lose all or a part of your investment.
We could fail to remain a going concern. We will need to raise substantial additional capital to
fund our operations through commercialization of our product candidates, and we do not have any
commitments for that capital.
There exists substantial doubt regarding our ability to continue as a going concern. As of
March 31, 2010 we had cash and cash equivalents of $2.5 million and working capital of $2.0
million. In early March 2010, we raised approximately
$3.8 million less fees as a result of the issuance of common stock and warrants. We believe our
existing capital resources are adequate to finance our operations through approximately mid-June
2010. We will need to access the capital markets in the future in order to fund future operations.
Beyond our efforts to obtain future financing, which may not occur, we are incurring losses from
operations, have limited capital resources, and do not have access to a line of credit or other
debt facility. As such, we will require additional cash resources prior to or during approximately
mid-June 2010, or we will likely cease operations.
We will need additional capital to achieve commercialization of our product candidates and to
execute our business strategy, and if we are unsuccessful in raising additional capital we will be
unable to achieve commercialization of our product candidates or unable to fully execute our
business strategy on a timely basis, if at all. If we raise additional capital through the issuance
of debt securities, the debt securities may be secured and any interest payments would reduce the
amount of cash available to operate and grow our business. If we raise additional capital through
the issuance of equity securities, such issuances will likely cause dilution to our stockholders,
particularly if we are required to do so during periods when our common stock is trading at low
price levels. If we file for bankruptcy, it is likely that our common stock will become worthless,
given that there currently exists approximately $6.4 million of debt as of March 31, 2010, which
has a priority over common shareholders. Additionally, we do not know whether any financing, if
obtained, will be adequate to meet our capital needs and to support our growth. If adequate capital
cannot be obtained on satisfactory terms, we may terminate or delay our efforts related to
regulatory approval of one or more of our product candidates, curtail or delay the implementation
of manufacturing process improvements or delay the expansion of our sales and marketing
capabilities, any of which could cause our business to fail.
If we do not obtain additional funding, we will likely enter into bankruptcy and/or cease
operations. Further, if we do raise additional cash resources prior to mid-June 2010, it may be
raised in contemplation of or in connection with bankruptcy. If we enter into bankruptcy, it is
likely that our common stock and common stock equivalents will become worthless and our creditors
will receive significantly less than what is owed to them.
Our independent registered public accounting firm issued their report for our fiscal year
ended December 31, 2009, which included an explanatory paragraph for our uncertainty to continue as
a going concern. If we became unable to continue as a going concern, we would have to liquidate our
assets and we may likely receive significantly less than the values at which they are carried on
our consolidated financial statements. The inclusion of a going concern explanatory paragraph in
our independent registered public accounting firms audit opinion for the year ended December 31,
2009 may materially and adversely affect our stock price and our ability to raise new capital.
Obtaining FDA and other regulatory approvals is complex, time consuming and expensive, and the
outcomes are uncertain.
The process of obtaining FDA and other regulatory approvals is time consuming, expensive and
difficult. Clinical trials are required and the marketing and manufacturing of our product
candidates are subject to rigorous testing procedures. We have finished injections related to our
pivotal Phase III clinical trial for our lead facial product candidate and have submitted the
related BLA to the FDA. In October 2009, the FDA Cellular, Tissue and Gene Therapies Advisory
Committee reviewed our nasolabial fold/wrinkles product candidate. The Committee voted 11 yes to
3 no that the data presented on our product demonstrated efficacy, and 6 yes to 8 no that the
data demonstrated safety; both for the proposed indication of treatment of nasolabial fold
wrinkles. The Committees recommendations are not binding on the FDA, but the FDA will consider
their
4
recommendations during their review of our application, which could adversely effect the
application. On December 21, 2009,
Fibrocell received a Complete Response letter from the FDA related to the BLA for azficel-T, an
autologous cell therapy for the treatment of moderate to severe nasolabial fold wrinkles in adults.
A Complete Response letter is issued by the FDAs Center for Biologics Evaluation and Research
(CBER) when the review of a file is completed and additional data are needed prior to approval. The
Complete Response letter requested that Fibrocell Science provide data from a histopathological
study on biopsied tissue samples from patients following injection of azficel-T. The letter also
requested finalized Chemistry, Manufacturing and Controls (CMC) information regarding the
manufacture of azficel-T as follow-up to discussions that occurred during the BLA review period, as
well as revised policies and procedures. To the extent that the data obtained from the
histopathological study is negative and/or the CMC information and revised policies and procedures
required by the FDA is not satisfactory, we may not obtain approval from the FDA or there may be a
delay in approval.
Our other product candidates will require additional clinical trials. The commencement and
completion of clinical trials for any of our product candidates could be delayed or prevented by a
variety of factors, including:
|
|
|
delays in obtaining regulatory approvals to commence a study; |
|
|
|
delays in identifying and reaching agreement on acceptable terms with prospective
clinical trial sites; |
|
|
|
delays or failures in obtaining approval of our clinical trial protocol from an
institutional review board, or IRB, to conduct a clinical trial at a prospective study
site; |
|
|
|
delays in the enrollment of subjects; |
|
|
|
manufacturing difficulties; |
|
|
|
failure of our clinical trials and clinical investigators to be in compliance with the
FDAs Good Clinical Practices, or GCP; |
|
|
|
failure of our third-party contract research organizations, clinical site organizations
and other clinical trial managers, to satisfy their contractual duties, comply with
regulations or meet expected deadlines; |
|
|
|
lack of efficacy during clinical trials; or |
|
|
|
unforeseen safety issues. |
We do not know whether our clinical trials will need to be restructured or will be completed
on schedule, if at all, or whether they will provide data necessary to support necessary regulatory
approval. Significant delays in clinical trials will impede our ability to commercialize our
product candidates and generate revenue, and could significantly increase our development costs.
We utilize bovine-sourced materials to manufacture our Fibrocell Therapy. Future FDA
regulations, as well as currently proposed regulations, may require us to change the source of the
bovine-sourced materials we use in our products or to cease using bovine-sourced materials. If we
are required to use alternative materials in our products, and in the event that such alternative
materials are available to us, or if we choose to change the materials used in our products in the
future, we would need to validate the new manufacturing process and run comparability trials with
the reformulated product, which could delay our submission for regulatory approval.
Even if marketing approval from the FDA is received for one or more of our product candidates,
the FDA may impose post-marketing requirements, such as:
|
|
|
labeling and advertising requirements, restrictions or limitations, including the
inclusion of warnings, precautions, contra-indications or use limitations that could have a
material impact on the future profitability of our product candidates; |
|
|
|
testing and surveillance to further evaluate or monitor our future products and their
continued compliance with regulatory standards and requirements; |
5
|
|
|
submitting products for inspection; or |
|
|
|
imposing a risk evaluation and mitigation strategy, or REMS, to ensure that the benefits
of the drug outweigh the risks. |
Because our consolidated financial statements for the year ended December 31, 2009 reflect
fresh-start accounting adjustments made on emergence from bankruptcy and because of the effects of
the transactions that became effective pursuant to the Plan, financial information in our current
and future financial statements will not be comparable to our financial information from prior
periods.
In connection with our emergence from bankruptcy, we adopted fresh-start accounting as of
September 1, 2009 in accordance with ASC 852-10. The adoption of fresh-start accounting resulted in
our becoming a new entity for financial reporting purposes. As required by fresh-start accounting,
our assets and liabilities have been preliminarily adjusted to fair value, and certain assets and
liabilities not previously recognized in our financial statements have been recognized. In addition
to fresh-start accounting, our financial statements reflect all effects of the transactions
implemented by the Plan. Accordingly, the financial statements prior to September 1, 2009 are not
comparable with the financial statements for periods on or after September 1, 2009. Furthermore,
the estimates and assumptions used to implement fresh-start accounting are inherently subject to
significant uncertainties and contingencies beyond our control. Accordingly, we cannot provide
assurance that the estimates, assumptions, and values reflected in the valuations will be realized,
and actual results could vary materially. For further information about fresh-start accounting, see
Note 5 Fresh-Start Accounting in Notes to Consolidated Financial Statements.
Protocol deviations may release the FDA from its binding acceptance of our SPA study design, which
may result in the delay, or non-approval, by the FDA of the Fibrocell Therapy.
In connection with preparations for FDA Investigator Inspections related to our nasolabial
fold/wrinkle Phase III studies, we identified protocol deviations related to the timing of visits
and other types of deviations. The possibility exists that our special protocol assessment could no
longer be binding on the FDA if the FDA considers these deviations, individually or in aggregate,
to be significant. Further, future investigator audits may identify deviations unknown at this
time. Accordingly, the possibility exists that although our Phase III studies yielded statistically
significant results, the studies may not be acceptable to the FDA under the SPA.
Clinical trials may fail to demonstrate the safety or efficacy of our product candidates, which
could prevent or significantly delay regulatory approval and prevent us from raising additional
financing.
Prior to receiving approval to commercialize any of our product candidates, we must
demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction
of the FDA and other regulatory authorities in the United States and abroad, that our product
candidates are both safe and effective. We will need to demonstrate our product candidates
efficacy and monitor their safety throughout the process. We have recently completed a pivotal
Phase III clinical trial related to our lead facial aesthetic product candidate. The success of
prior pre-clinical or clinical trials does not ensure the success of these trials, which are being
conducted in populations with different racial and ethnic demographics than our previous trials. If
our current trials or any future clinical trials are unsuccessful, our business and reputation
would be harmed and the price at which our stock trades could be adversely affected. In addition,
if our Phase III clinical trials related to our lead facial aesthetic product candidate is deemed
to be unacceptable or deficient in any way by the FDA, we may be unable to raise additional equity
or debt financing that we may require to continue our operations.
All of our product candidates are subject to the risks of failure inherent in the development
of biotherapeutic products. The results of early-stage clinical trials of our product candidates do
not necessarily predict the results of later-stage clinical trials. Product candidates in
later-stage clinical trials may fail to demonstrate desired safety and efficacy traits despite
having successfully progressed through initial clinical testing. Even if we believe the data
collected from clinical trials of our product candidates is promising, this data may not be
sufficient to support approval by the FDA or any other U.S. or foreign regulatory approval.
Pre-clinical and clinical data can be interpreted in different ways. Accordingly, FDA officials
could reach different conclusions in assessing such data than we do, which could delay, limit or
prevent regulatory approval. In addition, the FDA, other regulatory
authorities, our Institutional Review Boards or we, may suspend or terminate clinical trials
at any time.
6
Unlike our Phase III nasolabial/wrinkle trial, our Phase II/III Acne Scar trial is not subject
to a SPA with the FDA. In addition, we have developed a photo guide for use in the evaluators
assessment of acne study subjects. Our evaluator assessment scale and photo guide have not been
previously used in a clinical trial. To obtain FDA approval with respect to the acne scar
indication, we will require FDA concurrence with the use of our evaluator assessment scale and
photo guide.
Any failure or delay in completing clinical trials for our product candidates, or in receiving
regulatory approval for the sale of any product candidates, has the potential to materially harm
our business, and may prevent us from raising necessary, additional financing that we may need in
the future.
We may issue additional equity securities and thereby materially and adversely affect the price of
our common stock.
Sales of substantial amounts of shares of our common stock in the public market, or the
perception that those sales may occur, could cause the market price of our common stock to decline.
We have used and it is likely that we will continue to use our common stock or securities
convertible into or exchangeable for our common stock to fund our working capital needs or to
acquire technology, product rights or businesses, or for other purposes. If we issue additional
equity securities, particularly during times when our common stock is trading at relatively low
price levels, the price of our common stock may be materially and adversely affected.
We have a significant number of warrants and convertible preferred stock outstanding that contain
anti-dilution and price-protection provisions that may result in the reduction of their exercise
prices or conversion prices in the future.
In October 2009, we completed an offering of Series A Preferred Stock and warrants, and, in
March 2010, we completed an offering of common stock and warrants. Each of the foregoing securities
were subject to certain anti-dilution provisions, which provisions require the lowering the of
conversion price or exercise price, as applicable, to the purchase price of future offerings.
Furthermore, with respect to the warrants, if we complete an offering below the exercise price of
such warrants, the number of shares issuable under the warrants will be proportionately increased
such that the aggregate exercise price payable after taking into account the decrease in the
exercise price, shall be equal to the aggregate exercise price prior to such adjustment. The
conversion and exercise price of securities issued in the October 2009 offering were adjusted due
to the March 2010 offering. If in the future we issue securities for less than the conversion or
exercise price of the securities we issued in the October 2009 and March 2010 offering, we may be
required to further reduce the relevant conversion or exercise prices, and the number of shares
underlying the warrants may be increased.
During the term that the warrants and preferred stock are outstanding, the holders of those
securities are given the opportunity to profit from a rise in the market price of our common stock.
In addition, certain of the warrants are not redeemable by us. We may find it more difficult to
raise additional equity capital while these warrants or preferred stock are outstanding. At any
time during which these warrants are likely to be exercised, we may be able to obtain additional
equity capital on more favorable terms from other sources.
We have yet to be profitable, losses may continue to increase from current levels and we will
continue to experience significant negative cash flow as we expand our operations, which may limit
or delay our ability to become profitable.
We have incurred losses since our inception, have never generated significant revenue from
commercial sales of our products, and have never been profitable. We are focused on product
development, and we have expended significant resources on our clinical trials, personnel and
research and development. We expect these costs to continue to rise in the future. We expect to
continue to experience increasing operating losses and negative cash flow as we expand our
operations.
7
We expect to continue to incur significant additional costs and expenses related to:
|
|
|
FDA clinical trials and regulatory approvals; |
|
|
|
expansion of laboratory and manufacturing operations; |
|
|
|
research and development; |
|
|
|
development of relationships with strategic business partners, including physicians who
might use our future products; and |
|
|
|
interest expense and amortization of issuance costs related to our outstanding note
payables. |
If our product candidates fail in clinical trials or do not gain regulatory approval, if our
product candidates do not achieve market acceptance, or if we do not succeed in effectively and
efficiently implementing manufacturing process and technology improvements to make our product
commercially viable, we will not be profitable. If we fail to become and remain profitable, or if
we are unable to fund our continuing losses, our business may fail.
We will continue to experience operating losses and significant negative cash flow until we
begin to generate significant revenue from (a) the sale of our product candidates, which is
dependent on the receipt of FDA approval for our product candidates and is dependent on our ability
to successfully market and sell such product candidates, and (b) our Agera product line, which is
dependent on achieving significant market penetration in its markets.
We may be unable to successfully commercialize any of our product candidates currently under
development.
Before we can commercialize any of our product candidates in the United States, we will need
to:
|
|
|
conduct substantial additional research and development; |
|
|
|
successfully complete lengthy and expensive pre-clinical and clinical testing, including
the Phase II/III clinical trial for our acne scar product candidate; |
|
|
|
successfully improve our manufacturing process; and |
Even if our product development efforts are successful, we cannot assure you that we will be
able to commercialize any of our product candidates currently under development. In that event, we
will be unable to generate significant revenue, and our business will fail.
We have not generated significant revenue from commercial sales of our products to date, and we do
not know whether we will ever generate significant revenue.
We are focused on product development and have not generated significant revenue from
commercial sales of our products to date. Prior to the fourth quarter of 2006 we offered the
Fibrocell Therapy for sale in the United Kingdom. Our United Kingdom operation had been operating
on a negative gross margin as we investigated means to improve manufacturing technologies for the
Fibrocell Process.
8
We do not currently offer any products for sale that are based upon our Fibrocell Therapy, and
we cannot guarantee that we will ever market any such products. We must demonstrate that our
product candidates satisfy rigorous standards of safety and efficacy before the FDA and other
regulatory authorities in the United States and abroad will approve the product candidates for
commercial marketing. We will need to conduct significant
additional research, including potentially pre-clinical testing and clinical testing before we
can file additional applications with the FDA for approval of our product candidates. We must also
develop, validate and obtain FDA approval of any improved manufacturing process. In addition, to
compete effectively our future products must be easy to use, cost-effective and economical to
manufacture on a commercial scale. We may not achieve any of these objectives, and we may never
generate revenue from our product candidates.
Our ability to effectively commercialize our product candidates depends on our ability to improve
our manufacturing process and validate such future improvements.
As part of the approval process, we must pass a pre-approval inspection of our manufacturing
facility before we can obtain marketing approval for our product candidates. The Complete Response
letter that we received from the FDA in December 2009 requested finalized Chemistry, Manufacturing
and Controls (CMC) information regarding the manufacture of azficel-T as follow-up to discussions
that occurred during the BLA review period. FDA. We cannot guarantee that this CMC information will
satisfy the FDAs requirements for approval. All of our manufacturing methods, equipment and
processes for the active pharmaceutical ingredient and finished product must comply with the FDAs
current Good Manufacturing Practices, or cGMP, requirements. We will also need to perform extensive
audits of our suppliers, vendors and contract laboratories. The cGMP requirements govern all areas
of recordkeeping, production processes and controls, personnel and quality control. To ensure that
we meet these requirements, we will expend significant time, money and effort. Due to the unique
nature of our Fibrocell Therapy, we cannot predict the likelihood that the FDA will approve our
facility as compliant with cGMP requirements even if we believe that we have taken the steps
necessary to achieve compliance.
The FDA, in its regulatory discretion, may require us to undergo additional clinical trials
with respect to any new or improved manufacturing process we develop or utilize, in the future, if
any. This could include a requirement to change the materials used in our manufacturing process.
These improvements or modifications could delay or prevent approval of our product candidates. If
we fail to comply with cGMP requirements, pass an FDA pre-approval inspection or obtain FDA
approval of our manufacturing process, we would not receive FDA approval and would be subject to
possible regulatory action. The failure to successfully implement our manufacturing process may
delay or prevent our future profitability.
Even if we obtain FDA approval in the future and satisfy the FDA with regard to a validated
manufacturing process, we still may be unable to commercially manufacture the Fibrocell Therapy
profitably. Our manufacturing cost has been subject to fluctuation, depending, in part, on the
yields obtained from our manufacturing process. There is no guarantee that future manufacturing
improvements will result in a manufacturing cost low enough to effectively compete in the market.
Further, we currently manufacture the Fibrocell Therapy on a limited basis (for research and
development and for trial purposes only) and we have not manufactured commercial levels of the
Fibrocell Therapy in the United States. Such commercial manufacturing volumes, in the future, could
lead to unexpected inefficiencies and result in unprofitable performance results.
We may not be successful in our efforts to develop commercial-scale manufacturing technology and
methods.
In order to successfully commercialize any approved product candidates, we will be required to
produce such products on a commercial scale and in a cost-effective manner. As stated in the
preceding risk factor, we intend to seek FDA approval of our manufacturing process as a component
of the BLA application and approval process. However, we can provide no assurance that we will be
able to cost-effectively and commercially scale our operations using our current manufacturing
process. If we are unable to develop suitable techniques to produce and manufacture our product
candidates, our business prospects will suffer.
9
We depend on a third-party manufacturer for our Agera product line, the loss or unavailability of
which would require us to find a substitute manufacturer, if available, resulting in delays in
production and additional expenses.
Our Agera skin care product line is manufactured by a third party. We are dependent on this
third party to manufacture Ageras products, and the manufacturer is responsible for supplying the
formula ingredients for the Agera product lines. If for any reason the manufacturer discontinues
production of Ageras products at a time when we have a low volume of inventory on hand or are
experiencing a high demand for the products, significant delays
in production of the products and interruption of product sales may result as we seek to
establish a relationship and commence production with a new manufacturer, which would negatively
impact our results of operation.
The large majority of our revenue, which relates to the Agera business segment, is to one,
international customer.
Our revenues, which relate solely to the Agera business segment, are highly concentrated in
one large, international customer. This large customer represented 64% of 2009 and 2008
consolidated revenues. Further, this large customer represented 87% and 94% of consolidated
accounts receivable, net, at December 31, 2009 and December 31, 2008, respectively. A reduction of
revenue related to this large customer, due to competitor product alternatives, pricing pressures,
the financial health of the large customer, or otherwise, would have a significant, negative impact
on the business of Agera, and the related value thereof.
If our Fibrocell Therapy is found to be unsafe or ineffective, or if our Fibrocell Therapy is
perceived to be unsafe or ineffective, our business would be materially harmed.
Our product candidates utilize our Fibrocell Therapy. In addition, we expect to utilize our
Fibrocell Therapy in the development of any future product candidates. If our Fibrocell Therapy is
found to be, or perceived to be, unsafe or ineffective, we will not be successful in obtaining
marketing approval for any product candidates then pending, and we may have to modify or cease
production of any products that previously may have received regulatory approval. Negative media
exposure, whether founded or unfounded, related to the safety and/or effectiveness of our Fibrocell
Therapy may harm our reputation and/or competitive position.
If physicians do not follow our established protocols, the efficacy and safety of our product
candidates may be adversely affected.
We are dependent on physicians to follow our established protocols both as to the
administration and the handling of our product candidates in connection with our clinical trials,
and we will continue to be dependent on physicians to follow such protocols if our product
candidates are commercialized. The treatment protocol requires each physician to verify the
patients name and date of birth with the patient and the patient records immediately prior to
injection. In the event more than one patients cells are delivered to a physician or we deliver
the wrong patients cells to the physician, which has occurred in the past, it is the physicians
obligation to follow the treatment protocol and assure that the patient is treated with the correct
cells. If the physicians do not follow our protocol, the efficacy and safety of our product
candidates may be adversely affected.
Our business, which depends on one facility, is vulnerable to natural disasters, telecommunication
and information systems failures, terrorism and similar problems, and we are not fully insured for
losses caused by all of these incidents.
We currently conduct all our research, development and manufacturing operations in one
facility located in Exton, Pennsylvania. As a result, if we obtain FDA approval of any of our
product candidates, all of the commercial manufacturing for the U.S. market are currently expected
to take place at a single U.S. facility. If regulatory, manufacturing or other problems require us
to discontinue production at that facility, we will not be able to supply product, which would
adversely impact our business.
Our Exton facility could be damaged by fire, floods, power loss, telecommunication and
information systems failures or similar events. Our insurance policies have limited coverage levels
for loss or damages in these events and may not adequately compensate us for any losses that may
occur. In addition, terrorist acts or acts of war may cause harm to our employees or damage our
Exton facility. The potential for future terrorist attacks, the national and international
responses to terrorist attacks or perceived threats to national security, and other acts of war or
hostility have created many economic and political uncertainties that could adversely affect our
business and results of operations in ways that we cannot predict, and could cause our stock price
to fluctuate or decline. We are uninsured for these types of losses.
10
As a result of our limited operating history, we may not be able to correctly estimate our future
operating expenses, which could lead to cash shortfalls.
We have a limited operating history and our primary business activities consist of conducting
clinical trials. As such, our historical financial data is of limited value in estimating future
operating expenses. Our budgeted expense levels are based in part on our expectations concerning
the costs of our clinical trials, which depend on the success of such trials and our ability to
effectively and efficiently conduct such trials, and expectations related to our efforts to achieve
FDA approval with respect to our product candidates. In addition, our budgeted expense levels are
based in part on our expectations of future revenue that we may receive from our Agera product
line, and the size of future revenue depends on the choices and demand of individuals. Our limited
operating history and clinical trial experience make these costs and revenues difficult to forecast
accurately. We may be unable to adjust our operations in a timely manner to compensate for any
unexpected increase in costs or shortfall in revenue. Further, our fixed manufacturing costs and
business development and marketing expenses will increase significantly as we expand our
operations. Accordingly, a significant increase in costs or shortfall in revenue could have an
immediate and material adverse effect on our business, results of operations and financial
condition.
Our operating results may fluctuate significantly in the future, which may cause our results to
fall below the expectations of securities analysts, stockholders and investors.
Our operating results may fluctuate significantly in the future as a result of a variety of
factors, many of which are outside of our control. These factors include, but are not limited to:
|
|
|
the level of demand for the products that we may develop; |
|
|
|
the timely and successful implementation of improved manufacturing processes; |
|
|
|
our ability to attract and retain personnel with the necessary strategic, technical and
creative skills required for effective operations; |
|
|
|
the amount and timing of expenditures by practitioners and their patients; |
|
|
|
introduction of new technologies; |
|
|
|
product liability litigation, class action and derivative action litigation, or other
litigation; |
|
|
|
the amount and timing of capital expenditures and other costs relating to the expansion
of our operations; |
|
|
|
the state of the debt and/or equity markets at the time of any proposed offering we
choose to initiate; |
|
|
|
our ability to successfully integrate new acquisitions into our operations; |
|
|
|
government regulation and legal developments regarding our Fibrocell Therapy in the
United States and in the foreign countries in which we may operate in the future; and |
|
|
|
general economic conditions. |
As a strategic response to changes in the competitive environment, we may from time to time
make pricing, service, technology or marketing decisions or business or technology acquisitions
that could have a material adverse effect on our operating results. Due to any of these factors,
our operating results may fall below the expectations of securities analysts, stockholders and
investors in any future period, which may cause our stock price to decline.
11
We may be liable for product liability claims not covered by insurance, and, our predecessor
company was publicly threatened with claims related to our product in the United Kingdom.
Physicians who used our facial aesthetic product in the past, or who may use any of our future
products, and patients who have been treated by our facial aesthetic product in the past, or who
may use any of our future products, may bring product liability claims against us. In particular,
our predecessor company received negative publicity and negative correspondence from patients in
the United Kingdom that had previously received our
treatment. While we have taken, and continue to take, what we believe are appropriate
precautions, we may be unable to avoid significant liability exposure. We currently keep in force
product liability insurance, although such insurance may not be adequate to fully cover any
potential claims or may lapse in accordance with its terms prior to the assertion of claims. We may
be unable to obtain product liability insurance in the future, or we may be unable to do so on
acceptable terms. Any insurance we obtain or have obtained in the past may not provide adequate
coverage against any asserted claims. In addition, regardless of merit or eventual outcome, product
liability claims may result in:
|
|
|
diversion of managements time and attention; |
|
|
|
expenditure of large amounts of cash on legal fees, expenses and payment of damages; |
|
|
|
decreased demand for our products or any of our future products and services; or |
|
|
|
injury to our reputation. |
If we are the subject of any future product liability claims, our business could be adversely
affected, and if these claims are in excess of insurance coverage, if any, that we may possess, our
financial position will suffer.
Our failure to comply with extensive governmental regulation may significantly affect our operating
results.
Even if we obtain regulatory approval for some or all our product candidates, we will continue
to be subject to extensive ongoing requirements by the FDA, as well as by a number of foreign,
national, state and local agencies. These regulations will impact many aspects of our operations,
including testing, research and development, manufacturing, safety, efficacy, labeling, storage,
quality control, adverse event reporting, import and export, record keeping, approval,
distribution, advertising and promotion of our future products. We must also submit new or
supplemental applications and obtain FDA approval for certain changes to an approved product,
product labeling or manufacturing process. Application holders must also submit advertising and
other promotional material to the FDA and report on ongoing clinical trials. The FDA enforces
post-marketing regulatory requirements, including the cGMP requirements, through periodic
unannounced inspections. We do not know whether we will pass any future FDA inspections. Failure to
pass an inspection could disrupt, delay or shut down our manufacturing operations. Failure to
comply with applicable regulatory requirements could, among other things, result in:
|
|
|
administrative or judicial enforcement actions; |
|
|
|
changes to advertising; |
|
|
|
failure to obtain marketing approvals for our product candidates; |
|
|
|
revocation or suspension of regulatory approvals of products; |
|
|
|
product seizures or recalls; |
|
|
|
court-ordered injunctions; |
|
|
|
delay, interruption or suspension of product manufacturing, distribution, marketing and
sales; or |
|
|
|
civil or criminal sanctions. |
12
The discovery of previously unknown problems with our future products may result in
restrictions of the products, including withdrawal from the market. In addition, the FDA may
revisit and change its prior determinations with regard to the safety or efficacy of our future
products. If the FDAs position changes, we may be required to change our labeling or cease to
manufacture and market our future products. Even prior to any formal
regulatory action, we could voluntarily decide to cease the distribution and sale or recall
any of our future products if concerns about their safety or efficacy develop.
In their regulation of advertising and other promotion, the FDA and the FTC may issue
correspondence alleging that some advertising or promotional practices are false, misleading or
deceptive. The FDA and FTC are authorized to impose a wide array of sanctions on companies for such
advertising and promotion practices, which could result in any of the following:
|
|
|
incurring substantial expenses, including fines, penalties, legal fees and costs to
comply with the FDAs requirements; |
|
|
|
changes in the methods of marketing and selling products; |
|
|
|
taking FDA mandated corrective action, which may include placing advertisements or
sending letters to physicians rescinding previous advertisements or promotions; or |
|
|
|
disruption in the distribution of products and loss of sales until compliance with the
FDAs position is obtained. |
Improper promotional activities may also lead to investigations by federal or state
prosecutors, and result in criminal and civil penalties. If we become subject to any of the above
requirements, it could be damaging to our reputation and restrict our ability to sell or market our
future products, and our business condition could be adversely affected. We may also incur
significant expenses in defending ourselves.
Physicians may prescribe pharmaceutical or biologic products for uses that are not described
in a products labeling or differ from those tested by us and approved by the FDA. While such
off-label uses are common and the FDA does not regulate physicians choice of treatments, the FDA
does restrict a manufacturers communications on the subject of off-label use. Companies cannot
promote FDA-approved pharmaceutical or biologic products for off-label uses, but under certain
limited circumstances they may disseminate to practitioners articles published in peer-reviewed
journals. To the extent allowed by the FDA, we intend to disseminate peer-reviewed articles on our
future products to practitioners. If, however, our activities fail to comply with the FDAs
regulations or guidelines, we may be subject to warnings from, or enforcement action by, the FDA or
other regulatory or law enforcement authorities.
Our sales, marketing, and scientific/educational grant programs, if any in the future, must
also comply with applicable requirements of the anti-fraud and abuse provisions of the Social
Security Act, the False Claims Act, the federal anti-kickback law, and similar state laws, each as
amended. Pricing and rebate programs must comply with the Medicaid rebate requirements of the
Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as
amended. If products are made available to authorized users of the Federal Supply Schedule of the
General Services Administration, additional laws and requirements apply. All of these activities
are also potentially subject to federal and state consumer protection and unfair competition laws.
The distribution of product samples to physicians must comply with the requirements of the
Prescription Drug Marketing Act.
Depending on the circumstances, failure to meet post-approval requirements can result in
criminal prosecution, fines or other penalties, injunctions, recall or seizure of products, total
or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or
refusal to allow us to enter into supply contracts, including government contracts. Any government
investigation of alleged violations of law could require us to expend significant time and
resources in response, and could generate negative publicity.
13
Legislative or regulatory reform of the healthcare system may affect our ability to sell our future
products profitably.
In the United States and a number of foreign jurisdictions, there have been legislative and
regulatory proposals to change the healthcare system in ways that could impact our ability to sell
our future products profitably. For instance, there currently is no legal pathway for generic or
similar versions of BLA-approved biologics,
sometimes called follow-on biologics or biosimilars, but there is continuing interest by
Congress on this issue and on healthcare reform in general. It is unknown what type of regulatory
framework, what legal provisions, and what timeframes for issuance of regulations or guidance any
final legislation on biosimilars would contain, but the future profitability of any approved
biological product could be materially adversely impacted by the approval of a biosimilar product.
The FDAs policies may change and additional government regulations may be enacted, which could
prevent or delay regulatory approval of our product candidates. We cannot predict the likelihood,
nature or extent of adverse government regulation that may arise from future legislation or
administrative action, either in the United States or abroad. If we are not able to maintain
regulatory compliance, we might not be permitted to market our future products and our business
could suffer.
Any future products that we develop may not be commercially successful.
Even if we obtain regulatory approval for our product candidates in the United States and
other countries, those products may not be accepted by the market. A number of factors may affect
the rate and level of market acceptance of our products, including:
|
|
|
labeling requirements or limitations; |
|
|
|
market acceptance by practitioners and their patients; |
|
|
|
our ability to successfully improve our manufacturing process; |
|
|
|
the effectiveness of our sales efforts and marketing activities; and |
|
|
|
the success of competitive products. |
If our current or future product candidates fail to achieve market acceptance, our
profitability and financial condition will suffer.
Our competitors in the pharmaceutical, medical device and biotechnology industries may have
superior products, manufacturing capabilities, financial resources or marketing position.
The human healthcare products and services industry is extremely competitive. Our competitors
include major pharmaceutical, medical device and biotechnology companies. Most of these competitors
have more extensive research and development, marketing and production capabilities and greater
financial resources than we do. Our future success will depend on our ability to develop and market
effectively our future products against those of our competitors. If our future products receive
marketing approval but cannot compete effectively in the marketplace, our results of operations and
financial position will suffer.
We are dependent on our key scientific and other management personnel, and the loss of any of these
individuals could harm our business.
We are dependent on the efforts of our key management and scientific staff. The loss of any of
these individuals, or our inability to recruit and train additional key personnel in a timely
manner, could materially and adversely affect our business and our future prospects. A loss of one
or more of our current officers or key personnel could severely and negatively impact our
operations. We have employment agreements with most of our key management personnel, but some of
these people are employed at-will, and any of them may elect to pursue other opportunities at any
time. We have no present intention of obtaining key man life insurance on any of our executive
officers or key management personnel.
14
We may need to attract, train and retain additional highly qualified senior executives and
technical and managerial personnel in the future.
In the future, we may need to seek additional senior executives, as well as technical and
managerial staff members. There is a high demand for highly trained executive, technical and
managerial personnel in our industry.
We do not know whether we will be able to attract, train and retain highly qualified technical
and managerial personnel in the future, which could have a material adverse effect on our business,
financial condition and results of operations.
If we are unable to effectively promote our brands and establish a competitive position in the
marketplace, our business may fail.
Our Fibrocell Therapy brand names are new and unproven. We believe that the importance of
brand recognition will increase over time. In order to gain brand recognition, we may increase our
marketing and advertising budgets to create and maintain brand loyalty. We do not know whether
these efforts will lead to greater brand recognition. If we are unable effectively to promote our
brands, including our Agera product line, and establish competitive positions in the marketplace,
our business results will be materially adversely affected.
If we are unable to adequately protect our intellectual property and proprietary technology, the
value of our technology and future products will be adversely affected, and if we are unable to
enforce our intellectual property against unauthorized use by third parties our business may be
materially harmed.
Our long-term success largely depends on our future ability to market technologically
competitive products. Our ability to achieve commercial success will depend in part on obtaining
and maintaining patent protection and trade secret protection of our technology and future
products, as well as successfully defending these patents against third party challenges. In order
to do so we must:
|
|
|
obtain and protect commercially valuable patents or the rights to patents both
domestically and abroad; |
|
|
|
operate without infringing upon the proprietary rights of others; and |
|
|
|
prevent others from successfully challenging or infringing our proprietary rights. |
As of December 31, 2009, we had 9 issued U.S. patents, 4 pending U.S. patent applications, 28
granted foreign patents and 3 pending international patent application. However, we may not be able
to obtain additional patents relating to our technology or otherwise protect our proprietary
rights. If we fail to obtain or maintain patents from our pending and future applications, we may
not be able to prevent third parties from using our proprietary technology. We will be able to
protect our proprietary rights from unauthorized use only to the extent that these rights are
covered by valid and enforceable patents that we control or are effectively maintained by us as
trade secrets. Furthermore, the degree of future protection of our proprietary rights is uncertain
because legal means afford only limited protection and may not adequately protect our rights or
permit us to gain or keep a competitive advantage.
The patent situation of companies in the markets in which we compete is highly uncertain and
involves complex legal and factual questions for which important legal principles remain
unresolved. No consistent policy regarding the breadth of claims allowed in such companies patents
has emerged to date in the United States. The laws of other countries do not protect intellectual
property rights to the same extent as the laws of the United States, and many companies have
encountered significant problems in protecting and defending such rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the
enforcement of patents and other intellectual property protection, particularly those relating to
biotechnology and/or pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents in foreign countries in which we hold patents. Proceedings to enforce our patent
rights in the United States or in foreign jurisdictions would likely result in substantial cost and
divert our efforts and attention from other aspects of our business. Changes in either the patent
laws or in interpretations of patent laws in the United States or other countries may diminish the
value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may
be allowed or enforced in our patents or in third-party patents.
15
Other risks and uncertainties that we face with respect to our patents and other proprietary
rights include the following:
|
|
|
the inventors of the inventions covered by each of our pending patent applications might
not have been the first to make such inventions; |
|
|
|
we might not have been the first to file patent applications for these inventions or
similar technology; |
|
|
|
the future and pending applications we will file or have filed, or to which we will or
do have exclusive rights, may not result in issued patents or may take longer than we
expect to result in issued patents; |
|
|
|
the claims of any patents that are issued may not provide meaningful protection; |
|
|
|
our issued patents may not provide a basis for commercially viable products or may not
be valid or enforceable; |
|
|
|
we might not be able to develop additional proprietary technologies that are patentable; |
|
|
|
the patents licensed or issued to us may not provide a competitive advantage; |
|
|
|
patents issued to other companies, universities or research institutions may harm our
ability to do business; |
|
|
|
other individual companies, universities or research institutions may independently
develop or have developed similar or alternative technologies or duplicate our technologies
and commercialize discoveries that we attempt to patent; |
|
|
|
other companies, universities or research institutions may design around technologies we
have licensed, patented or developed; and |
|
|
|
many of our patent claims are method, rather than composition of matter, claims;
generally composition of matter claims are easier to enforce and are more difficult to
circumvent. |
Our business may be harmed and we may incur substantial costs as a result of litigation or other
proceedings relating to patent and other intellectual property rights.
A third party may assert that we, one of our subsidiaries or one of our strategic
collaborators has infringed his, her or its patents and proprietary rights or challenge the
validity or enforceability of our patents and proprietary rights. Likewise, we may need to resort
to litigation to enforce our patent rights or to determine the scope and validity of a third
partys proprietary rights.
We cannot be sure that other parties have not filed for or obtained relevant patents that
could affect our ability to obtain patents or operate our business. Even if we have previously
filed patent applications or obtain issued patents, others may file their own patent applications
for our inventions and technology, or improvements to our inventions and technology. We have become
aware of published patent applications filed after the issuance of our patents that, should the
owners pursue and obtain patent claims to our inventions and technology, could require us to
challenge such patent claims. Others may challenge our patent or other intellectual property rights
or sue us for infringement. In all such cases, we may commence legal proceedings to resolve our
patent or other intellectual property disputes or defend against charges of infringement or
misappropriation. An adverse determination in any litigation or administrative proceeding to which
we may become a party could subject us to significant liabilities, result in our patents being
deemed invalid, unenforceable or revoked, or drawn into an interference, require us to license
disputed rights from others, if available, or to cease using the disputed technology. In addition,
our involvement in any of these proceedings may cause us to incur substantial costs and result in
diversion of management and technical personnel. Furthermore, parties making claims against us may
be able to obtain injunctive or other equitable relief that could effectively block our ability to
develop, commercialize and sell products, and could result in the award of substantial damages
against us.
16
The outcome of these proceedings is uncertain and could significantly harm our business. If we
do not prevail in this type of litigation, we or our strategic collaborators may be required to:
|
|
|
expend time and funding to redesign our Fibrocell Therapy so that it does not infringe
others patents while still allowing us to compete in the market with a substantially
similar product; |
|
|
|
obtain a license, if possible, in order to continue manufacturing or marketing the
affected products or services, and pay license fees and royalties, which may be
non-exclusive. This license may be non-exclusive, giving our competitors access to the same
intellectual property, or the patent owner may require that we grant a cross-license to our
patented technology; or |
|
|
|
stop research and commercial activities relating to the affected products or services if
a license is not available on acceptable terms, if at all. |
Any of these events could materially adversely affect our business strategy and the value of
our business.
In addition, the defense and prosecution of intellectual property suits, interferences,
oppositions and related legal and administrative proceedings in the United States and elsewhere,
even if resolved in our favor, could be expensive and time consuming and could divert financial and
managerial resources. Some of our competitors may be able to sustain the costs of complex patent
litigation more effectively than we can because they have substantially greater financial
resources.
If we are unable to keep up with rapid technological changes, our future products may become
obsolete or unmarketable.
Our industry is characterized by significant and rapid technological change. Although we
attempt to expand our technological capabilities in order to remain competitive, research and
discoveries by others may make our future products obsolete. If we cannot compete effectively in
the marketplace, our potential for profitability and financial position will suffer.
We have not declared any dividends on our common stock to date, and we have no intention of
declaring dividends in the foreseeable future.
The decision to pay cash dividends on our common stock rests with our Board of Directors and
will depend on our earnings, unencumbered cash, capital requirements and financial condition. We do
not anticipate declaring any dividends in the foreseeable future, as we intend to use any excess
cash to fund our operations. Investors in our common stock should not expect to receive dividend
income on their investment, and investors will be dependent on the appreciation of our common stock
to earn a return on their investment.
Provisions in our charter documents could prevent or delay stockholders attempts to replace or
remove current management.
Our charter documents provide for staggered terms for the members of our Board of Directors.
Our Board of Directors is divided into three staggered classes, and each director serves a term of
three years. At stockholders meetings, only those directors comprising one of the three classes
will have completed their term and be subject to re-election or replacement.
In addition, our Board of Directors is authorized to issue blank check preferred stock, with
designations, rights and preferences as they may determine. Accordingly, our Board of Directors
may, without stockholder approval, issue shares of preferred stock with dividend, liquidation,
conversion, voting or other rights that could adversely affect the voting power or other rights of
the holders of our common stock. This type of preferred stock could also be issued to discourage,
delay or prevent a change in our control.
17
In May 2006, our Board of Directors declared a dividend of one right for each share of our
common stock to purchase our newly created Series C participating preferred stock in connection
with the adoption of a stockholder
rights plan. These rights may have certain anti-takeover effects. For example, the rights may
cause substantial dilution to a person or group that attempts to acquire us in a manner which
causes the rights to become exercisable. As such, the rights may have the effect of rendering more
difficult or discouraging an acquisition of our company which is deemed undesirable by our board of
directors.
The use of a staggered Board of Directors, the ability to issue blank check preferred stock,
and the adoption of stockholder rights plans are traditional anti-takeover measures. These
provisions in our charter documents make it difficult for a majority stockholder to gain control of
the Board of Directors and of our company. These provisions may be beneficial to our management and
our Board of Directors in a hostile tender offer and may have an adverse impact on stockholders who
may want to participate in such a tender offer, or who may want to replace some or all of the
members of our Board of Directors.
Provisions in our bylaws provide for indemnification of officers and directors, which could require
us to direct funds away from our business and future products.
Our bylaws provide for the indemnification of our officers and directors. We have in the past
and may in the future be required to advance costs incurred by an officer or director and to pay
judgments, fines and expenses incurred by an officer or director, including reasonable attorneys
fees, as a result of actions or proceedings in which our officers and directors are involved by
reason of being or having been an officer or director of our company. Funds paid in satisfaction of
judgments, fines and expenses may be funds we need for the operation of our business and the
development of our product candidates, thereby affecting our ability to attain profitability.
Future sales of our common stock may depress our stock price.
The market price of our common stock could decline as a result of sales of substantial amounts
of our common stock in the public market, or as a result of the perception that these sales could
occur, which could occur if we issue a large number of shares of common stock (or securities
convertible into our common stock) in connection with a future financing, as our common stock is
trading at low levels. These factors could make it more difficult for us to raise funds through
future offerings of common stock. As of June 8, 2010, there were 19,768,676 shares of common
stock issued and outstanding. All of our outstanding shares are freely transferable without
restriction or further registration under the Securities Act.
There is a limited, volatile and sporadic public trading market for our common stock.
There is a limited, volatile and sporadic public trading market for our common stock. Without
an active trading market, there can be no assurance of any liquidity or resale value of our common
stock, and stockholders may be required to hold shares of our common stock for an indefinite period
of time.
Lack of effectiveness of internal controls over financial reporting could adversely affect the
value of our securities.
As directed by Section 404 of the Sarbanes-Oxley Act, the SEC adopted rules requiring public
companies to include a report of management on the companys internal control over financial
reporting in their annual reports on Form 10-K that contains an assessment by management of the
effectiveness of the companys internal control over financial reporting. In addition, the
independent registered public accounting firm auditing the companys financial statements has been
required to and may be required in the future to attest to and report on the companys internal
control over financial reporting. Ineffective internal controls over our financial reporting have
occurred in the past and may arise in the future. As a consequence, our investors could lose
confidence in the reliability of our financial statements, which could result in a decrease in the
value of our securities.
18
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus
contains certain
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as information
relating to Fibrocell that is based on managements exercise of business judgment and assumptions
made by and information currently available to management. When used in this document and other
documents, releases and reports released by us, the words anticipate, believe, estimate,
expect, intend, the facts suggest and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these forward-looking
statements. These statements reflect our current view of future events and are subject to certain
risks and uncertainties as noted below. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, our actual results could differ
materially from those anticipated in these forward-looking statements. Actual events, transactions
and results may materially differ from the anticipated events, transactions or results described in
such statements. Although we believe that our expectations are based on reasonable assumptions, we
can give no assurance that our expectations will materialize. Many factors could cause actual
results to differ materially from our forward looking statements. Several of these factors include,
without limitation:
|
|
|
our ability to finance our business and continue in operations; |
|
|
|
|
whether the results of our full Phase III pivotal study and our BLA filing will
result in approval of our product candidate, and whether any approval will occur on a
timely basis; |
|
|
|
|
our ability to meet requisite regulations or receive regulatory approvals in the
United States, Europe, Asia and the Americas, and our ability to retain any regulatory
approvals that we may obtain; and the absence of adverse regulatory developments in the
United States, Europe, Asia and the Americas or any other country where we plan to
conduct commercial operations; |
|
|
|
|
whether our clinical human trials relating to the use of autologous cellular therapy
applications, and such other indications as we may identify and pursue can be conducted
within the timeframe that we expect, whether such trials will yield positive results,
or whether additional applications for the commercialization of autologous cellular
therapy can be identified by us and advanced into human clinical trials; |
|
|
|
|
our ability to develop autologous cellular therapies that have specific applications
in cosmetic dermatology, and our ability to explore (and possibly develop) applications
for periodontal disease, reconstructive dentistry, treatment of restrictive scars and
burns and other health-related markets; |
|
|
|
|
our ability to decrease our manufacturing costs for our Fibrocell Therapy product
candidates through the improvement of our manufacturing process, and our ability to
validate any such improvements with the relevant regulatory agencies; |
|
|
|
|
our ability to reduce our need for fetal bovine calf serum by improved use of less
expensive media combinations and different media alternatives; |
19
|
|
|
continued availability of supplies at satisfactory prices; |
|
|
|
|
new entrance of competitive products or further penetration of existing products in
our markets; |
|
|
|
|
the effect on us from adverse publicity related to our products or the company
itself; |
|
|
|
|
any adverse claims relating to our intellectual property; |
|
|
|
|
the adoption of new, or changes in, accounting principles; |
|
|
|
|
our issuance of certain rights to our shareholders that may have anti-takeover
effects; |
|
|
|
|
our dependence on physicians to correctly follow our established protocols for the
safe administration of our Fibrocell Therapy; and |
|
|
|
|
other risks referenced from time to time elsewhere in this prospectus and in our
filings with the SEC. |
These factors are not necessarily all of the important factors that could cause actual results
of operations to differ materially from those expressed in these forward-looking statements. Other
unknown or unpredictable factors also could have material adverse effects on our future results. We
undertake no obligation and do not intend to update, revise or otherwise publicly release any
revisions to these forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of any unanticipated events. We cannot assure you that
projected results will be achieved.
USE OF PROCEEDS
This prospectus relates to the resale of shares of our common stock issued pursuant to a
securities purchase agreement with certain accredited investors and share of our common stock to be
issued to persons who exercise warrants issued to them pursuant to the securities purchase
agreement. We will not receive any proceeds from the sale of shares of common stock in this
offering. However, to the extent the warrants are exercised for cash, as opposed to being exercised
on a cash-less basis as permitted in the warrants, we will receive proceeds from the exercise of
any warrants, up to a maximum amount of $5,373,141 (includes placement agent warrants) (assuming
the warrants are not exercised on a cash-less basis), and we will use any such proceeds for working
capital purposes.
MARKET PRICE OF AND DIVIDENDS ON OUR COMMON STOCK
AND RELATED STOCKHOLDER MATTERS
Market Information
On October 21, 2009, our common stock became available for trading OTCBB under the symbol
FCSC. Currently, there is only a limited, sporadic and volatile market for our stock on the
OTCBB. The table below presents the high and low bid price for our common stock each quarter during
the past two years and reflects inter-dealer prices, without retail markup, markdown, or
commission, and may not represent actual transactions.
|
|
|
|
|
|
|
|
|
|
|
High |
|
Low |
Year ended December 31, 2009
Fourth Quarter (from October 21, 2009)
|
|
$ |
2.40 |
|
|
$ |
0.50 |
|
Year ended December 31, 2010
First Quarter
|
|
$ |
1.18 |
|
|
$ |
0.75 |
|
The common stock of our predecessor company, Isolagen, Inc., traded on the NYSE Amex under the
symbol ILE. The common stock ceased trading on the NYSE Amex on May 6, 2009 and in June 2009 the
NYSE Amex delisted the common stock from listing on the NYSE Amex. Upon the effective date of our
bankruptcy plan,
20
the outstanding common stock of Isolagen was cancelled. Consequently, the stockholders of
Isolagen prior to the effective date of the bankruptcy plan no longer have any interest as
stockholders of Fibrocell by virtue of their ownership of Isolagens common stock prior to the
emergence from bankruptcy.
As
of June 8, 2010, there were 19,768,676 shares of our common stock outstanding and held by
203 stockholders of record. As of June 8, 2010, there were 3,250 shares of Series A Preferred
issued and outstanding.
On
June 8, 2010 the last sale price of our common stock as reported
on the OTCBB was $0.85
per share.
Dividends
We have never paid any cash dividends on our common stock and our board of directors does not
intend to do so in the foreseeable future. The declaration and payment of dividends in the future,
of which there can be no assurance, will be determined by the board of directors in light of
conditions then existing, including earnings, financial condition, capital requirements and other
factors.
Holders of the Series A Preferred are entitled to receive cumulative dividends at the rate per
share (as a percentage of the stated value per share) of 6% per annum (subject to increase in
certain circumstances), payable quarterly in arrears on January 15, April 15, July 15 and October
15, beginning on April 15, 2010. The dividends are payable in cash, or at our option, in duly
authorized, validly issued, fully paid and non-assessable shares of common stock equal to 110% of
the cash dividend amount payable on the dividend payment date, or a combination thereof; provided
that we may not pay the dividends in shares of common stock unless we meet certain conditions
described in the Certificate of Designation. If we pay the dividend in shares of common stock, the
common stock will be valued for such purpose at 80% of the average of the volume weighted average
price for the 10 consecutive trading days ending on the trading day that is immediately prior to
the dividend payment date.
Shares of common stock issued as dividends on the Series A Preferred are not being registered
under this prospectus. Such shares are deemed to be restricted securities under Rule 144 of the
Securities Act and may only be sold in compliance with Rule 144.
Penny Stock
The SEC has adopted rules that regulate broker-dealer practices in connection with
transactions in penny stocks. Our stock is currently a penny stock. Penny stocks are generally
equity securities with a price of less than $5.00, other than securities registered on certain
national securities exchanges. The penny stock rules require a broker-dealer, prior to a
transaction in a penny stock not otherwise exempt from those rules, deliver a standardized risk
disclosure document prepared by the SEC, which: (a) contains a description of the nature and level
of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains
a description of the brokers or dealers duties to the customer and of the rights and remedies
available to the customer with respect to a violation to such duties or other requirements of
securities laws; (c) contains a brief, clear, narrative description of a dealer market, including
bid and ask prices for penny stocks and significance of the spread between the bid and ask price;
(d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines
significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f)
contains such other information and is in such form as the SEC shall require by rule or regulation.
The broker-dealer also must provide to the customer, prior to effecting any transaction in a penny
stock, (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer
and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices
apply, or other comparable information relating to the depth and liquidity of the market for such
stock; and (d) monthly account statements showing the market value of each penny stock held in the
customers account. In addition, the penny stock rules require that prior to a transaction in a
penny stock not otherwise exempt from those rules, the broker-dealer must make a special written
determination that the penny stock is a suitable investment for the purchaser and receive the
purchasers written acknowledgment of the receipt of a risk disclosure statement, a written
agreement to transactions involving penny stocks, and a signed and dated copy of a written suitably
statement.
21
These disclosure requirements may have the effect of reducing the trading activity in the
secondary market for our stock.
MANAGEMENTS
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF
OPERATIONS
Overview
We are an aesthetic and therapeutic development stage biotechnology company focused on
developing novel skin and tissue rejuvenation products. Our clinical development product candidates
are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne
and burn scars with a patients own, or autologous, fibroblast cells produced by our proprietary
Fibrocell process. Our clinical development programs encompass both aesthetic and therapeutic
indications. Our most advanced indication is for the treatment of nasolabial folds/wrinkles (United
States adopted name, or USAN, is azficel-T) and has completed Phase III clinical studies, and the
related Biologics License Application, or BLA, has been submitted to the Food and Drug
Administration, or FDA. In October 2009, the FDAs Cellular, Tissue and Gene Therapies Advisory
Committee reviewed this indication. On December 21, 2009, Fibrocell Science received a Complete
Response letter from the FDA related to the BLA for azficel-T. A Complete Response letter is issued
by the FDAs Center for Biologics Evaluation and Research (CBER) when the review of a file is
completed and additional data are needed prior to approval. The Complete Response letter requested
that we provide data from a histopathological study on biopsied tissue samples from patients
following injection of azficel-T. The letter also requested finalized Chemistry, Manufacturing and
Controls (CMC) information regarding the manufacture of azficel-T as follow-up to discussions that
occurred during the BLA review period, as well as revised policies and procedures regarding
shipping practices, and proposed labeling.
During 2009 we completed a Phase II/III study for the treatment of acne scars. During 2008 we
completed our open-label Phase II study related to full face rejuvenation.
We also develop and market an advanced skin care product line through our Agera subsidiary, in
which we acquired a 57% interest in August 2006.
Emergence from Voluntary Reorganization Under Chapter 11 Proceedings and Reorganization Plan
Fibrocell emerged from Chapter 11 on September 3, 2009. See Note 1 in the accompanying
Consolidated Financial Statements.
Going Concern
The Successor Company emerged from Bankruptcy in September 2009 and continues to operate as a
going concern. At March 31, 2010, the Successor Company had cash and cash equivalents of
approximately $2.5 million and working capital of $2.0 million. In early March 2010, the Successor
Company raised approximately $3.8 million less fees as a result of the issuance of common stock and
warrants. The Successor Company believes that its existing capital resources are adequate to
sustain its operation through approximately mid-June 2010. As such, the Successor Company will
require additional cash resources prior to or during approximately mid-June 2010, or it will likely
cease operations. The Successor Company will need to access the capital markets in the future in
order to fund future operations. There is no guarantee that any such required financing will be
available on terms satisfactory to the Successor Company or available at all. These matters create
uncertainty relating to its ability to continue as a going concern. The accompanying consolidated
financial statements do not reflect any adjustments relating to the recoverability and
classification of assets or liabilities that might result from the outcome of these uncertainties.
Further, if the Successor Company raises additional cash resources prior to mid-June 2010, it
may be raised in contemplation of or in connection with bankruptcy. In the event of a bankruptcy,
it is likely that its common stock and common stock equivalents will become worthless and our
creditors will receive significantly less than what is owed to them.
Through March 31, 2010, the Successor Company has been primarily engaged in developing its
initial product technology. In the course of its development activities, the Company has sustained
losses and expects such losses to continue through at least 2010. During the three months ended
March 31, 2010, the Successor Company
financed its operations primarily through its existing cash, but as discussed above it now
requires additional financing. There is substantial doubt about the Successor Companys ability to
continue as a going concern.
The Successor Companys ability to complete additional offerings is dependent on the state of
the debt and/or equity markets at the time of any proposed offering, and such markets reception of
the Successor Company and the offering terms. The Successor Companys ability to complete an
offering is also dependent on the status of its FDA regulatory milestones and its clinical trials,
and in particular, the status of its indication for the treatment of nasolabial fold wrinkles and
the status of the related BLA, which cannot be predicted. There is no assurance that capital in any
form would be available to the Company, and if available, on terms and conditions that are
acceptable.
As a result of the conditions discussed above, and in accordance with GAAP, there exists
substantial doubt about the Successor Companys ability to continue as a going concern, and its
ability to continue as a going concern is contingent, among other things, upon its ability to
secure additional adequate financing or capital prior to or during approximately mid-June 2010. If
the Successor Company does not obtain additional funding, or does not anticipate additional
funding, prior to or during approximately mid-June 2010, it will likely enter into bankruptcy
and/or cease operations. Further, if it does raise additional cash resources prior to mid-June
2010, it may be raised in contemplation of or in connection with bankruptcy. If the Successor
Company enters into bankruptcy, it is likely that its common stock and common stock equivalents
will become worthless and its creditors will receive significantly less than what is owed to them.
Basis of Presentation
As of September 1, 2009, the Successor Company adopted fresh-start accounting in accordance
with ASC 852-10, Reorganizations. The Successor Company selected September 1, 2009, as the date to
effectively apply fresh-start accounting based on the absence of any material contingencies at the
August 27, 2009 confirmation hearing and the immaterial impact of transactions between August 27,
2009 and September 1, 2009. The adoption of fresh-start accounting resulted in the Successor
Company becoming a new entity for financial reporting purposes.
Accordingly, the financial statements prior to September 1, 2009 are not comparable with the
financial statements for periods on or after September 1, 2009. References to Successor or
Successor Company refer to the Company on or after September 1, 2009, after giving effect to the
cancellation of Isolagen, Inc. common stock issued prior to the Effective Date, the issuance of new
Fibrocell Science, Inc. common stock in accordance with the Plan, and the application of
fresh-start accounting. References to Predecessor or Predecessor Company refer to the Company
prior to September 1, 2009. See Note 5 Fresh Start Accounting in the notes to these
Consolidated Financial Statements for further details.
For discussions on the results of operations, the Successor Company has compared the results
of operations for the three months ended March 31, 2010, with the results of operations for the
three months ended March 31, 2009. The Successor Company believes that the comparison of the
financial results provide management and investors a more meaningful analysis of the Companys
performance and trends.
The following discussion should be read in conjunction with the Consolidated Financial
Statements and the accompanying Notes to the Consolidated Financial Statements in Part 1, Item 1 of
this report.
Results of OperationsComparison of the three months ended March 31, 2010 and 2009
REVENUES. Revenue remained relatively constant at $0.2 million for the three months ended
March 31, 2010 and for the three months ended March 31, 2009. Our revenue from continuing
operations is from the operations of Agera which we acquired on August 10, 2006. Agera markets and
sells a complete line of advanced skin care systems based on a wide array of proprietary
formulations, trademarks and non-peptide technology. Due to our financial statement presentation of
our United Kingdom operation as a discontinued operation, our revenue for all periods presented is
representative of only Agera, as all historical United Kingdom revenue is reflected in loss from
discontinued operations.
COST OF SALES. Cost of sales remained constant at $0.1 million for the three months ended
March 31, 2010 and March 31, 2009. Our cost of sales relates to the operation of Agera. As a
percentage of revenue, Agera cost of sales were approximately 48% for the three months ended March
31, 2010 and 40% for the three months ended March 31, 2009. Cost of sales as a percentage of
revenue has increased primarily due to the impact of a physical inventory adjustment in the first
quarter of 2010 and increased costs of components.
SELLING, GENERAL AND
ADMINISTRATIVE EXPENSES. Selling, general and administrative expenses
increased by approximately $0.8 million, or 68%, to $2.0 million for the three months
ended March 31, 2010 as compared to $1.2 million for the three months ended March 31, 2009. The increase primarily relates to a $0.3 million increase
in payroll related expenses, $0.2 million increase related to general and administrative expenses
associated with consultants for financing and marketing as well as office expenses and $0.3 million increase related to
legal expenses. Legal expenses for the three months ended March 31, 2009 were ($0.2) million due to a
$0.3 million reimbursement received from our insurance carrier related to defense costs associated
with our class action and derivative matters. Had we not received this reimbursement, legal
expenses for the three months ended March 31, 2010 and March 31, 2009 would have been consistent at $0.1
million.
RESEARCH AND DEVELOPMENT. Research and development expenses increased by approximately $0.2
million, or 18%, to $1.2 million for the three months ended March 31, 2010 as compared to $1.0 for
the three months ended March 31, 2009. The increase primarily relates to a $0.1 million increase
in payroll related expenses and $0.1 million increase in laboratory costs associated with clinical
and manufacturing activities in our Exton, Pennsylvania location. Research and development costs
are composed primarily of costs related to our efforts to gain FDA approval for our Fibrocell
Therapy for specific dermal applications in the United States, as well as costs related to other
potential indications for our Fibrocell Therapy, such as acne scars and burn scars. Also, research
and development expense includes costs to develop manufacturing, cell collection and logistical
process improvements. Research and development costs primarily include personnel and laboratory
costs related to these FDA trials and certain consulting costs. The total inception (December 28,
1995) cost of research and development as of August 31, 2009 for the Predecessor Company was $56.3
million and total inception (September 1, 2009) to date cost of research and development as of
March 31, 2010, for the Successor Company was $3.0 million.
The FDA approval process is extremely complicated and is dependent upon our study protocols
and the results of our studies. In the event that the FDA requires additional studies for our
product candidate or requires changes in our study protocols or in the event that the results of
the studies are not consistent with our expectations, the process will be more expensive and time
consuming. Due to the complexities of the FDA approval process, we are unable to predict what the
cost of obtaining approval for our dermal product candidate will be.
LOSS FROM DISCONTINUED OPERATIONS. Discontinued operations had a loss of less than $0.1
million for the three months ended March 31, 2010 and the three months ended March 31, 2009.
Administrative
costs related primarily to the Swiss operations comprised approximately less than $0.1 million
during the three months ended March 31, 2010 and the three months ended March 31, 2009.
22
REORGANIZATION ITEMS, NET. On June 15, 2009, Isolagen, Inc. and its wholly-owned, U.S.
subsidiary Isolagen Technologies, Inc., filed voluntary petitions for relief under Chapter 11 of
the federal bankruptcy laws in the United States Bankruptcy Court for the District of Delaware, as
more fully discussed under Note 1 in the accompanying Consolidated Financial Statements. A
reorganization gain, net of reorganization costs, of less than $0.1 million was recorded for the
three months ended March 31, 2010, which was comprised primarily of administrative costs offset by
the gain of discharge of liabilities.
INTEREST EXPENSE. Interest expense decreased $0.8 million to $0.2 million for the three months
ended March 31, 2010, as compared to $1.0 million for the three months ended March 31, 2009. Our
2010 interest expense is related to our $6.0 million (in original principal amount) 12.5% notes.
Our 2009 interest expense is related to our 3.5% convertible subordinated notes, of which $89.7
million was outstanding at March 31, 2009, as well as the related amortization of deferred debt
issuance costs of $0.2 million, for the three months ended March 31, 2009. With the emergence out
of bankruptcy, the 3.5% convertible subordinated notes were exchanged for $6.0 million of debt and
3,960,000 shares of the new common stock.
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS. Net loss attributable to common shareholders
increased approximately $1.6 million to a net loss of $4.7 million for the three months ended March
31, 2010, as compared to a net loss of $3.1 million for the three months ended March 31, 2009. This
increase in loss primarily represents the recording of the revaluation of the warrant liability for
the preferred stock issued in October 2009 and the warrant liability attached to the common shares
issued in March 2010.
23
Results of OperationsComparison of Years Ending December 31, 2009 and 2008
REVENUES. Revenue decreased $0.2 million to $0.9 million for the year ended December 31,
2009, as compared to $1.1 million for the year ended December 31, 2008. Our revenue from continuing
operations is from the operations of Agera which we acquired on August 10, 2006. Agera markets and
sells a complete line of advanced skin care systems based on a wide array of proprietary
formulations, trademarks and non-peptide technology. Due to our financial statement presentation of
our United Kingdom operation as a discontinued operation, our revenue for all periods presented is
representative of only Agera, as all historical United Kingdom revenue is reflected in loss from
discontinued operations. We believe that the decline in Ageras sales in fiscal 2009 was due to the
general economic conditions during 2009.
COST OF SALES. Costs of sales remained constant at $0.6 million for the year ended December
31, 2009 and December 31, 2008. Our cost of sales relates to the operation of Agera. As a
percentage of revenue, Agera cost of sales were approximately 70% for the year ended December 31,
2009 and 55% for the year ended December 31, 2008. Cost of sales as a percentage of revenue has
increased primarily due to a reserve recorded during the three months ended September 30, 2009 of
approximately $0.2 million, as compared to a reserve of less than $0.1 million recorded for slow
moving and/or obsolete inventory recorded during the three months ended September 30, 2008, and
changes in Ageras product mix.
IMPAIRMENT OF LONG-LIVED ASSETS. There was no impairment of assets in 2009. During 2008, due
to the likelihood of bankruptcy and in connection with the Companys review for impairment of
long-lived assets in accordance with ASC 360, Accounting for the Impairment or Disposal of
Long-lived Assets, we recorded a full
impairment on all of our long-lived assets as of December 31, 2008 in the consolidated statement of
operations, and as such, we have recorded an impairment charge of $6.7 million during the year
ended December 31, 2008.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. Selling, general and administrative expenses
decreased approximately $2.4 million, or 28%, to $6.1 million for the year ended December 31, 2009,
as compared to $8.5 million for the year ended December 31, 2008. The decrease in selling, general
and administrative expense is primarily due to the following:
a) Salaries, bonuses and payroll taxes decreased by approximately $1.0 million to $2.8
million for the year ended December 31, 2009, as compared to $3.8 million for the year ended
December 31, 2008, due to a decrease in the number of our employees which resulted in lower
salary expense.
b) Marketing expense decreased by less than $0.1 million to less than $0.1 million for
the year ended December 31, 2009, as compared to $0.1 million during the year ended December
31, 2008 due primarily to decreased marketing and promotional efforts related to marketing and
selling our Agera line of advanced skin care systems.
c) Travel expense decreased by approximately $0.1 million to $0.1 million for the year
ended December 31, 2009, as compared to $0.2 million for the year ended December 31, 2008 due
to the decrease in the number of our employees, primarily at the executive management level and
focused efforts to conserve cash resources during 2009.
d) Other general and administrative expenses decreased by approximately $1.1 million
to $3.0 million for the year ended December 31, 2009, as compared to $4.1 million for the year
ended December 31, 2008. The decrease of $1.1 million in other general and administrative
expenses are due to cost-saving measures continued during 2009, including savings related to
accounting and audit expenses, insurance premiums, consultants and other general costs.
e) Legal expenses decreased by approximately $0.1 million to $0.2 million for the
year ended December 31, 2009, as compared to $0.3 million for the year ended December 31, 2008.
For the years ended December 31, 2009 and December 30, 2008, we received $0.3 million and $1.3
million, respectively, of reimbursements from our insurance carrier as reimbursement for
defense costs related to our class action and derivative matters. If we had not received these
reimbursements, our legal expenses would have been $0.5 million for the year ended December 31,
2009 and $1.6 million for the year ended December 31, 2008. As such, excluding reimbursements
of legal defense costs, our legal expenses have decreased $1.1 million in 2009 from the prior
year as a result of the June 2008 mediation efforts which resulted in a settlement in principle
related to our class action and derivative action matters. Our legal expenses fluctuated
primarily as a result of the amount and timing of defense costs related to our class action and
derivative action matters, as well as a result of the amount and timing of defense cost
reimbursements from our insurance carrier. Such reimbursements are recorded when received. We
also incurred $0.2 million in legal costs, during the year ended December 31, 2008, related to
investigating and responding to claims related to our previous United Kingdom operation.
RESEARCH AND DEVELOPMENT. Research and development expenses decreased by approximately $6.3
million for the year ended December 31, 2009 to $3.9 million, as compared to $10.2 million for the
year ended December 31, 2008. Research and development costs are composed primarily of costs
related to our efforts to gain FDA approval for our Fibrocell Therapy for specific dermal
applications in the United States, as well as costs related to other potential indications for our
Fibrocell Therapy, such as acne scars and burn scars. Also, research and development expense
includes costs to develop manufacturing, cell collection and logistical process improvements.
Research and development costs primarily include personnel and laboratory costs related to these
FDA trials and certain consulting costs. The total inception cost of research and development as of
August 31, 2009 for the Predecessor Company was $56.3 million and total inception (September 1,
2009) to date cost of research and development as of December 31, 2009, for the Successor Company
was $1.8 million.
24
The FDA approval process is extremely complicated and is dependent upon our study protocols
and the results of our studies. In the event that the FDA requires additional studies for our
product candidate or requires
changes in our study protocols or in the event that the results of the studies are not
consistent with our expectations, the process will be more expensive and time consuming. Due to the
complexities of the FDA approval process, we are unable to predict what the cost of obtaining
approval for our dermal product candidate will be.
The major changes in research and development expenses are due primarily to the following:
a) Consulting expense decreased by approximately $3.3 million to $1.6 million for the year
ended December 31, 2009, as compared to $4.9 million for the year ended December 31, 2008,
primarily as a result of decreased expenditures related to our Phase III wrinkle/nasolabial fold
study, which concluded during 2008.
b) Salaries, bonuses and payroll taxes decreased by approximately $1.5 million to $0.9 million
for the year ended December 31, 2009, as compared to $2.4 million for the year ended December 31,
2008, as a result of decreased employees engaged in research and development activities.
c) Laboratory costs decreased by approximately $0.4 million to $0.6 million for the year ended
December 31, 2009, as compared to $1.0 million for the year ended December 31, 2008, as a result of
decreased clinical and manufacturing activities in our Exton, Pennsylvania location, primarily due
to the completion of the Phase III nasolabial folds trials during 2008.
d) Contract labor support related to our clinical manufacturing operation decreased $0.2
million to less than $0.1 million for the year ended December 31, 2009, as compared to $0.2 million
for the year ended December 31, 2008, as a result of decreased clinical activities in our Exton,
Pennsylvania location.
e) Facilities, depreciation and travel costs decreased $0.9 million to $0.8 million for the
year ended December 31, 2009 as compared to $1.7 million for the year ended December 31, 2008. The
decrease is due primarily to the impairment of fixes assets at December 31, 2008 resulting in no
depreciation for 2009.
LOSS FROM DISCONTINUED OPERATIONS.
Discontinued operations had income of less than $0.1 million for the year ended December 31,
2009 as compared to a loss of $4.5 million for the year ended December 31, 2008. The $4.5 million
loss from discontinued operations for the year ended December 31, 2008, primarily related to the
sale of our Swiss campus in March 2008. In connection with this sale, we recorded a loss on sale of
$6.3 million, offset by a foreign currency exchange gain of $2.1 million upon the substantial
liquidation of the Swiss subsidiary. The foreign exchange gain recorded during the three months
ended March 31, 2008 results from removing from the accumulated foreign currency translation
adjustment account in stockholders equity, a credit balance which related to the translation into
U.S. dollars of our Swiss franc assets and liabilities. The credit balance which had accumulated,
and the resulting gain recorded upon the substantial liquidation of our Swiss franc assets,
reflected the increase in the value of the Swiss franc relative to the U.S. dollar over the period
that we had operated in Switzerland. Administrative costs and facility costs related to the United
Kingdom and Swiss operations comprised approximately $0.3 million, net, during the year ended
December 31, 2008.
As of December 31, 2008, all previously leased facilities related to discontinued operations
have been exited, and all buildings, property and equipment related to discontinued operations have
been sold or otherwise disposed of.
INTEREST INCOME. Interest income decreased approximately $0.2 million to less than $0.1
million for the year ended December 31, 2009, as compared to $0.2 million for the year ended
December 31, 2008. The decrease in interest income of $0.2 million resulted from a decrease in the
amount of cash, cash equivalents and restricted cash balances, as a result of our use of these
balances primarily to fund our operating activities related to our efforts to gain FDA approval for
our Fibrocell Therapy.
REORGANIZATION ITEMS, NET. On June 15, 2009, Isolagen, Inc. and its wholly-owned, U.S.
subsidiary Isolagen Technologies, Inc., filed voluntary petitions for relief under Chapter 11 of
the federal bankruptcy laws in the United States Bankruptcy Court for the District of Delaware, as
more fully discussed under Bankruptcy, Debt and Going Concern. A reorganization gain, net of
reorganization costs, of $73.5 million was
recorded for the year ended December 31, 2009, which was comprised primarily of legal fees and
the unamortized debt acquisition costs, and gain of discharge of liabilities.
25
INTEREST EXPENSE. Interest expense decreased $1.4 million to $2.5 million for the year ended
December 31, 2009, as compared to $3.9 million for the year ended December 31, 2008. Our interest
expense is related to our $90.0 million, 3.5% convertible subordinated notes, as well as the
related amortization of deferred debt issuance costs of $0.1 million and interest expense related
to the secured bridge loan and DIP financing until the emergence out of bankruptcy for the year
ended December 31, 2009. With the emergence out of bankruptcy, the 3.5% convertible subordinated
notes were exchanged for $6.0 million of debt and 3,960,000 shares of the new common stock. There
is also interest expense related to the 12.5% note for the year end December 31, 2009. For the year
ended December 31, 2008, our interest expense is related to our $90.0 million, 3.5% convertible
subordinated notes, as well as the related amortization of deferred debt issuance costs of $0.8
million.
NONCONTROLLING INTEREST. The noncontrolling interest loss was $0.2 million for the year ended
December 31, 2009, as compared to noncontrolling interest income of $1.7 million for the year ended
December 31, 2008. The decrease in minority interest income of $1.5 million is primarily due to an
impairment charge recorded during the year ended December 31, 2008 of $3.7 million, which related
to the full impairment of the Agera segment intangible assets, and the associated 43% minority
interest ownership of Agera.
NET INCOME/(LOSS). Net loss, excluding reorganization items, was $12.8 million for the year
ended December 31, 2009 as compared to a net loss of $31.4 million for the year ended December 31,
2008. This decrease in our net loss primarily is a result of a decrease in research and development
expenses, general and administrative expenses, the reduction in employees and compensation expense
and cost saving measures continued in 2009, offset by the impairment charge of $6.7 million related
to long-lived assets for the year ended December 31, 2008, the increase in loss from discontinued
operations and reductions in interest income, as discussed above. Net income of $60.7 million for
the year ended December 31, 2009, included reorganization items of $73.5 million as a result of the
emergence out of bankruptcy and discharge of debt and unsecured liabilities.
Liquidity and Capital Resources
Cash Flows
Net cash provided by (used in) operating, investing and financing activities for the three
months ended March 31, 2010 and 2009, respectively, were as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2010 |
|
|
2009 |
|
|
|
(in millions) |
|
Cash flows from operating activities |
|
$ |
(2.3 |
) |
|
$ |
(2.0 |
) |
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
3.4 |
|
|
|
|
|
OPERATING ACTIVITIES. Cash used in operating activities during the three months ended March
31, 2010 amounted to $2.3 million, an increase of $0.3 million over the three months ended March
31, 2009. The increase in our cash used in operating activities over the prior year is primarily
due to an increase in net losses (adjusted for non-cash items) of $0.2 million, in addition to
operating cash inflows from changes in operating assets and liabilities.
Our negative operating cash flows for the three months ended March 31, 2010 were funded from
cash on hand at December 31, 2009, which were primarily the result of previously completed debt and
equity offerings as well as funds received from the secured bridge loan, DIP financing, exit
financing and the funds received for the issuance of preferred stock in 2009. Funds were also
received from the proceeds of the issuance of common stock in March 2010, discussed further below.
INVESTING ACTIVITIES. Less than $0.1 million cash was provided by or used for investing
activities during the three months ended March 31, 2010 and the three months ended March 31, 2009.
FINANCING ACTIVITIES. There was $3.4 million, net of fees, cash proceeds from financing
activities during the three months ended March 31, 2010, as compared to no cash received from
financing activities during the three months ended March 31, 2009. In March 2010, we sold to
investors in the aggregate 5,076,664 shares of
Company common stock at a purchase price of $0.75 per share. Each purchaser also received a
warrant to purchase the same number of shares of common stock acquired in the offering at an
exercise price of $0.98 per share.
Working Capital
As of March 31, 2010, we had cash and cash equivalents of approximately $2.5 million and
working capital of $2.0 million. As discussed in the above paragraph, in early March 2010, we
raised approximately $3.4 million, net of fees as a result of the issuance of common stock and
warrants. We believe that our existing capital resources are adequate to sustain our operation
through approximately mid-June 2010. As such, we will require additional cash resources prior to or
during approximately mid-June 2010, or we will likely cease operations. Even if we are able to
obtain financing prior to mid-June 2010, we will need to access the capital markets in the future
in order to continue to fund future operations. There is no guarantee that any such required
financing will be available on terms satisfactory to us or available at all. These matters create
uncertainty relating to our ability to continue as a going concern. The accompanying consolidated
financial statements do not reflect any adjustments relating to the recoverability and
classification of assets or liabilities that might result from the outcome of these uncertainties.
Factors Affecting Our Capital Resources
Inflation did not have a significant impact on the Companys results during the three months
ended March 31, 2010.
26
Off-Balance Sheet Transactions
We do not engage in material off-balance sheet transactions.
Critical Accounting Policies
The
preceding discussion and analysis of financial condition and results of operations are
based upon our consolidated financial statements, which have been prepared in conformity with
accounting principles generally accepted in the United States of America. However, certain
accounting policies and estimates are particularly important to the understanding of our financial
position and results of operations and require the application of significant judgment by our
management or can be materially affected by changes from period to period in economic factors or
conditions that are outside of the control of management. As a result they are subject to an
inherent degree of uncertainty. In applying these policies, our management uses their judgment to
determine the appropriate assumptions to be used in the determination of certain estimates. Those
estimates are based on our historical operations, our future business plans and projected financial
results, the terms of existing contracts, our observance of trends in the industry, information
provided by our customers and information available from other outside sources, as appropriate. The
following discusses our critical accounting policies and estimates.
Warrant Liability: The warrants for the Successor Company are measured at fair value and
liability-classified under ASC 815, Derivatives and Hedging, (ASC 815) because the warrants
contain down-round protection and therefore, do not meet the scope exception for treatment as a
derivative under ASC 815. Since down-round protection is not an input into the calculation of
the fair value of the warrants, the warrants cannot be considered indexed to the Companys own
stock which is a requirement for the scope exception as outlined under ASC 815. The fair value of
the warrants is determined using the Black-Scholes option pricing model and is affected by changes
in inputs to that model including our stock price, expected stock price volatility, the contractual
term, and the risk-free interest rate. We will continue to classify the fair value of the warrants
as a liability until the warrants are exercised, expire or are amended in a way that would no
longer require these warrants to be classified as a liability.
Stock-Based Compensation: We account for stock-based awards to employees and non-employees
using the fair value based method to determine compensation for all arrangements where shares of
stock or equity instruments are issued for compensation. We use a Black-Scholes options-pricing
model to determine the fair value of each option grant as of the date of grant for expense
incurred. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield,
volatility and expected lives of the options. Expected volatility is based on historical
volatility of our competitors stock since the Predecessor Company ceased trading as part of the
bankruptcy and emerged as a new entity. The risk-free rate for periods within the contractual
life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant.
The expected lives for options granted represents the period of time that options granted are
expected to be outstanding and is derived from the contractual terms of the options granted. We
estimate future forfeitures of options based upon expected forfeiture rates.
27
Research and Development Expenses: Research and development costs are expensed as incurred
and include salaries and benefits, costs paid to third-party contractors to perform research,
conduct clinical trials, develop and manufacture drug materials and delivery devices, and a portion
of facilities cost. Clinical trial costs are a significant component of research and development
expenses and include costs associated with third-party contractors. Invoicing from third-party
contractors for services performed can lag several months. We accrue the costs of services rendered
in connection with third-party contractor activities based on our estimate of management fees, site
management and monitoring costs and data management costs. Actual clinical trial costs may differ
from estimated clinical trial costs and are adjusted for in the period in which they become known.
Recently Issued Accounting Pronouncements
In October 2009, the FASB issued ASU No. 2009-13, Multiple-Deliverable Revenue Arrangements,
or ASU 2009-13. ASU 2009-13, amends existing revenue recognition accounting pronouncements that
are currently within the scope of FASB ASC Topic 605. This consensus provides accounting
principles and application guidance on how the arrangement should be separated, and the
consideration allocated. This guidance changes how to determine the fair value of undelivered
products and services for separate revenue recognition. Allocation of consideration is now based
on managements estimate of the selling price for an undelivered item where there is no other means
to determine the fair value of that undelivered item. This new approach is effective prospectively
for revenue arrangements entered into or materially modified in fiscal years beginning on or after
June 15, 2010.
In March 2010, the FASB ratified EITF Issue No. 08-9, Milestone Method of Revenue Recognition,
that the milestone method is a valid application of the proportional performance model for revenue
recognition if the milestones are substantive and there is substantive uncertainty about whether
the milestones will be achieved. The Task Force agreed that whether a milestone is substantive is
a judgment that should be made at the inception of the arrangement. To meet the definition of a
substantive milestone, the consideration earned by achieving the milestone (1) would have to be
commensurate with either the level of effort required to achieve the milestone or the enhancement
in the value of the item delivered, (2) would have to relate solely to past performance, and (3)
should be reasonable relative to all deliverables and payment terms in the arrangement. No
bifurcation of an individual milestone is allowed and there can be more than one milestone in an
arrangement. The new guidance will be effective for interim and annual periods beginning on or
after June 15, 2010.
28
BUSINESS AND PROPERTY
Overview
We are an aesthetic and therapeutic development stage biotechnology company focused on
developing novel skin and tissue rejuvenation products. Our clinical development product candidates
are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne
and burn scars with a patients own, or autologous, fibroblast cells produced by our proprietary
Fibrocell process. Our clinical development programs encompass both aesthetic and therapeutic
indications. Our most advanced indication is for the treatment of nasolabial folds/wrinkles (United
States adopted name, or USAN, is azficel-T) and has completed Phase III clinical studies, and the
related Biologics License Application, or BLA, has been submitted to the Food and Drug
Administration, or FDA. In October 2009, the FDAs Cellular, Tissue and Gene Therapies Advisory
Committee reviewed this indication. On December 21, 2009, Fibrocell Science received a Complete
Response letter from the FDA related to the BLA for azficel-T. A Complete Response letter is issued
by the FDAs Center for Biologics Evaluation and Research (CBER) when the review of a file is
completed and additional data are needed prior to approval. The Complete Response letter requested
that we provide data from a histopathological study on biopsied tissue samples from patients
following injection of azficel-T. The letter also requested finalized Chemistry, Manufacturing and
Controls (CMC) information regarding the manufacture of azficel-T as follow-up to discussions that
occurred during the BLA review period, as well as revised policies and procedures regarding
shipping practices, and proposed labeling. In addition, the Company has submitted a proposed protocol concerning a histopathological study on biopsied samples
to the FDA and to the Companys Investigational Review Board
(IRB). The IRB has approved the protocol and the Company received the
comments from the FDA on the protocol in May 2010.
During 2009 we completed a Phase II/III study for the treatment of acne scars. During 2008 we
completed our open-label Phase II study related to full face rejuvenation.
We also develop and market an advanced skin care product line through our Agera subsidiary, in
which we acquired a 57% interest in August 2006.
Exit from Bankruptcy
On August 27, 2009, the United States Bankruptcy Court for the District of Delaware in
Wilmington entered an order, or Confirmation Order, confirming the Joint First Amended Plan of
Reorganization dated July 30, 2009, as supplemented by the Plan Supplement dated August 21, 2009,
or the Plan, of Isolagen, Inc. and Isolagens wholly owned subsidiary, Isolagen Technologies, Inc.
The effective date of the Plan was September 3, 2009. Isolagen, Inc. and Isolagen Technologies,
Inc. were subsequently renamed Fibrocell Science, Inc. and Fibrocell Technologies, Inc.,
respectively.
Our officers and directors as of the effective date were all deemed to have resigned and a new
board of directors was appointed. As of the effective date, our initial board of directors
consisted of: David Pernock, Paul Hopper and Kelvin Moore. Dr. Robert Langer was appointed to the
Board in late September 2009. Declan Daly remained as chief operating officer and chief financial
officer of the reorganized company, and in November 2009, he was appointed to the Board of
Directors. Mr. Daly also acted as interim chief executive officer until February 1, 2010 when
David Pernock became the chief executive officer.
Pursuant to the Plan, all our equity interests, including without limitation our common stock,
options and warrants outstanding as of the effective date were cancelled. On the effective date, we
completed an exit financing of common stock in the amount of $2 million, after which the equity
holders of our Successor Company were:
|
|
|
7,320,000 shares, to our pre-bankruptcy lenders and the lenders that provided us our
debtor-in-possession facility, collectively; |
|
|
|
|
3,960,000 shares, to the holders of our 3.5% convertible subordinated notes; |
|
|
|
|
600,000 shares, to our management as of the effective date, which was our chief
operating officer; |
|
|
|
|
120,000 shares, to the holders of our general unsecured claims; and |
|
|
|
|
2,666,666 shares, to the purchasers of shares in the $2 million exit financing (our
pre-bankruptcy lenders, the lenders that provided us our debtor-in-possession facility and
the holders of our 3.5% convertible subordinated notes were permitted to participate in our
exit financing). |
29
In the Plan, in addition to the common stock set forth above, each holder of Isolagens 3.5%
convertible subordinated notes, due November 2024, in the approximate non-converted aggregate
principal amount of $81 million, received, in full and final satisfaction, settlement, release and
discharge of and in exchange for any and all claims arising out of the 3.5% convertible
subordinated notes, its pro rata share of an unsecured note in the principal amount of $6 million,
or the New Note. The New Note has the following features:
|
|
|
12.5% interest payable quarterly in cash or, at our option, 15% payable in kind by
capitalizing such unpaid amount and adding it to the principal as of the date it was due; |
|
|
|
|
matures June 1, 2012; |
|
|
|
|
at any time prior to the maturity date, we may redeem any portion of the outstanding
principal of the New Notes in cash at 125% of the stated face value of the New Notes;
provided that we will be obligated to redeem all outstanding New Notes upon the following
events: (a) we or our subsidiary, Fibrocell Technologies, Inc. (formerly, Isolagen
Technologies, Inc.) successfully complete a capital campaign raising in excess of
$10,000,000; or (b) we or our subsidiary, Fibrocell Technologies, Inc., are acquired by, or
sell a majority stake to, an outside party; |
|
|
|
|
the New Notes contain customary representations, warranties and covenants, including
a covenant that we and our subsidiary, Fibrocell Technologies, Inc., shall be prohibited
from the incurrence of additional debt without obtaining the consent of 66 2/3% of the New
Note holders. |
30
Fibrocell Sciences Technology Platform
We use our proprietary Fibrocell Science Process to produce an autologous living cell therapy.
We refer to this autologous living cell therapy as the Fibrocell Therapy. We believe this therapy
addresses the normal effects of aging or injury to the skin. Each of our product candidates is
designed to use Fibrocell Therapy to treat an indicated condition. We use our Fibrocell Science
Process to harvest autologous fibroblasts from a small skin punch biopsy from behind the ear with
the use of a local anesthetic. We chose this location both because of limited exposure to the sun
and to avoid creating a visible scar. In the case of our dental product candidate, the biopsy is
taken from the patients palette. The biopsy is then packed in a vial in a special shipping
container and shipped to our laboratory where the fibroblast cells are released from the biopsy and
initiated into our cell culture process where the cells proliferate until they reach the required
cell count. The fibroblasts are then harvested, tested by quality control and released by quality
assurance prior to shipment. The number of cells and the frequency of injections may vary and will
depend on the indication or application being studied.
If and when approved, we expect our product candidates will offer patients their own living
fibroblast cells in a personalized therapy designed to improve the appearance of damaged skin and
wrinkles; or in the case of restrictive burn scars, improve range of motion. Our product candidates
are intended to be a minimally invasive alternative to surgical intervention and a viable natural
alternative to other chemical, synthetic or toxic treatments. We also believe that because our
product candidates are autologous, the risk of an immunological or allergic response is low. With
regard to the therapeutic markets, we believe that our product candidates may address an
insufficiently met medical need for the treatment of each of restrictive burn scars, acne scars and
dental papillary insufficiency, or gum recession, and potentially help patients avoid surgical
intervention. Certain of our product candidates are still in clinical development and, as such,
benefits we expect to see associated with our product candidates may not be validated in our
clinical trials. In addition, disadvantages of our product candidates may become known in the
future.
Our Strategy
Our business strategy is primarily focused on our approval efforts related to our nasolabial
fold/wrinkle indication, for which we have submitted a BLA in March 2009. Our additional objectives
include achieving regulatory milestones related to our other Phase II/III Acne Scar program and
potentially pursuing other clinical trials in burn scarring, vocal scarring and the dental arena,
as funding permits in the future. Refer to Clinical Development Programs below for current status.
Trading of Common Stock
The Predecessors common stock ceased trading on the NYSE Amex on May 6, 2009 and in June 2009
the NYSE Amex delisted the Predecessors common stock from listing on the NYSE Amex. Upon the
Effective Date, the outstanding common stock of the Predecessor Company was cancelled for no
consideration. Consequently, the Predecessors stockholders prior to the Effective Date no longer
have any interest as stockholders of the Successor Company by virtue of their ownership of the
Predecessors common stock prior to the emergence from bankruptcy. On October 21, 2009, the
Successor Company was available for trading on the OTC Bulletin Board under the symbol FCSC.
Clinical Development Programs
Our product development programs are focused on the aesthetic and therapeutic markets. These
programs are supported by a number of clinical trial programs at various stages of development.
Our aesthetics development programs include product candidates to treat targeted areas or
wrinkles and to provide full-face rejuvenation that includes the improvement of fine lines,
wrinkles, skin texture and appearance. Our therapeutic development programs are designed to treat
acne scars, restrictive burn scars and dental papillary recession. All of our product candidates
are non-surgical and minimally invasive. Although the discussions below may include estimates of
when we expect trials to be completed, the prediction of when a clinical trial will be completed is
subject to a number of factors and uncertainties. Also, please refer to
the section contained herein entitled Risk Factors for a
discussion of certain of our risk factors related to our clinical development
programs, as well as other risk factors related to our business.
31
Aesthetic Development Programs
Nasolabial Fold Wrinkles Phase III Trials: In October 2006, we reached an agreement
with the FDA, on the design of a Phase III pivotal study protocol for the treatment of nasolabial
fold wrinkles (lines which run from the sides of the nose to the corners of the mouth). The
randomized, double-blind protocol was submitted to the FDA under the agencys Special Protocol
Assessment, or SPA. Pursuant to this assessment process, the FDA has agreed that our study design
for two identical trials, including subject numbers, clinical endpoints, and statistical analyses,
is adequate to provide the necessary data that, depending on the outcome, could form the basis of
an efficacy claim for a marketing application. The pivotal Phase III trials evaluated the efficacy
and safety of our Fibrocell therapy (USAN name azficel-T) against placebo in approximately 400
subjects total with approximately 200 subjects enrolled in each trial. The injections were
completed in January 2008 and the trial data results were disclosed in October 2008. The Phase III
trial data results indicated statistically significant efficacy results for the treatment of
nasolabial fold wrinkles. The Phase III data analysis, including safety results, was disclosed in
October 2008. We submitted the related BLA to the FDA in March 2009. In May 2009, the FDA accepted
our BLA submission for filing. On October 9, 2009, the FDAs Cellular, Tissue and Gene Therapies
Advisory Committee reviewed azficel-T. The committee voted 11 yes to 3 no that the data
presented on azficel-T demonstrated efficacy, and 6 yes to 8 no that the data demonstrated
safety, both for the proposed indication. The Committees recommendations are not binding on the
FDA, but the FDA will consider their recommendations during their review of our application. On
December 21, 2009, Fibrocell Science received a Complete Response letter from the FDA related to
the BLA for azficel-T. A Complete Response letter is issued by the FDAs Center for Biologics
Evaluation and Research (CBER) when the review of a file is completed and additional data are
needed prior to approval. The Complete Response letter requested that Fibrocell Science provide
data from a histopathological study on biopsied tissue samples from patients following injection of
azficel-T. The letter also requested finalized Chemistry, Manufacturing and Controls (CMC)
information regarding the manufacture of azficel-T as follow-up to discussions that occurred during
the BLA review period, as well as revised policies and procedures regarding shipping practices, and
proposed labeling. The Company is currently working on obtaining the finalized CMC information for
the FDA as well as the revised policies and procedures regarding shipping practices and the
proposed labeling. In addition, the Company has submitted a proposed protocol concerning a
histopathological study on biopsied samples to the FDA and to the Companys Investigational Review
Board (IRB). The IRB has approved the protocol and the
Company received comments from the FDA on the protocol in May 2010.
On May 13, 2010, the Company announced the initiation of a small histology study (ITH-001) of azficel-T, an autologous cell therapy currently under review by the U.S. Food and
Drug Administration (FDA) for the treatment of moderate to severe nasolabial fold wrinkles.
The study has a target enrollment of approximately 20 participants from the completed and
statistically significant pivotal Phase III studies of azficel-T (IT-R-005 and IT-R-006).
The FDA requested the comparative histological data from this study in a Complete
Response letter issued to the Company on December 21, 2009 related to the Biologics License
Application (BLA) for azficel-T for the treatment of moderate to severe nasolabial fold wrinkles
in adults.
The histology study will evaluate tissue treated with azficel-T as compared to tissue
treated with sterile saline (placebo). The study will also provide information about the skin after
treatment, including evaluation of collagen and elastin fibrils, and cellular structure of the
sampled tissues.
The United States Adopted Names (USAN) Council adopted the USAN name, azficel-T, on October
28, 2009, and the FDA is currently evaluating a proposed brand name, Laviv.
Full Face Rejuvenation Phase II Trial: In March 2007, the Predecessor Company
commenced an open label (unblinded) trial of approximately 50 subjects. Injections of azficel-T
began to be administered in July 2007. This trial was designed to further evaluate the safety and
use of azficel-T to treat fine lines and wrinkles for the full face. Five investigators across the
United States participated in this trial. The subjects received two series of injections
approximately one month apart. In late December 2007, all 45 remaining subjects completed
injections. The subjects were followed for twelve months following each subjects last injection.
Data results related to this trial were disclosed in August 2008, which included top line positive
efficacy results related to this open label Phase II trial.
Additional safety data from this trial, collected through telephone calls placed to
participating subjects twelve months from the date of their final study treatment, were submitted
to the FDA on November 1, 2009. No changes to the safety profile of azficel-T were identified
during our review of this data.
Therapeutic Development Programs
Acne Scars Phase II/III Trial: In November 2007, the Predecessor Company commenced
an acne scar Phase II/III study. This study included approximately 95 subjects. This placebo
controlled trial was designed to evaluate the use of azficel-T to correct or improve the appearance
of acne scars. Each subject served as their own control, receiving azficel-T on one side of their
face and placebo on the other. The subjects received three treatments two weeks apart. The
follow-up and evaluation period was completed four months after each subjects last injection. In
March 2009, the Predecessor Company disclosed certain trial data results, which included
statistically significant
efficacy results for the treatment of moderate to severe acne scars. Compilation of safety data and
data related to the validation of the study photo guide assessment scale discussed below is ongoing
and is also subject to additional financing.
32
In connection with this acne scar program, the Predecessor Company developed a photo guide for
use in the evaluators assessment of acne study subjects. The Predecessor Company had originally
designed the acne scar clinical program as two randomized, double-blind, Phase III,
placebo-controlled trials. However, our evaluator assessment scale and photo guide have not
previously been utilized in a clinical trial. In November 2007, the FDA recommended that the
Predecessor Company consider conducting a Phase II study in order to address certain study issues,
including additional validation related to our evaluator assessment scale. As such, the Predecessor
Company modified our clinical plans to initiate a single Phase II/III trial. This Phase II/III
study, was powered to demonstrate efficacy, and has allowed for a closer assessment of the
evaluator assessment scale and photo guide that is ongoing. The
Successor Company is currently in the process of finalizing the
Clinical Study Program Report and the next step is to
initiate a discussion with the FDA concerning the validation of the evaluator assessment scale and
agree the path forward. These steps will be subject to obtaining sufficient financial resources.
Restrictive Burn Scars Phase II Trial: In January 2007, the Predecessor Company met
with the FDA to discuss our clinical program for the use of azficel-T for restrictive burn scar
patients. This Phase II trial would evaluate the use of azficel-T to improve range of motion,
function and flexibility, among other parameters, in existing restrictive burn scars in
approximately 20 patients. However, the Predecessor Company delayed the screening and enrollment in
this trial until such time as we raise sufficient additional financing and gather additional data
regarding the burn scar market.
Dental Study Phase II Trial: In late 2003, the Predecessor Company completed a Phase
I clinical trial for the treatment of condition relating to periodontal disease, specifically to
treat Interdental Papillary Insufficiency. In the second quarter of 2005, the Predecessor Company
concluded the Phase II dental clinical trial with the use of azficel-T and subsequently announced
that investigator and subject visual analog scale assessments demonstrated that the azficel-T was
statistically superior to placebo at four months after treatment. Although results of the
investigator and subject assessment demonstrated that the azficel-T was statistically superior to
placebo, an analysis of objective linear measurements did not yield statistically significant
results.
In 2006, the Predecessor Company commenced a Phase II open-label dental trial for the
treatment of Interdental Papillary Insufficiency. This single site study included 11 subjects. All
study treatment and follow up visits were completed, but full analysis of the study was previously
placed on internal hold due to our financial resource constraints. The Company is also currently
reviewing potential other clinical paths in the dental arena.
Agera Skincare Systems
The Successor Company markets and sells a skin care product line through our majority-owned
subsidiary, Agera Laboratories, Inc., which the Predecessor Company acquired in August 2006. Agera
offers a complete line of skincare systems based on a wide array of proprietary formulations,
trademarks and nano-peptide technology. These skincare products can be packaged to offer
anti-aging, anti-pigmentary and acne treatment systems. Agera primarily markets its products
primarily in the United States and Europe (primarily the United Kingdom).
Our Target Market Opportunities
Aesthetic Market Opportunity
Our product candidate for wrinkles/nasolabial folds and full face rejuvenation are directed
primarily at the aesthetic market. Aesthetic procedures have traditionally been performed by
dermatologists, plastic surgeons and other cosmetic surgeons. According to the American Society for
Aesthetic Plastic Surgery, or ASAPS, the total market for non-surgical cosmetic procedures was
approximately $4.5 billion in 2009. We believe the aesthetic procedure market is driven by:
|
|
|
aging of the baby boomer population, which currently includes ages approximately
46 to 64; |
|
|
|
the desire of many individuals to improve their appearance; |
33
|
|
|
impact of managed care and reimbursement policies on physician economics, which
has motivated physicians to establish or expand the menu of elective, private-pay aesthetic
procedures that they offer; and |
|
|
|
broadening base of the practitioners performing cosmetic procedures beyond
dermatologists and plastic surgeons to non-traditional providers. |
According to the ASAPS, 10.0 million surgical and non-surgical cosmetic procedures were
performed in 2009, as compared to 10.3 million in 2008. Also according to the ASAPS, approximately
8.5 million non-surgical procedures were performed in 2009 and 2008. We believe that the concept of
non-surgical cosmetic procedures involving injectable materials has become more mainstream and
accepted. According to the ASAPS, the following table shows the top five non-surgical cosmetic
procedures performed in 2009:
|
|
|
|
|
Procedure |
|
Number |
|
Botulinum toxin type A |
|
|
2,557,068 |
|
Hyaluronic acid |
|
|
1,313,038 |
|
Laser hair removal |
|
|
1,280,031 |
|
Microdermabrasion |
|
|
621,943 |
|
Chemical peel |
|
|
529,285 |
|
Procedures among the 35 to 50 year old age group made up approximately 44% of all cosmetic
procedures in 2009. The 51 to 64 year old age group made up 27% of all cosmetic procedures in 2009,
while the 19 to 34 year old age group made up 20% of cosmetic procedures in 2009. The Botulinum
toxin type A injection was the most popular treatment among the 35 to 50 year old age group.
Therapeutic Market Opportunities
In addition to the aesthetic market, we believe there are opportunities for our Fibrocell
Therapy to treat certain medical conditions such as acne scars, restrictive burn scars and tissue
loss due to papillary recession. Presently, we are studying therapeutic applications of our
technology for acne scars. Indications related to restrictive burn scars and periodontal disease
are on internal company hold. We are not aware of other autologous cell-based treatments for any of
these therapeutic applications.
Sales and Marketing
While our Fibrocell Therapy product candidates are still in the pre-approval phase in the
United States, no marketing or sales can occur within the United States. Our Agera skincare
products are primarily sold directly to our established distributors and salons, with historically
and recently very little focus on marketing efforts. We continue to attempt to identify additional
third party distributors for our Agera product line. We believe that our Agera products have the
potential to complement our Fibrocell Therapy product candidates in the future.
Intellectual Property
We believe that patents, trademarks, copyrights, proprietary formulations (related to our
Agera skincare products) and other proprietary rights are important to our business. We also rely
on trade secrets, know-how and continuing technological innovations to develop and maintain our
competitive position. We seek to protect our intellectual property rights by a variety of means,
including obtaining patents, maintaining trade secrets and proprietary know-how, and technological
innovation to operate without infringing on the proprietary rights of others and to prevent others
from infringing on our proprietary rights. Our policy is to seek to protect our proprietary
position by, among other methods, actively seeking patent protection in the United States and
certain foreign countries.
As of December 31, 2009, we had 9 issued U.S. patents, 4 pending U.S. patent applications, 28
granted foreign patents and 3 pending international patent applications. Our issued patents and
patent applications primarily cover the method of using autologous cell fibroblasts for the repair
of skin and soft tissue defects and the use of autologous fibroblast cells for tissue regeneration.
We are in the process of pursuing several other patent applications.
34
In January 2003, we acquired two pending U.S. patent applications. As consideration, we issued
100,000 shares of our common stock and agreed to pay a royalty on revenue from commercial
applications and licensing, up to a maximum of $2.0 million.
In August 2006, we acquired 57% of the common stock of Agera Laboratories. Agera has a number
of trade names, trademarks, exclusive proprietary rights to product formulations and specified
peptides that are used in the Agera skincare products.
Our success depends in part on our ability to maintain our proprietary position through
effective patent claims and their enforcement against our competitors, and through the protection
of our trade secrets. Although we believe our patents and patent applications provide a competitive
advantage, the patent positions of companies like ours are generally uncertain and involve complex
legal and factual questions. We do not know whether any of our patent applications or those patent
applications which we have acquired will result in the issuance of any patents. Our issued patents,
those that may be issued in the future or those acquired by us, may be challenged, invalidated or
circumvented, and the rights granted under any issued patent may not provide us with proprietary
protection or competitive advantages against competitors with similar technology. In particular, we
do not know if competitors will be able to design variations on our treatment methods to circumvent
our current and anticipated patent claims. Furthermore, competitors may independently develop
similar technologies or duplicate any technology developed by us. Because of the extensive time
required for the development, testing and regulatory review of a potential product, it is possible
that, before any of our products can be commercialized or marketed, any related patent claim may
expire or remain in force for only a short period following commercialization, thereby reducing the
advantage of the patent.
We also rely upon trade secrets, confidentiality agreements, proprietary know-how and
continuing technological innovation to remain competitive, especially where we do not believe
patent protection is appropriate or obtainable. We continue to seek ways to protect our proprietary
technology and trade secrets, including entering into confidentiality or license agreements with
our employees and consultants, and controlling access to and distribution of our technologies and
other proprietary information. While we use these and other reasonable security measures to protect
our trade secrets, our employees or consultants may unintentionally or willfully disclose our
proprietary information to competitors.
Our commercial success will depend in part on our ability to operate without infringing upon
the patents and proprietary rights of third parties. It is uncertain whether the issuance of any
third party patents would require us to alter our products or technology, obtain licenses or cease
certain activities. Our failure to obtain a license to technology that we may require to discover,
develop or commercialize our future products may have a material adverse impact on us. One or more
third-party patents or patent applications may conflict with patent applications to which we have
rights. Any such conflict may substantially reduce the coverage of any rights that may issue from
the patent applications to which we have rights. If third parties prepare and file patent
applications in the United States that also claim technology to which we have rights, we may have
to participate in interference proceedings in the United States Patent and Trademark Office to
determine priority of invention.
We have collaborated and may collaborate in the future with other entities on research,
development and commercialization activities. Disputes may arise about inventorship and
corresponding rights in know-how and inventions resulting from the joint creation or use of
intellectual property by us and our subsidiaries, collaborators, partners, licensors and
consultants. As a result, we may not be able to maintain our proprietary position.
Competition
The pharmaceutical and dermal aesthetics industries are characterized by intense competition,
rapid product development and technological change. Competition is intense among manufacturers of
prescription pharmaceuticals and dermal injection products. Our core products are considered dermal
injection products.
If certain of our product candidates are approved, we will compete with a variety of companies
in the dermatology and plastic surgery markets, many of which offer substantially different
treatments for similar problems. These include silicone injections, laser procedures, facial
surgical procedures, such as facelifts and eyelid surgeries, fat injections, dermabrasion,
collagen, allogenic cell therapies, hyaluronic acid injections and Botulinum toxin injections, and
other dermal fillers. Indirect competition comes from facial care treatment products. Items
catering to the growing
demand for therapeutic skin care products include facial scrubs, anti-aging treatments, tonics,
astringents and skin-restoration formulas.
35
Many of our competitors are large, well-established pharmaceutical, chemical, cosmetic or
health care companies with considerably greater financial, marketing, sales and technical resources
than those available to us. Additionally, many of our present and potential competitors have
research and development capabilities that may allow them to develop new or improved products that
may compete with our product lines. Our products could be rendered obsolete or made uneconomical by
the development of new products to treat the conditions addressed by our products, technological
advances affecting the cost of production, or marketing or pricing actions by one or more of our
competitors. Our facial aesthetics product may compete for a share of the existing market with
numerous products and/or technologies that have become relatively accepted treatments recommended
or prescribed by dermatologists and administered by plastic surgeons and aesthetic dermatologists.
There are several dermal filler products under development and/or in the FDA pipeline for
approval which claim to offer certain facial aesthetic benefits. Depending on the clinical outcomes
of the Fibrocell Science Therapy trials in aesthetics, the success or failure of gaining approval
and the label granted by the FDA if and when the therapy is approved, the competition for the
Fibrocell Therapy may prove to be direct competition to certain dermal fillers, laser technologies
or new technologies. However, if we gain approval, we believe our Fibrocell Therapy would be a
first to market autologous cellular technology that could complement other modalities of
treatment and represent a significant additional market opportunity.
The field for therapeutic treatments or tissue regeneration for use in wound healing is
rapidly evolving. A number of companies are either developing or selling therapies involving stem
cells, human-based, animal-based or synthetic tissue products. If approved as a therapy for acne
scars, restrictive burn scars or periodontal disease, our product candidates would or may compete
with synthetic, human or animal derived cell or tissue products marketed by companies larger and
better capitalized than us.
The market for skincare products is quite competitive with low barriers to entry.
Government Regulation
Our Fibrocell Therapy technologies are subject to extensive government regulation, principally
by the FDA and state and local authorities in the United States and by comparable agencies in
foreign countries. Governmental authorities in the United States extensively regulate the
pre-clinical and clinical testing, safety, efficacy, research, development, manufacturing,
labeling, storage, record-keeping, advertising, promotion, import, export, marketing and
distribution, among other things, of pharmaceutical products under various federal laws including
the Federal Food, Drug and Cosmetic Act, or FFDCA, the Public Health Service Act, or PHSA, and
under comparable laws by the states and in most foreign countries.
Domestic Regulation
In the United States, the FDA, under the FFDCA, the PHSA, and other federal statutes and
regulations, subjects pharmaceutical and biologic products to rigorous review. If we do not comply
with applicable requirements, we may be fined, the government may refuse to approve our marketing
applications or allow us to manufacture or market our products or product candidates, and we may be
criminally prosecuted. The FDA also has the authority to discontinue or suspend manufacture or
distribution, require a product withdrawal or recall or revoke previously granted marketing
authorizations if we fail to comply with regulatory standards or if we encounter problems following
initial marketing.
36
FDA Approval Process
To obtain approval of a new product from the FDA, we must, among other requirements, submit
data demonstrating the products safety and efficacy as well as detailed information on the
manufacture and composition of the product candidate. In most cases, this entails extensive
laboratory tests and pre-clinical and clinical trials. This testing and the preparation of
necessary applications and processing of those applications by the FDA are expensive and typically
take many years to complete. The FDA may deny our applications or may not act quickly or favorably
in
reviewing these applications, and we may encounter significant difficulties or costs in our efforts
to obtain FDA approvals that could delay or preclude us from marketing any products we may develop.
The FDA also may require post-marketing testing and surveillance to monitor the effects of approved
products or place conditions on any approvals that could restrict the commercial applications of
these products. Regulatory authorities may withdraw product approvals if we fail to comply with
regulatory standards or if we encounter problems following initial marketing. With respect to
patented products or technologies, delays imposed by the governmental approval process may
materially reduce the period during which we will have the exclusive right to exploit the products
or technologies.
The FDA does not apply a single regulatory scheme to human tissues and the products derived
from human tissue. On a product-by-product basis, the FDA may regulate such products as drugs,
biologics, or medical devices, in addition to regulating them as human cells, tissues, or cellular
or tissue-based products (HCT/Ps), depending on whether or not the particular product triggers
any of an enumerated list of regulatory factors. A fundamental difference in the treatment of
products under these classifications is that the FDA generally permits HCT/Ps that do not trigger
any of those regulatory factors to be commercially distributed without marketing approval. In
contrast, products that trigger those factors, such as if they are more than minimally manipulated
when processed or manufactured, are regulated as drugs, biologics, or medical devices and require
FDA approval. We have determined that our Fibrocell Therapy triggers regulatory factors that
make it a biologic, in addition to an HCT/P, and consequently, we must obtain approval from FDA
before marketing Fibrocell Therapy and must also satisfy all regulatory requirements for
HCT/Ps.
The process required by the FDA before a new drug or biologic may be marketed in the United
States generally involves the following:
|
|
|
completion of pre-clinical laboratory tests or trials and formulation studies; |
|
|
|
submission to the FDA of an IND for a new drug or biologic, which must become
effective before human clinical trials may begin; |
|
|
|
performance of adequate and well-controlled human clinical trials to establish the
safety and efficacy of the proposed drug or biologic for its intended use; |
|
|
|
detailed information on product characterization and manufacturing process; and |
|
|
|
submission and approval of a New Drug Application, or NDA, for a drug, or a
Biologics License Application, or BLA, for a biologic. |
Pre-clinical tests include laboratory evaluation of product chemistry formulation and
stability, as well as animal and other studies to evaluate toxicity. In view of the autologous
nature of our product candidates and our prior clinical experience with our product candidates, we
concluded that it was reasonably safe to initiate clinical trials without pre-clinical studies and
that the clinical trials would be adequate to further assess both the safety and efficacy of our
product candidates. Under FDA regulations, the results of any pre-clinical testing, together with
manufacturing information and analytical data, are submitted to the FDA as part of an IND
application. The FDA requires a 30-day waiting period after the filing of each IND application
before clinical trials may begin, in order to ensure that human research subjects will not be
exposed to unreasonable health risks. At any time during this 30-day period or at any time
thereafter, the FDA may halt proposed or ongoing clinical trials, or may authorize trials only on
specified terms. The IND application process may become extremely costly and substantially delay
development of our products. Moreover, positive results of pre-clinical tests will not necessarily
indicate positive results in clinical trials.
37
The sponsor typically conducts human clinical trials in three sequential phases, which may
overlap. These phases generally include the following:
|
|
|
Phase I: The product is usually first introduced into healthy humans or, on
occasion, into patients, and is tested for safety, dosage tolerance, absorption,
distribution, excretion and metabolism. |
|
|
|
Phase II: The product is introduced into a limited subject population to: |
|
|
|
assess its efficacy in specific, targeted indications; |
|
|
|
assess dosage tolerance and optimal dosage; and |
|
|
|
identify possible adverse effects and safety risks. |
|
|
|
Phase III: These are commonly referred to as pivotal studies. If a product is found
to have an acceptable safety profile and to be potentially effective in Phase II
clinical trials, new clinical trials will be initiated to further demonstrate clinical
efficacy, optimal dosage and safety within an expanded and diverse subject population
at geographically-dispersed clinical study sites. |
|
|
|
If the FDA does ultimately approve the product, it may require post-marketing
testing, including potentially expensive Phase IV studies, to confirm or further
evaluate its safety and effectiveness. |
Before proceeding with a study, sponsors may seek a written agreement from the FDA regarding
the design, size, and conduct of a clinical trial. This is known as a Special Protocol Assessment,
or SPA. Among other things, SPAs can cover clinical studies for pivotal trials whose data will form
the primary basis to establish a products efficacy. SPAs thus help establish up-front agreement
with the FDA about the adequacy of a clinical trial design to support a regulatory approval, but
the agreement is not binding if new circumstances arise. Even if the FDA agrees to an SPA, the
agreement may be changed by the sponsor or the FDA on written agreement by both parties, or a
senior FDA official determines that a substantial scientific issue essential to determining the
safety or effectiveness of the product was identified after the testing began. There is no
guarantee that a study will ultimately be adequate to support an approval even if the study is
subject to an SPA. The FDA retains significant latitude and discretion in interpreting the terms of
the SPA agreement and the data and results from any study that is the subject of the SPA agreement.
Clinical trials must meet requirements for Institutional Review Board, or IRB, oversight,
patient informed consent and the FDAs Good Clinical Practices. Prior to commencement of each
clinical trial, the sponsor must submit to the FDA a clinical plan, or protocol, accompanied by the
approval of the committee responsible for overseeing clinical trials at the clinical trial sites.
The FDA or the IRB at each institution at which a clinical trial is being performed may order the
temporary or permanent discontinuation of a clinical trial at any time if it believes that the
clinical trial is not being conducted in accordance with FDA requirements or presents an
unacceptable risk to the clinical trial subjects. Data safety monitoring committees, who monitor
certain studies to protect the welfare of study subjects, may also require that a clinical study be
discontinued or modified.
The sponsor must submit to the FDA the results of the pre-clinical and clinical trials,
together with, among other things, detailed information on the manufacturing and composition of the
product, and proposed labeling, in the form of an NDA, or, in the case of a biologic, a BLA. The
applicant must also submit with the NDA or BLA a substantial user fee payment, unless a waiver or
reduction applies. On February 17, 2009, the US Small Business Administration issued a letter
formally determining that we are a small business and therefore qualify for the Small Business
Exception to the Prescription Drug and User fee Act of 1992 (21 USC § 379h(b)(2)) related to our
BLA submission for the nasolabial folds/wrinkles indication. For fiscal year 2009, this fee was
$1,247,200 for companies that did not receive an exception. The FDA has advised us it is regulating
our Fibrocell Therapy as a biologic. Therefore, we expect to submit BLAs to obtain approval of our
product candidates. In some cases, we may be able to expand the indications in an approved BLA
through a Prior Approval Supplement. Each NDA or BLA submitted for FDA approval is usually reviewed
for administrative completeness and reviewability within 45 to 60 days following submission of the
application. If deemed complete, the FDA will file the NDA or BLA, thereby triggering substantive
review of the application. The FDA can refuse to file any NDA or BLA that it deems incomplete or
not properly reviewable. Once the submission has been accepted for filing, the FDA will review the
application and will usually respond to the applicant in accordance with performance goals the FDA
has established for the review of NDAs and BLAs six months from the receipt of the application
for priority applications and ten months for regular applications. The review process is often
significantly extended by FDA requests for additional information, preclinical or clinical studies,
clarification, or a risk evaluation and mitigation strategy, or REMS, or by changes to the
application submitted by the applicant in the form of amendments. The FDA may refer the BLA to an
advisory committee for review, evaluation and recommendation as to whether the application should
be approved, but the FDA is not bound by the recommendation of an advisory committee.
38
It is possible that our product candidates will not successfully proceed through this approval
process or that the FDA will not approve them in any specific period of time, or at all. The FDA
may deny or delay approval of applications that do not meet applicable regulatory criteria, or if
the FDA determines that the clinical data do not adequately establish the safety and efficacy of
the product. Satisfaction of FDA pre-market approval requirements for a new biologic is a process
that may take a number of years and the actual time required may vary substantially based upon the
type, complexity and novelty of the product or disease. The FDA reviews these applications and,
when and if it decides that adequate data are available to show that the product is both safe and
effective and that other applicable requirements have been met, approves the drug or biologic for
marketing. Government regulation may delay or prevent marketing of potential products for a
considerable period of time and impose costly procedures upon our activities. Success in early
stage clinical trials does not assure success in later stage clinical trials. Data obtained from
clinical activities is not always conclusive and may be susceptible to varying interpretations that
could delay, limit or prevent regulatory approval. Upon approval, a product candidate may be
marketed only for those indications approved in the BLA or NDA and may be subject to labeling and
promotional requirements or limitations, including warnings, precautions, contraindications and use
limitations, which could materially impact profitability. Once approved, the FDA may withdraw the
product approval if compliance with pre- and post-market regulatory standards is not maintained or
if safety, efficacy or other problems occur after the product reaches the marketplace.
The FDA may, during its review of an NDA or BLA, ask for additional test data. If the FDA does
ultimately approve the product, it may require post-marketing testing, including potentially
expensive Phase IV studies, to confirm or otherwise further evaluate the safety and effectiveness
of the product. The FDA also may require, as a condition to approval or continued marketing of a
drug, a risk evaluation and mitigation strategy, or REMS, if deemed necessary to manage a known or
potential serious risk associated with the product. An REMS can include additional educational
materials for healthcare professionals and patients such as Medication Guides and Patient Package
Inserts, a plan for communicating information to healthcare professionals, and restricted
distribution of the product.
In addition, the FDA may, in some circumstances, impose restrictions on the use of the product,
which may be difficult and expensive to administer and may require prior approval of promotional
materials. Following approval, FDA may require labeling changes or impose new post-approval study,
risk management, or distribution restriction requirements.
Ongoing FDA Requirements
Before approving an NDA or BLA, the FDA usually will inspect the facilities at which the
product is manufactured and will not approve the product unless the manufacturing facilities are in
compliance with the FDAs current Good Manufacturing Practices, or cGMP, requirements which govern
the manufacture, holding and distribution of a product. Manufacturers of human cellular or
tissue-based biologics also must comply with the FDAs Good Tissue Practices, as applicable, and
the general biological product standards. Following approval, the FDA periodically inspects drug
and biologic manufacturing facilities to ensure continued compliance with the cGMP requirements.
Manufacturers must continue to expend time, money and effort in the areas of production, quality
control, record keeping and reporting to ensure compliance with those requirements. Failure to
comply with these requirements subjects the manufacturer to possible legal or regulatory action,
such as suspension of manufacturing, seizure of product, voluntary recall of product, withdrawal of
marketing approval or civil or criminal penalties. Adverse experiences with the product must be
reported to the FDA and could result in the imposition of marketing restrictions through labeling
changes or market removal. Product approvals may be withdrawn if compliance with regulatory
requirements is not maintained or if problems concerning safety or efficacy of the product occur
following approval.
The labeling, advertising, promotion, marketing and distribution of a drug or biologic product
also must be in compliance with FDA and FTC requirements which include, among others, standards and
regulations for direct-to-consumer advertising, industry-sponsored scientific and educational
activities, and promotional activities involving the internet. In general, all product promotion
must be consistent with the FDA approval for such product, contain a balanced presentation of
information on the products uses and benefits and important safety information and limitations on
use, and otherwise not be false or misleading. The FDA and FTC have very broad enforcement
authority, and failure to abide by these regulations can result in penalties, including the
issuance of a Warning Letter directing a
company to correct deviations from regulatory standards and enforcement actions that can include
seizures, injunctions and criminal prosecution.
39
Manufacturers are also subject to various laws and regulations governing laboratory practices,
the experimental use of animals and the use and disposal of hazardous or potentially hazardous
substances in connection with their research. In each of the above areas, the FDA has broad
regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend
or delay issuance of approvals, seize or recall products and deny or withdraw approvals.
HIPAA Requirements
Other federal legislation may affect our ability to obtain certain health information in
conjunction with our research activities. The Health Insurance Portability and Accountability Act
of 1996, or HIPAA, mandates, among other things, the adoption of standards designed to safeguard
the privacy and security of individually identifiable health information. In relevant part, the
U.S. Department of Health and Human Services, or HHS, has released two rules to date mandating the
use of new standards with respect to such health information. The first rule imposes new standards
relating to the privacy of individually identifiable health information. These standards restrict
the manner and circumstances under which covered entities may use and disclose protected health
information so as to protect the privacy of that information. The second rule released by HHS
establishes minimum standards for the security of electronic health information. While we do not
believe we are directly regulated as a covered entity under HIPAA, the HIPAA standards impose
requirements on covered entities conducting research activities regarding the use and disclosure of
individually identifiable health information collected in the course of conducting the research. As
a result, unless they meet these HIPAA requirements, covered entities conducting clinical trials
for us may not be able to share with us any results from clinical trials that include such health
information.
Other U.S. Regulatory Requirements
In the United States, the research, manufacturing, distribution, sale, and promotion of drug
and biological products are potentially subject to regulation by various federal, state and local
authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services
(formerly the Health Care Financing Administration), other divisions of the U.S. Department of
Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice
and individual U.S. Attorney offices within the Department of Justice, and state and local
governments. For example, sales, marketing and scientific/educational grant programs must comply
with the anti-fraud and abuse provisions of the Social Security Act, the False Claims Act, and
similar state laws, each as amended. Pricing and rebate programs must comply with the Medicaid
rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care
Act of 1992, each as amended. If products are made available to authorized users of the Federal
Supply Schedule of the General Services Administration, additional laws and requirements apply. All
of these activities are also potentially subject to federal and state consumer protection, unfair
competition, and other laws.
International Regulation
The regulation of our product candidates outside of the United States varies by country.
Certain countries regulate human tissue products as a pharmaceutical product, which would require
us to make extensive filings and obtain regulatory approvals before selling our product candidates.
Certain other countries classify our product candidates as human tissue for transplantation but may
restrict its import or sale. Other countries have no application regulations regarding the import
or sale of products similar to our product candidates, creating uncertainty as to what standards we
may be required to meet.
Manufacturing
We currently have one operational manufacturing facility located in Exton, Pennsylvania. The
costs incurred in operating our Exton facility (except for costs related to general corporate
administration) are currently classified as research and development expenses as the activities
there have been devoted to the research and development of our clinical applications and the
development of a commercial scale and in a cost-effective production method. All component parts
used in our Exton, Pennsylvania manufacturing process are readily available with short lead times,
and all machinery is maintained and calibrated. We believe we have made improvements in our
manufacturing processes, and we expect to continue such efforts in the future.
40
Our Agera products are manufactured by a third-party contract manufacturer under a contract
manufacturing agreement. The agreement is effective through July 2014.
Research and Development
In addition to our clinical development activities, our research and development activities
include improving our manufacturing processes and reducing manufacturing costs. We expense research
and development costs as they are incurred. For the years ended December 31, 2009 and 2008, we
incurred research and development expenses of $3.9 million and $10.2 million, respectively. For the
three months ended March 31, 2010, we incurred research and development expenses of $1.2 million, which is an 18% increase over the research and development expenses we incurred for the three months ended March 31, 2009.
Employees
As
of June 8, 2010, we employed 23 people on a full-time basis, all located in the United
States, and one employee, our Chief Operating and Chief Financial Officer, who is based in Ireland
and works in both Ireland and the United States. We also employ one full-time and one part-time
Agera employees. None of our employees are covered by a collective bargaining agreement, and we
consider our relationship with our employees to be good. We also employ consultants and temporary
labor on an as needed basis to supplement existing staff.
Segment Information
Financial information concerning the Companys business segments and geographic areas of
operation is included in Note 17 in the Notes to Consolidated Financial Statements contained herein.
Discontinued Operations
As part of our continuing efforts to evaluate the best uses of our resources, in the fourth
quarter of 2006 our Board of Directors approved the closing of our United Kingdom operation. On
March 31, 2007, we completed the closure of the United Kingdom manufacturing facility. As a result
of the completion of the closure of the United Kingdom manufacturing facility, as of March 31, 2007
our United Kingdom operation was classified as a discontinued operation. In addition, as a result
of the closure of our United Kingdom operation, the operations that we previously conducted in
Switzerland and Australia, which had been absorbed into the United Kingdom operation, were also
classified as discontinued operations as of March 31, 2007. Accordingly, the historical results of
the United Kingdom, Switzerland and Australia have been retrospectively adjusted herein, for all
periods presented, to reflect the treatment of these operations as discontinued operations.
Corporate History
On August 10, 2001, our company, then known as American Financial Holding, Inc., acquired
Isolagen Technologies through the merger of our wholly-owned subsidiary, Isolagen Acquisition
Corp., and an affiliated entity, Gemini IX, Inc., with and into Isolagen Technologies. As a result
of the merger, Isolagen Technologies became our wholly owned subsidiary. On November 13, 2001, we
changed our name to Isolagen, Inc. On August 27, 2009, the United States Bankruptcy Court for the
District of Delaware in Wilmington entered an order, or Confirmation Order, confirming the Joint
First Amended Plan of Reorganization dated July 30, 2009, as supplemented by the Plan Supplement
dated August 21, 2009, or the Plan, of Isolagen, Inc. and Isolagens wholly owned subsidiary,
Isolagen Technologies, Inc. The effective date of the Plan was September 3, 2009. Isolagen, Inc.
and Isolagen Technologies, Inc. were subsequently renamed Fibrocell Science, Inc. and Fibrocell
Technologies, Inc. respectively.
Properties
Our corporate headquarters and manufacturing operations are located in
one location, Exton, Pennsylvania. The Exton, Pennsylvania location
is leased and consists of approximately 86,500 square feet. The lease is noncancelable through March 31, 2013.
41
MANAGEMENT
The following table sets forth the names and ages of all of our directors and executive
officers as of June 8, 2010. Our officers are appointed by, and serve at the pleasure of, the
Board of Directors.
|
|
|
|
|
|
|
Name |
|
Title |
|
Age |
David Pernock
|
|
Director and Chief Executive Officer
|
|
|
55 |
|
|
|
|
|
|
|
|
Declan Daly
|
|
Director, Chief Operating Officer and Chief
Financial Officer
|
|
|
47 |
|
|
|
|
|
|
|
|
Paul Hopper
|
|
Director
|
|
|
53 |
|
|
|
|
|
|
|
|
Kelvin Moore
|
|
Director
|
|
|
61 |
|
|
|
|
|
|
|
|
Robert Langer
|
|
Director
|
|
|
61 |
|
|
|
|
|
|
|
|
Marc Mazur
|
|
Director
|
|
|
51 |
|
Biographical information with respect to our directors and executive officers is provided
below. There are no family relationships between any of our executive officers or directors.
David Pernock. Mr. Pernock has served as a chairman of the board of Fibrocell since September
2009 and as our Chief Executive Officer since February 2010. From December 1993 until November
2009, Mr. Pernock held various positions at GlaxoSmithKline, eventually serving as Senior Vice
President of Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care, and HIV Divisions. Mr.
Pernock is a director of Martek Biosciences Corporation. Mr. Pernock holds a B.S. in Business
Administration from Arizona State University.
Declan Daly. Mr. Daly has served as Fibrocells Chief Operating Officer and Chief Financial
Officer since September 2009, and as a director of Fibrocell since November 2009. Mr. Daly served
as Isolagens Chief Executive Officer and President from January 2008 until September 3, 2009, as
Chief Financial Officer from June 2006 until March 2008, and as Chief Operating Officer from June
2007 until January 2008. Mr. Daly was elected to the Board of Directors of Isolagen in June 2008.
Mr. Daly served as Executive Vice President and Chief Financial Officer of Inamed Corp. from
November 2004 until March 2006, prior to which he served as Inameds Senior Vice President since
September 2002 and as the Corporate Controller and Principal Accounting Officer since March 2002.
He was previously Vice President of Finance & Administration for Inamed International Corp. from
1998 to 2002. From 1996 to 1998, Mr. Daly was a Senior Manager with BDO Simpson Xavier, Chartered
Accountants or BDO, in Dublin. Prior to joining BDO, he worked with PricewaterhouseCoopers in
Dublin and London. Mr. Daly holds a B.A. in Management Science and Industrial Systems Studies from
Trinity College, Dublin and he is also a Fellow of the Institute of Chartered Accountants in
Ireland.
Paul Hopper. Mr. Hopper has served as a director of Fibrocell since September 2009. Mr. Hopper
has served as Managing Director of Cappello Group, Inc, an investment bank based in Los Angeles,
since November 2005. From September 2003 to February 2005, Mr. Hopper served as Managing Director
of Australian Cancer Technology Ltd, an oncology biotechnology company. Mr. Hopper is also a
Director of Somnomed Ltd, Viralytics Ltd, and pSivida Corp.
Kelvin Moore. Mr. Moore has served as a director of Fibrocell since September 2009. Since
March 2009, Mr. Moore has served as the consultant sales director for the UK based Seaborne Group
developing their business in building constructions from converting shipping sea containers. Since
July 2008, Mr. Moore has been a director of Acorn Cultural Developments Limited which is developing
a social networking site. Between June 2004 and May 2008, Mr. Moore was a senior advisor with Exit
Strategy Planning dealing with the sale of businesses. Mr. Moore holds a London University Degree
in Geography and Pure Mathematics.
42
Robert Langer. Dr. Langer has served as a director of Fibrocell since September 2009. Dr.
Langer was named an Institute Professor at Massachusetts Institute of Technology in 2006 and has
been on the faculty of Massachusetts Institute of Technology since 1978. Dr. Langer is also a
Director of Alseres Pharmaceuticals, Inc. and Echo Therapeutics, Inc. Dr. Langer received his
Bachelors Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of
Technology in 1974, both in Chemical Engineering.
Marc B. Mazur. Mr. Mazur has served as a director of Fibrocell since April 2010. Since
May 2009, Mr. Mazur has served as the Chairman of Elsworthy Capital Management Ltd., a
London-based European equity hedge fund. From October 2006 until December 2009, Mr.
Mazur served as the CEO of Brevan Howard U.S. Asset Management, the U.S. arm of London-based
Brevan Howard. In 2001 Mr. Mazur founded Ambassador Capital Group, a privately held
investment and advisory entity providing capital, business development and strategic planning
advice to companies in the healthcare, financial services and real estate fields. Mr. Mazur
received his B.A. in political science from Columbia University in 1981 and a J.D. from
Villanova University in 1984.
In connection with our emergence from bankruptcy, our plan of reorganization provided that our
directors prior to our emergence from bankruptcy were all deemed to have resigned, and a new board
of directors was appointed as of the effective date of our emergence from bankruptcy. Pursuant to
the plan of reorganization, the new board of directors was determined by the lenders that provided
us debtor-in-possession while we were in bankruptcy and the investors that provided us exit
financing. The members of our board of directors that were designated in our plan of reorganization
are David Pernock, Paul Hopper and Kelvin Moore.
No director is related to any other director or executive officer of our company or our
subsidiaries, and, subject to the above paragraph, there are no arrangements or understandings
between a director and any other person pursuant to which such person was elected as director.
Our Certificate of Incorporation, as amended, provides that the Board of Directors be divided
into three classes. Each director serves a term of three years. At each annual meeting, the
stockholders elect directors for a full term or the remainder thereof, as the case may be, to
succeed those whose terms have expired. Each director holds office for the term for which elected
or until his or her successor is duly elected.
No director or officer of our company has, during the last five years: (i) been convicted of
any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party
to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a
result of such proceeding was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, United States federal or state
securities laws or finding any violations with respect to such laws.
Board Committees
We do not currently have an audit committee, compensation committee or nominating committee.
Our full board currently performs the duties and responsibilities of such committees.
Executive Officer Compensation
The following table sets forth information regarding compensation with respect to the fiscal
years ended December 31, 2009 and 2008 paid or accrued by us to or on behalf of those persons who,
during the fiscal year ended December 31, 2009, served as our Chief Executive Officer or Chief
Financial Officer, as well as our most highly compensated key employees as of December 31, 2009
(the named executive officers).
Summary Compensation Table 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock |
|
Option |
|
All Other |
|
|
|
|
|
|
|
|
Salary |
|
Bonus |
|
Awards |
|
Awards |
|
Compensation |
|
Total |
Name and Principal Position |
|
Year |
|
($) |
|
($) |
|
($) (1) |
|
($) (1) |
|
($) |
|
($) |
Declan Daly,
Chief Financial Officer and |
|
|
2009 |
|
|
|
403,538 |
|
|
|
100,000 |
|
|
|
288,000 |
(3) |
|
|
17,908 |
(4) |
|
|
|
|
|
|
809,446 |
|
Chief Operating Officer (2) |
|
|
2008 |
|
|
|
427,635 |
|
|
|
25,000 |
|
|
|
|
|
|
|
766,839 |
(5) |
|
|
|
|
|
|
1,219,474 |
|
Todd Greenspan, |
|
|
2009 |
|
|
|
176,308 |
|
|
|
50,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
226,308 |
|
Former Chief Financial
Officer (6) |
|
|
2008 |
|
|
|
231,385 |
|
|
|
|
|
|
|
|
|
|
|
78,663 |
(7) |
|
|
|
|
|
|
310,048 |
|
John Maslowski,
Vice President of Operations |
|
|
2009 |
|
|
|
149,279 |
|
|
|
|
|
|
|
|
|
|
|
16,117 |
(8) |
|
|
|
|
|
|
165,396 |
|
Karen Donhauser,
Vice President of Quality |
|
|
2009 |
|
|
|
110,936 |
|
|
|
|
|
|
|
|
|
|
|
9,670 |
(9) |
|
|
|
|
|
|
120,606 |
|
43
|
|
|
|
(1) |
|
Except as disclosed in footnotes (8) and (9), represents the full grant date fair value of
the stock award or option grant, as applicable, calculated in accordance with FASB ASC Topic
718. For the purposes of making the stock award calculation, an assumed value of $0.48 per
share was utilized. For the purposes of making the option calculation for 2009, the following
assumptions were made: (a) expected life (years) 3.5 (for the options issued to Mr.
Maslowski and Ms. Donhauser); expected life (years) 2.5 (for the options issued to Mr.
Daly); (b) volatility 65.87%; (c) dividend yield none; and (d) discount rate 1.64%
(for the options issued to Mr. Maslowski and Ms. Donhauser); discount rate 0.99% (for the
options issued to Mr. Daly). For the purposes of making the option calculation for 2008, the following assumptions were
made: (a) expected life (years) 10 (for the options issued to Mr. Daly); expected life (years)
6 (for the options issued to Mr. Greenspan); (b) volatility 82.87% (for the options issued to
Mr. Daly); volatility 105.41% (for the options issued to Mr. Greenspan); (c) dividend yield
none; and (d) discount rate 3.89% (for the options issued to Mr. Daly); discount rate 2.83%
(for the options issued to Mr. Greenspan).
We excluded the assumed forfeiture rate for the purposes of the
calculations in the table. |
|
|
(2) |
|
Mr. Daly served as our Chief Executive Officer during 2009. Mr. Daly is currently our Chief
Financial Officer and Chief Operating Officer. |
|
(3) |
|
Pursuant to our bankruptcy plan, our management was granted shares of our common stock. Mr.
Daly received 600,000 shares of common stock, of which 300,000 shares vested immediately and
150,000 shares vest on each successive one-year anniversary; provided that if we do not renew
Mr. Dalys employment agreement at the end of its term or in the event of a change of control,
any unvested shares will automatically vest. |
|
(4) |
|
Consists of an option issued in connection with Mr. Daly joining our board of directors in
November 2009 to purchase 50,000 shares of common stock at an exercise price of $0.75 per
share. |
|
(5) |
|
During 2008, Mr. Daly was granted options to purchase 450,000 shares of common stock.
These options were terminated in our bankruptcy and are no longer outstanding. |
|
(6) |
|
Mr. Greenspan served as our Chief Financial Officer until September 2009. |
|
(7) |
|
During 2008, Mr. Greenspan was granted options to purchase 200,000 shares of common stock.
These options were terminated in our bankruptcy and are no longer outstanding. |
|
(8) |
|
Consists of an option to purchase 100,000 shares of common stock at an exercise price of
$0.75 per share of which 50,000 shares vest on October 6, 2010 and 50,000 shares vest if our
BLA is approved by the FDA. The grant date fair value in the table above excludes the 50,000
shares that would vest if our BLA is approved by the FDA as that portion of the option is
subject to performance conditions and is not considered to be probable pursuant to FASB ASC
Topic 718. The full grant date fair value of the option assuming the performance conditions
are met is $32,234. |
|
(9) |
|
Consists of an option to purchase 60,000 shares of common stock at an exercise price of
$0.75 per share of which 30,000 shares vest on October 6, 2010 and 30,000 shares vest if our
BLA is approved by the FDA. The grant date fair value in the table above excludes the 30,000
shares that would vest if our BLA is approved by the FDA as that portion of the option is
subject to performance conditions and is not considered to be probable pursuant to FASB ASC
Topic 718. The full grant date fair value of the option assuming the performance conditions
are met is $19,341. |
Equity Awards
The following table sets forth certain information concerning our outstanding options for our
named executive officers at December 31, 2009.
44
Outstanding Equity Awards At Fiscal Year-End2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of |
|
Number of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities |
|
Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Underlying |
|
Underlying |
|
|
|
|
|
|
|
|
|
Number of |
|
Market value of |
|
|
Unexercised |
|
Unexercised |
|
|
|
|
|
|
|
|
|
shares of stock |
|
shares of stock |
|
|
Options |
|
Options |
|
Option Exercise |
|
|
|
|
|
that have not |
|
that have not |
|
|
(#) |
|
(#) |
|
Price |
|
Option Expiration |
|
vested |
|
vested |
Name |
|
Exercisable |
|
Unexercisable |
|
($) |
|
Date |
|
(#) |
|
($) |
Declan Daly |
|
|
50,000 |
|
|
|
|
|
|
|
0.75 |
|
|
|
11/20/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
300,000 |
|
|
|
345,000 |
(1) |
Todd Greenspan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John Maslowski |
|
|
|
|
|
|
100,000 |
(2) |
|
|
0.75 |
|
|
|
10/6/2014 |
|
|
|
|
|
|
|
|
|
Karen Donhauser |
|
|
|
|
|
|
60,000 |
(3) |
|
|
0.75 |
|
|
|
10/6/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Based on the closing price of our common stock of $1.15 on December 31, 2009. |
|
(2) |
|
Consists of an option to purchase 100,000 shares of common stock at an exercise price of
$0.75 per share of which 50,000 shares vest on October 6, 2010 and 50,000 shares vest if our
BLA is approved by the FDA. |
|
(3) |
|
Consists of an option to purchase 60,000 shares of common stock at an exercise price of $0.75
per share of which 30,000 shares vest on October 6, 2010 and 30,000 shares vest if our BLA is
approved by the FDA. |
None of our named executive officers has exercised any options.
Pension Benefits
None of our named executives participate in or have account balances in qualified or
non-qualified defined benefit plans sponsored by us.
Nonqualified Deferred Compensation
None of our named executives participate in or have account balances in non-qualified defined
contribution plans or other deferred compensation plans maintained by us.
Director Compensation
In September 2009, our board of directors approved a compensation plan for its non-executive
directors pursuant to which each such director will receive an annual fee of $50,000, payable in
monthly installments, and upon appointment to the board of directors will receive an initial option
grant to purchase 200,000 shares of Company common stock at the fair market value of the Company on
the date of issuance. On September 30, 2009, the board of directors agreed to provide Mr. David
Pernock, the Chairman of the Board, with the above cash compensation, as well as an option to
purchase 450,000 shares of Company common stock at the fair market value of the Company on the date
of issuance, of which 300,000 shares vest immediately and 150,000 shares vest in 12 months,
provided Mr. Pernock is Chairman of the Board on such date.
Director Compensation Table2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned or Paid |
|
|
|
|
|
All other |
|
|
|
|
in Cash |
|
Option Awards |
|
compensation |
|
Total |
Name |
|
($) |
|
($) (1) |
|
($) |
|
($) |
Post-bankruptcy directors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Pernock |
|
|
12,639 |
|
|
|
151,537 |
(2) |
|
|
15,000 |
(3) |
|
|
179,176 |
|
Paul Hopper |
|
|
16,250 |
|
|
|
61,866 |
(4) |
|
|
|
|
|
|
78,116 |
|
Robert Langer |
|
|
13,333 |
|
|
|
61,866 |
(4) |
|
|
16,667 |
(3) |
|
|
91,866 |
|
Kelvin Moore |
|
|
16,250 |
|
|
|
61,866 |
(4) |
|
|
|
|
|
|
78,116 |
|
Declan Daly |
|
|
|
(5) |
|
|
|
(5) |
|
|
|
|
|
|
|
(5) |
Pre-bankruptcy directors (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned or Paid |
|
|
|
|
|
All other |
|
|
|
|
in Cash |
|
Option Awards |
|
compensation |
|
Total |
Name |
|
($) |
|
($)(1) |
|
($) |
|
($) |
Steven Morrell |
|
|
29,015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Kenneth A. Selzer |
|
|
28,308 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Nicholas L. Teti |
|
|
95,154 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Henry Y.L. Toh |
|
|
29,015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Terry E. Vandewarker |
|
|
37,508 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Marshall G. Webb |
|
|
35,385 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Represents the full grant date fair value of the option grant calculated in accordance
with FASB ASC Topic 718. For the purposes of making the option calculation, the following
assumptions were made: (a) expected life (years) 2.5 (for the options issued to Messrs.
Hopper, Langer and Moore); expected life (years) 3.0 (for the options issued to Mr.
Pernock); (b) volatility 66.75%; (c) dividend yield none; and (d) discount rate 1.36%
(for the options issued to Messrs. Hopper, Langer and Moore); discount rate 1.45% (for the
options issued to Mr. Pernock). |
|
(2) |
|
As of December 31, 2009, Mr. Pernock held options to purchase an aggregate of 450,000
shares of our common stock with an exercise price of $0.75 per share. |
|
(3) |
|
Consists of consulting fees. |
|
(4) |
|
As of December 31, 2009, Messrs. Hopper, Langer and Moore each held an option to purchase
200,000 shares of our common stock with an exercise price of $0.75 per share. |
|
(5) |
|
See Executive Officer Compensation Summary Compensation Table 2009. |
|
(6) |
|
All options issued to our pre-bankruptcy directors were terminated in the bankruptcy and
are no longer outstanding. No options were issued to these directors in 2009. |
Equity Incentive Plan
We currently have an outstanding equity incentive plan, the Fibrocell Science, Inc. 2009
Equity Incentive Plan, or Incentive Plan, that permits us to grant awards in the form of incentive
stock options, as defined in Section 422 of the Internal Revenue Code, or Code, as well as options
which do not so qualify, called non-qualified stock options, stock units, stock awards, stock
appreciation rights, and other stock-based awards. The purpose of the plan is to promote the
interests of Fibrocell, and to motivate, attract and retain the services of the people upon whose
efforts and contributions our success depends.
The three outstanding stock option plans we had prior to our reorganization, (a) our 2001
Stock Option and Appreciation Rights Plan reserving 5,000,000 shares of common stock for the
issuance of options to employees, directors and consultants, (b) our 2003 Stock Option and
Appreciation Rights Plan reserving 2,250,000 shares of common stock for the issuance of options to
employees, directors and consultants, and (c) our 2005 Equity Incentive Plan reserving 2,100,000
shares of common stock for the issuance of options to employees, directors and consultants,
terminated as of the effective date of our reorganization and all outstanding options issued
pursuant to the plans were cancelled.
Management Agreements
Effective upon our exit from bankruptcy on September 3, 2009, we entered into an employment
agreement, pursuant to which Mr. Daly agreed to serve as our chief operating officer until December
31, 2011, subject to the automatic renewal of the agreement for an additional one-year term unless
we notify Mr. Daly prior to the expiration of the agreement of our intention not to renew the
agreement. Notwithstanding the foregoing, if a change of control occurs during the term of the
agreement, we may not terminate the agreement for a period of two years after such change of
control. The agreement provides Mr. Daly with an annual base salary of $300,000, which will be
periodically reviewed and may be increased at the Boards discretion. Mr. Daly received a one-time
signing bonus payment in the amount of $100,000. Mr. Daly is entitled to receive an annual bonus,
payable each year subsequent
46
to the issuance of final audited financial statements, but in no case later than 120 days
after the end of our most recently completed fiscal year. The final determination on the amount of
the annual bonus will be made by the Compensation Committee of the Board of Directors, based
primarily on criteria mutually agreed upon with Mr. Daly. The targeted amount of the annual bonus
shall be 50% of Mr. Dalys base salary. The actual annual bonus for any given period may be higher
or lower than 50%. For any fiscal year in which Mr. Daly is employed for less than the full year
(other than for 2009), he shall receive a bonus which is prorated based on the number of full
months in the year which are worked. Mr. Daly is entitled to a bonus of $50,000 if we are able to
complete a capital raise or series of capital raises in excess of $6.0 million, provided Mr. Daly
is our chief operating officer at such time. Mr. Daly is entitled to a bonus of $50,000 if our BLA
is approved by the FDA, provided Mr. Daly is our chief operating officer at such time.
If we terminate the employment agreement without cause or if Mr. Daly dies or become disabled,
we will continue to pay Mr. Daly (or his heirs) his base salary at such time for the longer of the
remainder of the term of the employment agreement or 12 months from the date of termination. If we
terminate the employment agreement without cause following a change of control or if Mr. Daly
terminates the employment agreement for good reason, we must pay Mr. Daly, within 30 days of
termination, a cash payment equal to the amounts payable for the greater of the remainder of the
term of the employment agreement or 12 months from the date of termination.
Pursuant to the employment agreement and as provided in our bankruptcy reorganization plan,
Mr. Daly received a grant of 600,000 shares of common stock, of which 300,000 shares vested
immediately and 150,000 shares vest on each successive one-year anniversary; provided that if we do
not renew the employment agreement at the end of the term or in the event of a change of control,
any unvested shares will automatically vest. We have agreed to make a tax gross-up payment with
respect to the equity grant.
Mr. Daly has agreed that during his employment and for a period of 12 months after termination
or expiration of his employment agreement he will not compete with us, solicit our employees, or
attempt to divert or take away our customers and clients.
Effective upon our exit from bankruptcy on September 3, 2009, we entered into a consultant
agreement, pursuant to which Dr. Langer agreed to provide consulting services to us, including
serving a scientific advisor. The agreement has a one year term, provided that either party may
terminate the agreement on 30 days notice. The agreement provides Dr. Langer annual compensation of
$50,000.
On February 1, 2010, the Company entered into an employment agreement with Mr. Pernock
pursuant to which Mr. Pernock agreed to serve as Chief Executive Officer of the Company for an
initial term ending February 1, 2013, which may be renewed for an additional one-year term by
mutual agreement. The agreement provides for an annual salary of $450,000. Mr. Pernock is entitled
to receive an annual bonus each year, payable subsequent to the issuance of the Companys final
audited financial statements, but in no case later than 120 days after the end of its most recently
completed fiscal year. The final determination on the amount of the annual bonus will be made by
the Board of Directors (or the Compensation Committee of the Board of Directors, if such committee
has been formed), based on criteria established by the Board of Directors (or the Compensation
Committee of the Board of Directors, if such committee has been formed). The targeted amount of the
annual bonus shall be 60% of Mr. Pernocks base salary, although the actual bonus may be higher or
lower.
Under the agreement, Mr. Pernock was granted a ten-year option to purchase 1,650,000 shares at
an exercise price per share equal to the closing price of the Companys common stock on the date of
execution of the agreement, or February 1, 2010. The options vest as follows: (i) 250,000 shares
upon execution of the agreement; (ii) 100,000 shares upon the closing of a strategic partnership or
licensing deal with a major partner that enables the Company to significantly improve and/or
accelerate its capabilities in such areas as research, production, marketing and/or sales and
enable the Company to reach or exceed its major business milestones within the Companys strategic
and operational plans, provided Mr. Pernock is the CEO on the closing date of such partnership or
licensing deal (the determination of whether any partnership or licensing deal meets the foregoing
criteria will be made in good faith by the Board upon the closing of such partnership or licensing
deal); and (iii) 1,300,000 shares in equal 1/36th installments (or 36,111 shares per installment)
monthly over a three-year period, provided Executive is the CEO on each vesting date. The vesting
of all options set forth above shall accelerate upon a change in control as
47
defined in the agreement, provided Mr. Pernock is employed by the Company within 60 days prior
to the date of such change in control.
If Mr. Pernocks employment is terminated at the Companys election at any time, for reasons
other than death, disability, cause (as defined in the agreement) or a voluntary resignation, or by
Mr. Pernock for good reason (as defined in the agreement), Mr. Pernock shall be entitled to receive
severance payments equal to twelve months of Mr. Pernocks base salary and of the premiums
associated with continuation of Mr. Pernocks benefits pursuant to COBRA to the extent that he is
eligible for them following the termination of his employment; provided that if anytime within
eighteen months after a change in control either (i) Mr. Pernock is terminated, at the Companys
election at any time, for reasons other than death, disability, cause or voluntary resignation, or
(ii) Mr. Pernock terminates the agreement for good reason, Mr. Pernock shall be entitled to receive
severance payments equal to: (1) two years of Mr. Pernocks base salary, (2) Mr. Pernocks most
recent annual bonus payment, and (3) the premiums associated with continuation of Mr. Pernocks
benefits pursuant to COBRA to the extent that he is eligible for them following the termination of
his employment for a period of one year after termination. All severance payments shall be made in
a lump sum within ten business days of Mr. Pernocks execution and delivery of a general release of
the Company, its parents, subsidiaries and affiliates and each of its officers, directors,
employees, agents, successors and assigns in a form acceptable to the Company. If severance
payments are being made, Mr. Pernock has agreed not to compete with the Company until twelve months
after the termination of his employment.
RELATED PARTY TRANSACTIONS
Review and Approval Policies and Procedures for Related Party Transactions
Pursuant to Board policy, our executive officers and directors, and principal stockholders,
including their immediate family members and affiliates, are not permitted to enter into a related
party transaction with us without the prior consent of our audit committee, or other independent
committee of our board of directors in the case it is inappropriate for our audit committee to
review such transaction due to a conflict of interest. Any request for us to enter into a
transaction with an executive officer, director, principal stockholder, or any of such persons
immediate family members or affiliates, in which the amount involved exceeds $120,000 must first be
presented to our audit committee for review, consideration and approval. All of our directors,
executive officers and employees are required to report to our audit committee any such related
party transaction. In approving or rejecting the proposed agreement, our audit committee shall
consider the relevant facts and circumstances available and deemed relevant to the audit committee.
Our audit committee shall approve only those agreements that, in light of known circumstances, are
in, or are not inconsistent with, our best interests, as our audit committee determines in the good
faith exercise of its discretion. We do not currently have an audit committee and our full board
currently performs the duties and responsibilities of the audit committee.
PRINCIPAL STOCKHOLDERS
The following table sets forth information regarding the beneficial ownership of our common
stock as of June 8, 2010 by:
|
|
|
each person known by us to be the beneficial owner of more than 5% of our
outstanding shares of common stock; |
|
|
|
|
each of our named executive officers and directors; and |
|
|
|
|
all of our officers and directors as a group. |
Unless otherwise indicated, we believe that all persons named in the table have sole voting
and investment power with respect to all shares of common stock beneficially owned by them. Unless
otherwise indicated, the address for our named executive officers and directors is c/o Fibrocell
Science Inc., 405 Eagleview Boulevard, Exton, Pennsylvania 19341.
48
|
|
|
|
|
|
|
|
|
|
|
Common stock |
|
|
|
|
Beneficially |
|
Percent of |
Name of Beneficial Owner |
|
Owned(1) |
|
Class(2) |
Declan Daly |
|
|
650,000 |
(3) |
|
|
3.3 |
% |
David Pernock |
|
|
694,444 |
(4) |
|
|
3.4 |
% |
Paul Hopper |
|
|
200,000 |
(5) |
|
|
1.0 |
% |
Kelvin Moore |
|
|
200,000 |
(5) |
|
|
1.0 |
% |
Robert Langer |
|
|
200,000 |
(5) |
|
|
1.0 |
% |
Marc Mazur |
|
|
100,000 |
(6) |
|
|
* |
|
John Maslowski |
|
|
100,000 |
(7) |
|
|
* |
|
Karen Donhauser |
|
|
60,000 |
(8) |
|
|
* |
|
Todd Greenspan (9) |
|
|
|
|
|
|
|
|
All Executive Officers and Directors as a Group (5 persons) |
|
|
2,204,444 |
(10) |
|
|
10.3 |
% |
|
|
|
|
|
|
|
|
|
Five percent or more of shareholders |
|
|
|
|
|
|
|
|
James E. Flynn (11) |
|
|
2,000,000 |
|
|
|
10.1 |
% |
|
|
|
(1) |
|
Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act.
Unless otherwise noted, all listed shares of common stock are owned of record by each person or
entity named as beneficial owner and that person or entity has sole voting and dispositive power
with respect to the shares of common stock owned by each of them. As to each person or entity named
as beneficial owners, that persons or entitys percentage of ownership is determined based on the
assumption that any options or convertible securities held by such person or entity which are
exercisable or convertible within 60 days of the date of this report have been exercised or
converted, as the case may be. |
|
(2) |
|
Based upon 19,768,676 shares of common stock outstanding as
of June 8, 2010. |
|
(3) |
|
Includes 50,000 shares underlying an option exercisable at $0.75 per share. |
|
(4) |
|
Includes: (i) 300,000 shares underlying an option exercisable at $0.75 per
share; and (ii) 394,444 shares underlying an option exercisable at $1.08 per share (which
represents the vested portion, plus the shares that will vest within 60 days of the date of this
filing, of an option to purchase 1,650,000 shares issued in connection with Mr. Pernocks
employment agreement). In addition, Mr. Pernock holds an option to purchase 150,000 shares at $0.75
per share, which is exercisable in September 2010. |
|
(5) |
|
Consists of 200,000 shares underlying an option exercisable at $0.75 per share. |
|
(6) |
|
Consists of 100,000 shares underlying an option exercisable at $1.04 per share. In
addition, Mr. Mazur holds an option to purchase 100,000 shares at $1.04 per share, which is
exercisable in April 2011. |
|
(7) |
|
Consists of 100,000 shares underlying an option exercisable at $0.75 per share. |
|
(8) |
|
Consists of 60,000 shares underlying an option exercisable at $0.75 per share. |
|
(9) |
|
Mr. Greenspan ceased providing services to the company on the effective date of
the bankruptcy in September 2009. |
|
(10) |
|
Includes options to purchase 1,604,444 shares of common stock. |
|
(11) |
|
Reflects the beneficial ownership of the reported entities and their affiliates as
reported in the Schedule 13G filed March 2, 2010. The business address for James E. Flynn,
Deerfield Capital, L.P., Deerfield |
49
Special Situations Fund, L.P., and Deerfield Management Company, L.P. is 780 Third Avenue,
37th Floor, New York, NY 10017. The business address for Deerfield Special Situations Fund
International Limited is c/o Bisys Management, Bison Court, Columbus Centre, P.O. Box 3460, Road
Town, Tortola, British Virgin Islands. Deerfield Capital, L.P. and Deerfield Special Situations
Fund, L.P. have shared investment discretion over 708,000 shares. Deerfield Management Company,
L.P. and Deerfield Special Situations Fund International Limited have shared investment discretion
over 1,292,000 shares. James E. Flynn has shared investment discretion over 2,000,000 shares.
DESCRIPTION OF SECURITIES
General
We are authorized to issue 250,000,000 shares of common stock and 5,000,000 shares of
preferred stock. As of June 8, 2010, we had 19,768,676 shares of common stock outstanding and
3,250 shares of Series A Preferred outstanding. In addition, as of such date we had:
|
|
|
4,457,000 shares of common stock issuable upon the exercise of options issued
pursuant to our current stock option plan and outside our stock option plan; |
|
|
|
|
543,000 shares of common stock available for issuance upon the exercise of options
available for future grant under our stock option plan; |
|
|
|
|
4,766,667 shares of common stock issuable upon the conversion of the Series A
Preferred; |
|
|
|
|
1,083,331 shares of common stock for issuance upon exercise of the Class A warrants;
1,083,332 shares of common stock for issuance upon exercise of the Class B warrants;
and 433,333 shares of common stock for issuance upon exercise of the warrants issued to
the placement agents for our Series A Preferred offering; and |
|
|
|
|
5,076,664 shares of common stock issuable upon exercise of common stock purchase
warrants issued in the March 2010 offering and 406,133 shares of common stock
underlying the warrants issued to the placement agents in such offering. |
Common Stock
Subject to preferences that may be applicable to any preferred stock outstanding at the time,
the holders of our common stock are entitled to receive dividends out of legally available assets
at such times and in such amounts as our Board of Directors may from time to time determine. Each
stockholder is entitled to one vote for each share of common stock held on all matters submitted to
a vote of stockholders. Cumulative voting for the election of directors is not authorized.
Our common stock is not subject to conversion or redemption and holders of our common stock
are not entitled to preemptive rights. Upon the liquidation, dissolution or winding up of our
company, the remaining assets legally available for distribution to stockholders, after payment of
claims or creditors and payment of liquidation preferences, if any, on outstanding preferred stock,
are distributable ratably among the holders of our common stock and any participating preferred
stock outstanding at that time. Each outstanding share of common stock is fully paid and
nonassessable.
Preferred Stock
Our Board of Directors has the authority, without action by our stockholders, to designate and
issue preferred stock in one or more series. Our Board of Directors may also designate the rights,
preferences and privileges of each series of preferred stock, any or all of which may be greater
than the rights of the common stock. It is not possible to state the actual effect of the issuance
of any shares of preferred stock on the rights of holders of the common stock until our Board of
Directors determines the specific rights of the holders of the preferred stock.
50
However, these effects might include: (a) restricting dividends on the common stock; (b)
diluting the voting power of the common stock; (c) impairing the liquidation rights of the common
stock; and (d) delaying or preventing a change in control of our company without further action by
our stockholders.
As of the date of this prospectus, we have authorized two classes of preferred stock, Series A
Convertible Preferred Stock, or Series A Preferred and Series C Junior Participating Preferred
Stock, or Series C Preferred. As of June 8, 2010, there were 3,250 shares of Series A Preferred
outstanding and no shares of Series C Preferred outstanding.
Series A Preferred
The Series A Preferred shares were issued in October 2009 pursuant to an agreement between us
and certain accredited investors. To designate and establish the shares of Series A Preferred, our
board approved, and on October 8, 2009, we filed with the Delaware Secretary of State, a
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred
Stock, or Certificate of Designation.
Dividends; Rank; Liquidation
Holders of the Series A Preferred are entitled to receive cumulative dividends at the rate per
share (as a percentage of the stated value per share) of 6% per annum (subject to increase in
certain circumstances), payable quarterly in arrears on January 15, April 15, July 15 and October
15, beginning on April 15, 2010. The dividends are payable in cash, or at our option, in duly
authorized, validly issued, fully paid and non-assessable shares of common stock equal to 110% of
the cash dividend amount payable on the dividend payment date, or a combination thereof; provided
that we may not pay the dividends in shares of common stock unless we meet certain conditions
described in the Certificate of Designation. If we pay the dividend in shares of common stock, the
common stock will be valued for such purpose at 80% of the average of the volume weighted average
price for the 10 consecutive trading days ending on the trading day that is immediately prior to
the dividend payment date.
Shares of common stock issued as dividends on the Series A Preferred are not being registered
under this prospectus. Such shares are deemed to be restricted securities under Rule 144 of the
Securities Act and may only be sold in compliance with Rule 144.
The Series A Preferred ranks senior to all shares of common stock.
Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, the holders
of the Series A Preferred shall be entitled to receive out of our assets, whether capital or
surplus, an amount equal to the stated value of the common stock, plus any accrued and unpaid
dividends thereon and any other fees or liquidated damages then due and owing thereon under the
Certificate of Designation, for each share of Series A Preferred before any distribution or payment
shall be made to the holders of any junior securities, and if our assets are insufficient to pay in
full such amounts, then the entire assets to be distributed to the holders of the Series A
Preferred shall be ratably distributed among the holders in accordance with the respective amounts
that would be payable on such shares if all amounts payable thereon were paid in full.
Conversion; Conversion Price; Forced Conversion; Optional Redemption
Each share of Series A Preferred is convertible into a number of shares of common stock equal
to (1) the stated value of the share ($1,000), divided by (2) the conversion price, which is
currently $0.75, but is subject to adjustment as discussed below. We refer to this price as the
Conversion Price.
With certain exceptions, if, at any time while the Series A Preferred is outstanding, we sell
or grant any option to purchase or sell or grant any right to reprice, or otherwise dispose of or
issue (or announce any sale, grant or any option to purchase or other disposition), any common
stock or common stock equivalents at an effective price per share that is lower than the then
Conversion Price, then the Conversion Price will be reduced to equal the lower price. The
Conversion Price is also subject to proportional adjustment in the event of any stock split, stock
dividend, reclassification or similar event with respect to the common stock.
51
Commencing six months from the date of the agreement pursuant to which we issued the Series A
Preferred, if the volume weighted average price for each of any 20 consecutive trading days exceeds
200% of the then effective Conversion Price and various other equity conditions are satisfied
(including that the resale of the shares underlying the Series A Preferred has been registered
under the Securities Act), upon 30 days notice, the Series A Preferred plus all accrued and unpaid
dividends will automatically convert into shares of common stock.
Commencing two years from the date of the agreement pursuant to which we issued the Series A
Preferred, upon 30 days notice and provided various other equity conditions are satisfied
(including that the resale of the shares underlying the Series A Preferred has been registered
under the Securities Act), we may redeem some or all of the then outstanding Series A Preferred for
cash in an amount equal to the 150% of the stated value of the Series A Preferred.
Voting
The holders of the Series A Preferred have no voting rights except with respect to specified
matters affecting the rights of the Series A Preferred.
Negative Covenants
As long as any shares of Series A Preferred are outstanding, we may not, directly or
indirectly: (a) amend our charter documents in any manner that materially and adversely affects any
rights of the holders of the Series A Preferred; (b) pay cash dividends or distributions on our
junior securities (including the common stock); or (c) enter into any transaction with any
affiliate of ours which would be required to be disclosed in any public filing, unless such
transaction is made on an arms-length basis and expressly approved by a majority of our
disinterested directors.
Triggering Events
In the event of a Triggering Event (as defined in the Certificate of Designation and described
below), any holder of Series A Preferred may require us to redeem all of its Series A Preferred, at
a redemption price equal to the greater of (a) 130% of the stated value and (b) the product of (i)
the volume weighted average price on the trading day immediately preceding the date of the
Triggering Event and (ii) the stated value divided by the then Conversion Price, plus all accrued
but unpaid dividends thereon and all liquidated damages and other costs, expenses or amounts due in
respect of the Series A Preferred. Triggering Events include, among other things, bankruptcy
related events, change of control transactions (as defined in the Certificate of Designation), and
various types of failures to perform under, and breaches of, the transaction documents.
Series C Preferred
In 2006, our Board of Directors declared a dividend distribution of one right for each
outstanding share of common stock to stockholders of record at the close of business on May 22,
2006, the record date. Each right entitles the registered holder to purchase from us a unit
consisting of one ten-thousandth of a share of Series C Preferred at a purchase price of $35.00 per
unit, subject to adjustment. The rights are not exercisable until the distribution date and will
expire at 5:00 P.M. (New York City time) on May 12, 2016, unless such date is extended or the
rights are earlier redeemed or exchanged by us. The distribution date occurs upon the earlier of:
|
|
|
ten business days following a public announcement that a person or group of
affiliated or associated persons has acquired beneficial ownership of 15% or more of
our outstanding common stock (20%, in the case of certain institutional investors)
other than as a result of repurchases of stock by us or certain inadvertent actions by
institutional or certain other stockholders; or |
|
|
|
|
ten business days (or such later date as the Board shall determine) following the
commencement of a tender offer or exchange offer that would result in a person or group
becoming an acquiring person. |
52
Warrants
Class A Warrants, Class B Warrants and Placement Agent Warrants
Pursuant to, and contemporaneous with the execution of, the agreement in which we issued the
Series A Preferred, we issued Class A warrants to purchase 501,542 shares of common stock and Class
B warrants to purchase 416,666 shares of common stock to the investors that purchased our Series A
Preferred pursuant to the agreement in which we issued the Series A Preferred. At the same time we
also issued warrants to purchase 250,000 shares of common stock to the placement agents for the
Series A Preferred. Each of the warrants is exercisable upon issuance and has a five-year term. The
initial exercise price of the Class A warrants was $1.62 per share, the initial exercise price of
the Class B warrants was $1.95 per share, and the initial exercise price of the warrants issued to
the placement agents was $1.30 per share.
With certain exceptions, the Class A warrants, Class B warrants and placement agent warrants
provide that if at any time while the warrants are outstanding, we sell or grant any option to
purchase or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any
sale, grant or any option to purchase or other disposition), any common stock or common stock
equivalents at an effective price per share that is lower than the then exercise price of the
relevant warrant, then the exercise price of such warrant will be reduced to equal the lower price
and the number of shares issuable thereunder will be increased such that the aggregate exercise
price after the exercise price adjustment will be equal to the aggregate exercise price prior to
the adjustment.
On March 4, 2010 pursuant to a securities purchase agreement, we completed an offering,
referred to as the Private Offering, in which we issued to certain accredited investors shares of
common stock at a purchase price of $0.75 per share. Consequently, as a result of the purchase
price of the common stock sold in the Private Offering, effective as of March 4, 2010, (a) the
conversion price of the Series A Preferred has been reduced from $1.30 to $0.75, (b) the exercise
prices for the Class A, Class B and placement agent warrants have been reduced from $1.62, $1.95
and $1.30 per share, respectively, to $0.75 per share and (c) the numbers of shares underlying the
Class A, Class B and placement agent warrants have been increased to 1,083,331, 1,083,332 and
433,333 respectively.
March 2010 Private Offering Warrants
We entered a securities purchase agreement dated March 4, 2010 with certain accredited
investors pursuant to which the Company agreed to sell in the aggregate 5,076,664 shares of our
common stock. In addition to the common stock purchased, each investor received a warrant to
purchase the same number of shares of common stock acquired in the offering at an exercise price of
$0.98 per share. Each of the warrants was exercisable immediately and has a five-year term. The
warrants may be exercised on a cash-less basis and are non-redeemable.
With certain exceptions, the warrants provide that if, at any time while the warrants are
outstanding, we sell or grant any option to purchase or sell or grant any right to reprice, or
otherwise dispose of or issue (or announce any sale, grant or any option to purchase or other
disposition), any common stock or common stock equivalents at an effective price per share that is
lower than the then exercise price of the relevant warrant, then the exercise price of such warrant
will be reduced to equal the lower price and the number of shares issuable thereunder will be
increased such that the aggregate exercise price after the exercise price adjustment will be equal
to the aggregate exercise price prior to the adjustment.. If we enter into a fundamental
transaction (which term is defined in the warrants), then at the warrant holders option,
exercisable at any time concurrently with, or within 30 days after, the announcement of a
fundamental transaction, we must redeem all or any portion of the warrant from the holder by paying
to the holder an amount of cash equal to the Black Scholes value of the remaining unexercised
portion of this warrant on or prior to the date of the consummation of such fundamental
transaction. Any cash payments to be made pursuant to the preceding sentence shall have priority to
payments to holders of common stock in connection with a fundamental transaction. The assumptions
to be used in calculating the Black Scholes value are set forth in Schedule 1 to the warrant.
Registration Rights
In connection with the Series A Preferred purchase agreement, we also entered into a
Registration Rights Agreements with the purchasers of the Series A Preferred, which requires us to
register the resale of the 110% of the
53
shares of common stock underlying the Series A Preferred and the shares of common stock
underlying the Class A warrants, Class B warrants and placement agent warrant. We are required to
file the registration statement within 45 days of the date of execution of the purchase agreement
and the registration statement must be declared effective within 90 days of the date of the
agreement (or 120 days if the registration statement is fully reviewed by the SEC), or we will be
required to pay liquidated damages as set forth in the agreement.
In connection with the March 4, 2010 securities purchase agreement, we also entered into
registration rights agreements with the purchasers of the common stock, which requires us to
register the resale of the shares of common stock issued and the shares of common stock underlying
the warrants issued.
12.5% Notes
In our bankruptcy reorganization plan, each holder of Isolagens 3.5% convertible subordinated
notes, due November 2024, in the approximate non-converted aggregate principal amount of $81
million, received, in full and final satisfaction, settlement, release and discharge of and in
exchange for any and all claims arising out of the 3.5% convertible subordinated notes, its pro
rata share of an unsecured note in the principal amount of $6 million, or the New Notes. The New
Notes have the following features:
|
|
|
12.5% interest payable quarterly in cash or, at our option, 15% payable in kind by
capitalizing such unpaid amount and adding it to the principal as of the date it was
due; |
|
|
|
|
mature June 1, 2012; |
|
|
|
|
at any time prior to the maturity date, we may redeem any portion of the outstanding
principal of the New Notes in cash at 125% of the stated face value of the New Notes;
provided that we will be obligated to redeem all outstanding New Notes upon the
following events: (a) we or our subsidiary, Fibrocell Technologies, Inc. (formerly,
Isolagen Technologies, Inc.) successfully complete a capital campaign raising in excess
of $10,000,000; or (b) we or our subsidiary, Fibrocell Technologies, Inc., are acquired
by, or sell a majority stake to, an outside party; |
|
|
|
|
the New Notes contain customary representations, warranties and covenants, including
a covenant that we and our subsidiary, Fibrocell Technologies, Inc., shall be
prohibited from the incurrence of additional debt without obtaining the consent of 66
2/3% of the New Note holders. |
|
|
Anti-Takeover Effects of Provisions of Delaware Law |
Provisions of Delaware law and our Certificate of Incorporation, as amended, and Bylaws could
make the acquisition of our company through a tender offer, a proxy contest or other means more
difficult and could make the removal of incumbent officers and directors more difficult. We expect
these provisions to discourage coercive takeover practices and inadequate takeover bids and to
encourage persons seeking to acquire control of our company to first negotiate with our Board of
Directors. We believe that the benefits provided by our ability to negotiate with the proponent of
an unfriendly or unsolicited proposal outweigh the disadvantages of discouraging these proposals.
We believe the negotiation of an unfriendly or unsolicited proposal could result in an improvement
of its terms.
Anti-Takeover Effects of Provisions of Our Charter Documents
Our Certificate of Incorporation, as amended, provides for our Board of Directors to be
divided into three classes serving staggered terms. Approximately one-third of the Board of
Directors will be elected each year. The provision for a classified board could prevent a party who
acquires control of a majority of the outstanding voting stock from obtaining control of the Board
of Directors until the second annual stockholders meeting following the date the acquirer obtains
the controlling stock interest. The classified board provision could discourage a potential
acquirer from making a tender offer or otherwise attempting to obtain control of our company and
could increase the likelihood that incumbent directors will retain their positions.
54
Our Bylaws do not permit stockholders to call a special meeting of stockholders. Our Bylaws
provide that special meetings of the stockholders may be called only by a majority of the members
of our Board of Directors, our Chairman of the Board of Directors, our Chief Executive Officer or
our President. Our Bylaws require that all stockholder actions be taken by a vote of the
stockholders at an annual or special meeting, and do not permit our stockholders to act by written
consent without a meeting. Our Bylaws provide for an advance notice procedure for stockholder
proposals to be brought before an annual meeting of our stockholders, including proposed
nominations of persons for election to the Board of Directors. At an annual meeting, stockholders
may only consider proposals or nominations specified in the notice of meeting or brought before the
meeting by or at the direction of the Board of Directors. Stockholders may also consider a proposal
or nomination by a person who was a stockholder of record on the record date for the meeting, who
is entitled to vote at the meeting and who has given to our Secretary timely written notice, in
proper form, of his, her or its intention to bring that business before the meeting. The Bylaws do
not give our Board of Directors the power to approve or disapprove stockholder nominations of
candidates or proposals regarding other business to be conducted at a special or annual meeting of
the stockholders. However, our Bylaws may have the effect of precluding the conduct of business at
a meeting if the proper procedures are not followed. These provisions may also discourage or deter
a potential acquirer from conducting a solicitation of proxies to elect the acquirers own slate of
directors or otherwise attempting to obtain control of our company.
Listing
Our common stock is listed on the OTCBB under the symbol FCSC.
Transfer Agent
The transfer agent for our common stock is American Stock Transfer & Trust Company located at
59 Maiden Lane, New York, New York 11038.
SHARES ELIGIBLE FOR FUTURE SALE
As
of June 8, 2010, there were approximately 19,768,676 shares of our common stock
outstanding.
Future sales of a substantial number of shares of our common stock in the public market could
adversely affect market prices prevailing from time to time. Under the terms of this prospectus,
the shares of common stock underlying the Series A Preferred and the warrants may be resold without
restriction or further registration under the Securities Act, except that any shares offered by our
affiliates, as that term is defined under the Securities Act, may generally only be sold in
compliance with Rule 144 under the Securities Act.
Shares Covered by this Prospectus
The following shares may be offered for resale under this prospectus:
|
|
|
up to 5,076,664 shares of common stock issued in our March 4, 2010 Private Offering;
and |
|
|
|
|
up to 5,076,664 shares of common stock underlying common stock purchase warrants
issued in our March 4, 2010 Private Offering and up to 406,133 shares of common
stock underlying the warrants issued to the placement agents in such offering. |
All of the shares being registered in this offering may be resold by the investors without
restriction under the Securities Act.
Rule 144
The SEC adopted amendments to Rule 144 which became effective on February 15, 2008, and apply
to securities acquired both before and after that date. Under these amendments, a person who has
beneficially owned restricted shares of our common stock for at least six months would be entitled
to sell their securities provided that (i) such person is not deemed to have been one of our
affiliates at the time of, or at any time during the three months
55
preceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements
for at least three months before the sale.
Of
the 19,768,676 shares of our common stock issued and outstanding as
of June 8, 2010, a
total of 600,000 shares are deemed control securities, within the meaning of Rule 144. Absent
registration under the Securities Act, the sale of such shares is subject to Rule 144, as
promulgated under the Securities Act. Similarly, any shares we issue as dividends on the Series A
Preferred are deemed restricted securities under Rule 144 and may only be sold in compliance with
Rule 144. The remainder of our outstanding shares may be sold without limitation or restriction.
Sales under Rule 144 by Affiliates
Persons who have beneficially owned restricted shares of our common stock for at least six
months but who are our affiliates at the time of, or at any time during the three months preceding,
a sale, would be subject to additional restrictions, by which such person would be entitled to sell
within any three-month period only a number of securities that does not exceed the greater of
either of the following:
(a) 1%
of the number of shares of common stock then outstanding, which will equal 197,687
shares as of the date of this prospectus; or
(b) if the common stock is listed on a national securities exchange, the average weekly
trading volume of the common stock during the four calendar weeks preceding the filing of a notice
on Form 144 with respect to the sale.
However, since our shares are quoted on the OTCBB, our stockholders will not be able to rely
on the market-based volume limitation described in the second bullet above. If, in the future, our
securities are listed on an exchange, then our stockholders would be able to rely on the
market-based volume limitation. Unless and until our stock is so listed or quoted, our stockholders
can only rely on the percentage based volume limitation described in the first bullet above.
Such sales by affiliates must also comply with the manner of sale, current public information
and notice provisions of Rule 144. The selling stockholders will not be governed by the foregoing
restrictions when selling their shares pursuant to this prospectus.
Sales Under Rule 144 by Non-Affiliates
Under Rule 144, a person who is not deemed to have been one of our affiliates at the time of
or at any time during the three months preceding a sale, and who has beneficially owned their
shares proposed to be sold for at least six months, including the holding period of any prior owner
other than an affiliate, is entitled to sell their shares without complying with the manner of sale
and volume limitation or notice provisions of Rule 144. We must be current in our public reporting
if the non-affiliate is seeking to sell under Rule 144 after holding his shares between six months
and one year. After one year, non-affiliates do not have to comply with any other Rule 144
requirements.
The possibility that substantial amounts of our common stock may be sold under Rule 144 into
the public market may adversely affect prevailing market prices for the common stock and could
impair our ability to raise capital in the future through the sale of equity securities.
56
SELLING SECURITY HOLDERS
The following table presents information regarding the Selling Stockholders. The percentage of
outstanding shares beneficially owned is based on 19,768,676 shares of common stock issued and
outstanding on June 8, 2010. Beneficial ownership is determined in accordance with Rule 13d-3
under the Exchange Act. As to each person or entity named as beneficial owners, that persons or
entitys percentage of ownership is determined based on the assumption that any warrants or
convertible securities held by such person or entity which are exercisable or convertible within
60 days of the date of this report have been exercised or converted, as the case may be.
The warrants issued in the March 2010 offering each provide that at no time may a holder
exercise the warrants if the number of shares of common stock to be issued pursuant to such
exercise would exceed, when aggregated with all other shares of common stock owned by such holder
at such time, the number of shares of common stock which would result in such holder beneficially
owning (as determined in accordance with Section 13(d) of the Exchange Act and the rules
thereunder) in excess of 9.98% of the then issued and outstanding shares of our common stock;
provided, however, that upon the holder providing us with 61 days notice that such holder would
like to waive this provision then this provision will be of no force or effect; provided, further,
that this provision will be of no force or effect during the 61 days immediately preceding the
expiration of the warrants.
Except as may be otherwise described below, to the best of our knowledge, the named Selling
Stockholder beneficially owns and has sole voting and investment authority as to all of the shares
set forth opposite his name, none of the selling stockholders is known to us to be a registered
broker-dealer or an affiliate of a registered broker-dealer, and none of the Selling Stockholders
has not held any position or office, or has had any material relationship with us or any of our
affiliates within the past three years. Each of the Selling Stockholders has acquired his, her or
its shares solely for investment and not with a view to or for resale or distribution of such
securities.
Information with respect to beneficial ownership is based upon information provided to us by
the Selling Stockholders. For purposes of presentation, we have assumed that the Selling
Stockholders will sell all shares offered hereby, including the shares issuable on the exercise of
warrants.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Approximate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No. of Shares |
|
|
Percentage of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuable Upon |
|
|
Issued and |
|
|
|
|
|
|
|
|
|
|
|
|
No. of Shares of |
|
|
Exercise of the |
|
|
Outstanding Shares |
|
|
Number of Shares |
|
|
Number Of Shares To |
|
|
Approximate |
|
|
|
Common Stock Owned |
|
|
Warrants Owned |
|
|
Beneficially Owned |
|
|
Registered and To |
|
|
Be Beneficially |
|
|
Percentage of |
|
Name of Selling |
|
Prior to the |
|
|
Prior to the |
|
|
Prior to the |
|
|
Be Sold In This |
|
|
Owned After The |
|
|
Shares To Be Owned |
|
Stockholders |
|
Offering (1) |
|
|
Offering |
|
|
Offering |
|
|
Offering |
|
|
Offering |
|
|
After the Offering |
|
Straus Healthcare
Partners, L.P. |
|
|
931,623 |
(2) |
|
|
560,666 |
(2) |
|
|
7.18 |
% |
|
|
666,666 |
|
|
|
825,623 |
|
|
|
4.04 |
% |
Margus Ehatamm &
Sarah Ehatamm |
|
|
20,000 |
|
|
|
20,000 |
|
|
|
|
* |
|
|
40,000 |
|
|
|
|
|
|
|
|
|
Deerfield Special
Situations Fund, LP (3) |
|
|
708,000 |
|
|
|
708,000 |
|
|
|
6.92 |
% |
|
|
1,416,000 |
|
|
|
|
|
|
|
|
|
Deerfield Special
Situations Fund
Intl (3) |
|
|
1,292,000 |
|
|
|
1,292,000 |
|
|
|
9.98 |
%(3) |
|
|
2,584,000 |
|
|
|
|
|
|
|
|
|
57
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Approximate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No. of Shares |
|
|
Percentage of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuable Upon |
|
|
Issued and |
|
|
|
|
|
|
|
|
|
|
|
|
No. of Shares of |
|
|
Exercise of the |
|
|
Outstanding Shares |
|
|
Number of Shares |
|
|
Number Of Shares To |
|
|
Approximate |
|
|
|
Common Stock Owned |
|
|
Warrants Owned |
|
|
Beneficially Owned |
|
|
Registered and To |
|
|
Be Beneficially |
|
|
Percentage of |
|
Name of Selling |
|
Prior to the |
|
|
Prior to the |
|
|
Prior to the |
|
|
Be Sold In This |
|
|
Owned After The |
|
|
Shares To Be Owned |
|
Stockholders |
|
Offering (1) |
|
|
Offering |
|
|
Offering |
|
|
Offering |
|
|
Offering |
|
|
After the Offering |
|
MOG Capital, LLC (4) |
|
|
2,000,000 |
(5) |
|
|
1,333,333 |
(5) |
|
|
9.98 |
%(3) |
|
|
1,333,334 |
|
|
|
1,999,333 |
|
|
|
9.19 |
% |
Robert Sagarino |
|
|
165,333 |
|
|
|
165,333 |
|
|
|
1.66 |
% |
|
|
330,666 |
|
|
|
|
|
|
|
|
|
Stephen M. Karlya |
|
|
6,100 |
|
|
|
6,100 |
|
|
|
| * |
|
|
12,200 |
|
|
|
|
|
|
|
|
|
Fergus McGovern |
|
|
768,628 |
|
|
|
333,333 |
|
|
|
5.48 |
% |
|
|
666,666 |
|
|
|
435,295 |
|
|
|
2.20 |
% |
Robert Siegal |
|
|
33,333 |
|
|
|
33,333 |
|
|
|
| * |
|
|
66,666 |
|
|
|
|
|
|
|
|
|
Peter Bowden |
|
|
697,752 |
|
|
|
200,000 |
|
|
|
4.50 |
% |
|
|
400,000 |
|
|
|
497,752 |
|
|
|
2.52 |
% |
Denis Bowden |
|
|
688,589 |
|
|
|
200,000 |
|
|
|
4.45 |
% |
|
|
400,000 |
|
|
|
488,589 |
|
|
|
2.47 |
% |
Jerry and Janet
Magro |
|
|
19,700 |
|
|
|
14,000 |
|
|
|
| * |
|
|
28,000 |
|
|
|
5,700 |
|
|
|
| * |
Raymond Cincotti |
|
|
14,000 |
|
|
|
14,000 |
|
|
|
| * |
|
|
28,000 |
|
|
|
|
|
|
|
|
|
David Boral |
|
|
12,567 |
|
|
|
269,128 |
(6) |
|
|
1.41 |
% |
|
|
73,362 |
|
|
|
208,333 |
|
|
|
1.04 |
% |
David Batista |
|
|
33,333 |
|
|
|
696,505 |
(7) |
|
|
3.57 |
% |
|
|
221,505 |
|
|
|
508,333 |
|
|
|
2.51 |
% |
George Carris |
|
|
33,333 |
|
|
|
953,066 |
(8) |
|
|
4.76 |
% |
|
|
269,732 |
|
|
|
716,667 |
|
|
|
3.50 |
% |
Jane Scotti |
|
|
200,000 |
|
|
|
200,000 |
|
|
|
2.00 |
% |
|
|
400,000 |
|
|
|
|
|
|
|
|
|
Bowden
Transportation
Services Ltd. (9) |
|
|
1,151,548 |
|
|
|
133,333 |
|
|
|
6.46 |
% |
|
|
266,666 |
|
|
|
1,018,215 |
|
|
|
5.15 |
% |
Anthony V. Milone |
|
|
73,333 |
|
|
|
73,333 |
|
|
|
| * |
|
|
146,666 |
|
|
|
|
|
|
|
|
|
David Speciale |
|
|
6,667 |
|
|
|
6,667 |
|
|
|
| * |
|
|
13,334 |
|
|
|
|
|
|
|
|
|
Margery Scotti |
|
|
266,666 |
(10) |
|
|
200,001 |
(10) |
|
|
2.32 |
% |
|
|
266,666 |
|
|
|
200,001 |
|
|
|
1.00 |
% |
Gavin Scotti |
|
|
133,333 |
|
|
|
133,333 |
|
|
|
1.34 |
% |
|
|
266,666 |
|
|
|
|
|
|
|
|
|
Super-Tek, Inc. |
|
|
271,333 |
|
|
|
271,333 |
|
|
|
2.71 |
% |
|
|
542,666 |
|
|
|
|
|
|
|
|
|
Anthony Milone
Profit Sharing Plan |
|
|
60,000 |
|
|
|
60,000 |
|
|
|
| * |
|
|
120,000 |
|
|
|
|
|
|
|
|
|
|
|
|
* |
|
Stockholder owns less than 1% |
|
(1) |
|
The Selling Stockholders and any broker-dealers or agents that are involved in selling these
shares are deemed to be underwriters within the meaning of the Securities Act for such sales. An
underwriter is a person who has purchased shares from an issuer with a view towards distributing
the shares to the public. In such event, any commissions received by such broker-dealers or agents
and any profit on the resale of the shares purchased by them may be considered to be underwriting
commissions or discounts under the Securities Act. |
|
(2) |
|
The number of shares listed consists of (i) 476,956 shares of common stock (including 333,333
shares of common stock that were acquired in our March 4, 2010 Private Offering being registered in
this prospectus), and (ii) 454,667 shares underlying our Series A Preferred stock. The number of
warrants listed consists of (i) warrants to purchase 333,333 shares of common stock that were
acquired in our March 4, 2010 Private Offering being registered in this prospectus, and (ii)
warrants to purchase 227,333 shares acquired in our Series A Preferred stock offering. Ravinder
Holder, general partner of the selling stockholder, holds voting and dispositive power over the
securities held by the selling stockholder. |
58
|
|
|
(3) |
|
James E. Flynn exercises voting and dispositive power over the securities held by Deerfield Special Situations Fund, L.P. and Deerfield Special Situations Fund International, Limited. The warrants issued in the March 2010 offering
provide that at no time may a holder exercise
the warrants if the number of shares of common stock to be issued pursuant to such exercise would
exceed, when aggregated with all other shares of common stock owned by such holder at such time,
the number of shares of common stock which would result in such holder beneficially owning (as
determined in accordance with Section 13(d) of the Exchange Act and the rules thereunder) in excess
of 9.98% of the then issued and outstanding shares of our common stock; provided, however, that
upon the holder providing us with 61 days notice that such holder would like to waive this
provision then this provision will be of no force or effect; provided, further, that this provision
will be of no force or effect during the 61 days immediately preceding the expiration of the
warrants. |
|
(4) |
|
MOG Capital, LLC is a registered broker dealer. The registrable securities were acquired in
the ordinary course of business and not as compensation for investment banking services.
Accordingly, the selling security holder is an underwriter within the meaning of Section 2(a)(11)
of the Securities Act under the interpretations of the SEC. Jason Adler, in his capacity as
managing member of MOG Capital, LLC has voting and dispositive power over the securities held by
MOG Capital, LLC. Mr. Adler disclaims beneficial ownership of such securities. |
|
(5) |
|
The number of shares listed consists of (i) 666,667 shares of common stock that were acquired
in our March 4, 2010 Private Offering being registered in this prospectus, and (ii) 1,333,333
shares underlying our Series A Preferred stock. The number of warrants listed consists of (i)
warrants to purchase 666,667 shares of common stock that were acquired in our March 4, 2010 Private
Offering being registered in this prospectus, and (ii) warrants to purchase 666,666 shares acquired
in our Series A Preferred stock offering. |
|
(6) |
|
Consists of (i) warrants to purchase 12,567 shares of common stock that were acquired in our
March 4, 2010 Private Offering being registered in this prospectus, (ii) warrants to purchase
48,228 shares of common stock being registered in this prospectus, (iii) an option to purchase
100,000 shares of common stock at $0.75 per share, and (iv) warrants to purchase 108,333 shares of
common stock. The warrants set forth in (ii) were issued by us to our placement agent in
connection with the March 2010 offering. Mr. Boral is an affiliate of the placement agent. |
|
(7) |
|
Consists of (i) warrants to purchase 33,333 shares of common stock that were acquired in our
March 4, 2010 Private Offering being registered in this prospectus, (ii) warrants to purchase
154,839 shares of common stock being registered in this prospectus, (iii) an option to purchase
400,000 shares of common stock at $0.75 per share, and (iv) warrants to purchase 108,333 shares of
common stock. The warrants set forth in (ii) were issued by us to our placement agent in
connection with the March 2010 offering. Mr. Batista is an affiliate of the placement agent. |
|
(8) |
|
Consists of (i) warrants to purchase 33,333 shares of common stock that were acquired in our
March 4, 2010 Private Offering being registered in this prospectus, (ii) warrants to purchase
203,066 shares of common stock being registered in this prospectus, (iii) an option to purchase
500,000 shares of common stock at $0.75 per share, and (iv) warrants to purchase 216,667 shares of
common stock. The warrants set forth in (ii) were issued by us to our placement agent in
connection with the March 2010 offering. Mr. Carris is an affiliate of the placement agent. |
|
(9) |
|
Peter Bowden holds voting and dispositive power over the securities held by the selling
stockholder. |
|
(10) |
|
The number of shares listed consists of (i) 133,333 shares of common stock that were acquired
in our March 4, 2010 Private Offering being registered in this prospectus, and (ii) 133,333 shares
underlying our Series A Preferred stock. The number of warrants listed consists of (i) warrants to
purchase 133,333 shares of common stock that were acquired in our March 4, 2010 Private Offering
being registered in this prospectus, and (ii) warrants to purchase 66,668 shares acquired in our
Series A Preferred stock offering. |
We may require the Selling Stockholders to suspend the sales of the securities offered by this
prospectus upon the occurrence of any event that makes any statement in this prospectus or the
related registration statement untrue in any material respect or that requires the changing of
statements in these documents in order to make statements in those documents not misleading.
PLAN OF DISTRIBUTION
59
Each Selling Stockholder of the common stock and any of their pledgees, assignees and
successors-in-interest may, from time to time, sell any or all of their shares of common stock
covered hereby on the principal trading market or any other stock exchange, market or trading
facility on which the shares are traded or in private transactions. These sales may be at fixed or
negotiated prices. A Selling Stockholder may use any one or more of the following methods when
selling shares:
|
|
|
ordinary brokerage transactions and transactions in which the broker-dealer
solicits purchasers; |
|
|
|
|
block trades in which the broker-dealer will attempt to sell the shares as
agent but may position and resell a portion of the block as principal to facilitate the
transaction; |
|
|
|
|
purchases by a broker-dealer as principal and resale by the broker-dealer
for its account; |
|
|
|
|
an exchange distribution in accordance with the rules of the applicable
exchange; |
|
|
|
|
privately negotiated transactions; |
|
|
|
|
settlement of short sales entered into after the effective date of the registration
statement of which this prospectus is a part; |
|
|
|
|
in transactions through broker-dealers that agree with the Selling
Stockholders to sell a specified number of such shares at a stipulated price per share; |
|
|
|
|
through the writing or settlement of options or other hedging
transactions, whether through an options exchange or otherwise; |
|
|
|
|
a combination of any such methods of sale; or |
|
|
|
|
any other method permitted pursuant to applicable law. |
The Selling Stockholders may also sell shares under Rule 144 under the Securities Act, if
available, rather than under this prospectus.
Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to
participate in sales. Broker-dealers may receive commissions or discounts from the Selling
Stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the
purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this
Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission
in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown
in compliance with FINRA IM-2440.
In connection with the sale of the common stock or interests therein, the Selling Stockholders
may enter into hedging transactions with broker-dealers or other financial institutions, which may
in turn engage in short sales of the common stock in the course of hedging the positions they
assume. The Selling Stockholders may also sell shares of the common stock short and deliver these
securities to close out their short positions, or loan or pledge the common stock to broker-dealers
that in turn may sell these securities. The Selling Stockholders may also enter into option or
other transactions with broker-dealers or other financial institutions or create one or more
derivative securities which require the delivery to such broker-dealer or other financial
institution of shares offered by this prospectus, which shares such broker-dealer or other
financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect
such transaction).
The Selling Stockholders and any broker-dealers or agents that are involved in selling the
shares may be deemed to be underwriters within the meaning of the Securities Act in connection
with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the shares purchased by them may be deemed to be underwriting commissions
or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it
does not have any written or oral agreement or understanding,
60
directly or indirectly, with any
person to distribute the Common Stock. In no event shall any broker-dealer receive fees,
commissions and markups which, in the aggregate, would exceed 8%.
The Company is required to pay certain fees and expenses incurred by the Company incident to
the registration of the shares. The Company has agreed to indemnify the Selling Stockholders
against certain losses, claims, damages and liabilities, including liabilities under the Securities
Act.
Because Selling Stockholders may be deemed to be underwriters within the meaning of the
Securities Act, they will be subject to the prospectus delivery requirements of the Securities Act
including Rule 172 thereunder. The Selling Stockholders have advised us that there is no
underwriter or coordinating broker acting in connection with the proposed sale of the resale shares
by the Selling Stockholders.
We agreed to keep this prospectus effective until the earlier of (i) the date on which the
shares may be resold by the Selling Stockholders without registration and without regard to any
volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company
to be in compliance with the current public information under Rule 144 under the Securities Act or
any other rule of similar effect or (ii) all of the shares have been sold pursuant to this
prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale
shares will be sold only through registered or licensed brokers or dealers if required under
applicable state securities laws. In addition, in certain states, the resale shares of Common Stock
covered hereby may not be sold unless they have been registered or qualified for sale in the
applicable state or an exemption from the registration or qualification requirement is available
and is complied with.
Under applicable rules and regulations under the Exchange Act, any person engaged in the
distribution of the resale shares may not simultaneously engage in market making activities with
respect to the common stock for the applicable restricted period, as defined in Regulation M, prior
to the commencement of the distribution. In addition, the Selling Stockholders will be subject to
applicable provisions of the Exchange Act and the rules and regulations thereunder, including
Regulation M, which may limit the timing of purchases and sales of shares of the common stock by
the Selling Stockholders or any other person. We will make copies of this prospectus available to
the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to
each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the
Securities Act).
61
EXPERTS
The financial statements as of December 31, 2009 (Successor) and 2008 (Predecessor as
described in Note 1 of the notes to the consolidated financial
statements included herein) and for the year ended December 31, 2008 (Predecessor), for the period from January 1,
2009 to August 31, 2009 (Predecessor) and for the period from the Successors inception
(September 1, 2009) through December 31, 2009 and included in this Prospectus and in the
Registration Statement have been so included in reliance on the report of BDO Seidman, LLP, an
independent registered public accounting firm, the report on the financial statements contains an
explanatory paragraph regarding the Companys ability to continue as a going concern, appearing
elsewhere herein and in the Registration Statement, given on the authority of said firm as experts
in auditing and accounting.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement on Form S-1 under the Securities Act with
respect to the common stock offered in this offering. This prospectus does not contain all of the
information set forth in the registration statement. For further information with respect to us and
the common stock offered in this offering, we refer you to the registration statement and to the
attached exhibits. With respect to each such document filed as an exhibit to the registration
statement, we refer you to the exhibit for a more complete description of the matters involved.
You may inspect our registration statement and the attached exhibits and schedules without
charge at the public reference facilities maintained by the SEC at 100 F Street, N.E., Washington,
D.C. 20549. You may obtain
copies of all or any part of our registration statement from the SEC
upon payment of prescribed fees. You may obtain information on the operation of the public
reference room by calling the SEC at 1-800-SEC-0330.
Our SEC filings, including the registration statement and the exhibits filed with the registration
statement, are also available from the SECs website at www.sec.gov, which contains reports, proxy
and information statements and other information regarding issuers that file electronically with
the SEC.
62
FIBROCELL SCIENCE, INC.
10,559,461 Shares of Common Stock
PROSPECTUS
June 21, 2010
You should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is correct only as of the date of this prospectus, regardless of the time of the delivery of this prospectus or the sale of these securities.